Viral-mRNA-Translation
|
73
|
2.05e-33
|
1.52e-30
|
1.07000
|
7.01e-01
|
-0.802000
|
3.15e-25
|
1.64e-32
|
Peptide-chain-elongation
|
73
|
1.36e-32
|
6.71e-30
|
1.05000
|
6.99e-01
|
-0.789000
|
4.63e-25
|
1.69e-31
|
Response-of-EIF2AK4-(GCN2)-to-amino-acid-deficiency
|
85
|
1.11e-34
|
1.65e-31
|
1.01000
|
6.65e-01
|
-0.757000
|
2.47e-26
|
1.35e-33
|
Eukaryotic-Translation-Elongation
|
77
|
2.80e-31
|
6.91e-29
|
1.00000
|
6.65e-01
|
-0.753000
|
5.05e-24
|
2.61e-30
|
Formation-of-a-pool-of-free-40S-subunits
|
85
|
2.20e-32
|
8.16e-30
|
0.97600
|
6.53e-01
|
-0.725000
|
2.00e-25
|
5.44e-31
|
Eukaryotic-Translation-Termination
|
77
|
4.39e-29
|
5.92e-27
|
0.97000
|
6.46e-01
|
-0.723000
|
9.58e-23
|
4.67e-28
|
Formation-of-the-ternary-complex,-and-subsequently,-the-43S-complex
|
46
|
2.88e-17
|
1.71e-15
|
0.96300
|
6.60e-01
|
-0.701000
|
9.20e-15
|
1.88e-16
|
Selenocysteine-synthesis
|
76
|
9.92e-27
|
1.13e-24
|
0.93500
|
6.24e-01
|
-0.696000
|
4.92e-21
|
7.72e-26
|
Nonsense-Mediated-Decay-(NMD)-independent-of-the-Exon-Junction-Complex-(EJC)
|
79
|
3.34e-27
|
4.12e-25
|
0.92500
|
6.17e-01
|
-0.690000
|
2.42e-21
|
2.63e-26
|
Phosphorylation-of-CD3-and-TCR-zeta-chains
|
17
|
1.36e-06
|
4.02e-05
|
0.89600
|
-5.23e-01
|
0.727000
|
1.86e-04
|
2.08e-07
|
GTP-hydrolysis-and-joining-of-the-60S-ribosomal-subunit
|
96
|
2.23e-31
|
6.62e-29
|
0.89500
|
5.78e-01
|
-0.684000
|
1.14e-22
|
3.98e-31
|
PD-1-signaling
|
17
|
2.65e-06
|
7.41e-05
|
0.89500
|
-5.55e-01
|
0.702000
|
7.37e-05
|
5.30e-07
|
Translocation-of-ZAP-70-to-Immunological-synapse
|
14
|
2.05e-05
|
3.38e-04
|
0.89200
|
-5.35e-01
|
0.714000
|
5.27e-04
|
3.69e-06
|
L13a-mediated-translational-silencing-of-Ceruloplasmin-expression
|
95
|
4.56e-30
|
9.66e-28
|
0.88300
|
5.74e-01
|
-0.671000
|
3.79e-22
|
1.08e-29
|
Ribosomal-scanning-and-start-codon-recognition
|
53
|
1.26e-15
|
6.90e-14
|
0.84100
|
5.45e-01
|
-0.641000
|
6.61e-12
|
6.60e-16
|
Cap-dependent-Translation-Initiation
|
103
|
4.08e-29
|
5.92e-27
|
0.83700
|
5.51e-01
|
-0.630000
|
4.15e-22
|
1.83e-28
|
Eukaryotic-Translation-Initiation
|
103
|
4.08e-29
|
5.92e-27
|
0.83700
|
5.51e-01
|
-0.630000
|
4.15e-22
|
1.83e-28
|
Activation-of-the-mRNA-upon-binding-of-the-cap-binding-complex-and-eIFs,-and-subsequent-binding-to-43S
|
54
|
3.11e-15
|
1.53e-13
|
0.82500
|
5.41e-01
|
-0.623000
|
6.13e-12
|
2.24e-15
|
Gluconeogenesis
|
30
|
1.22e-08
|
4.53e-07
|
0.82400
|
6.00e-01
|
-0.565000
|
1.25e-08
|
8.28e-08
|
Translation-initiation-complex-formation
|
53
|
1.24e-14
|
5.72e-13
|
0.81500
|
5.32e-01
|
-0.617000
|
1.96e-11
|
7.69e-15
|
Acetylcholine-regulates-insulin-secretion
|
10
|
3.40e-03
|
2.03e-02
|
0.79100
|
-5.20e-01
|
0.596000
|
4.40e-03
|
1.09e-03
|
SRP-dependent-cotranslational-protein-targeting-to-membrane
|
96
|
6.92e-26
|
7.33e-24
|
0.78600
|
4.65e-01
|
-0.633000
|
3.24e-15
|
6.67e-27
|
Response-of-EIF2AK1-(HRI)-to-heme-deficiency
|
15
|
2.72e-04
|
2.65e-03
|
0.75900
|
4.66e-01
|
-0.599000
|
1.76e-03
|
5.85e-05
|
Nonsense-Mediated-Decay-(NMD)-enhanced-by-the-Exon-Junction-Complex-(EJC)
|
99
|
5.66e-23
|
4.66e-21
|
0.75800
|
5.07e-01
|
-0.564000
|
2.59e-18
|
2.75e-22
|
Nonsense-Mediated-Decay-(NMD)
|
99
|
5.66e-23
|
4.66e-21
|
0.75800
|
5.07e-01
|
-0.564000
|
2.59e-18
|
2.75e-22
|
Organic-cation/anion/zwitterion-transport
|
12
|
1.99e-03
|
1.29e-02
|
0.75700
|
-5.02e-01
|
0.567000
|
2.61e-03
|
6.75e-04
|
Complex-I-biogenesis
|
54
|
7.15e-13
|
3.12e-11
|
0.75700
|
5.00e-01
|
-0.568000
|
1.98e-10
|
5.21e-13
|
Selenoamino-acid-metabolism
|
91
|
3.37e-21
|
2.63e-19
|
0.75600
|
4.96e-01
|
-0.570000
|
2.52e-16
|
5.20e-21
|
Synthesis-of-PE
|
12
|
2.52e-03
|
1.60e-02
|
0.74800
|
5.28e-01
|
-0.530000
|
1.52e-03
|
1.48e-03
|
Citric-acid-cycle-(TCA-cycle)
|
22
|
2.15e-05
|
3.47e-04
|
0.73800
|
5.01e-01
|
-0.542000
|
4.71e-05
|
1.06e-05
|
Cellular-response-to-starvation
|
138
|
2.09e-29
|
3.87e-27
|
0.73400
|
5.17e-01
|
-0.521000
|
8.43e-26
|
3.42e-26
|
Defective-GALNT12-causes-colorectal-cancer-1-(CRCS1)
|
12
|
1.35e-03
|
9.66e-03
|
0.72900
|
6.06e-01
|
-0.405000
|
2.78e-04
|
1.50e-02
|
STING-mediated-induction-of-host-immune-responses
|
12
|
3.31e-03
|
2.00e-02
|
0.71800
|
-4.59e-01
|
0.552000
|
5.94e-03
|
9.18e-04
|
CD22-mediated-BCR-regulation
|
17
|
3.16e-04
|
2.98e-03
|
0.71200
|
-5.55e-01
|
0.447000
|
7.52e-05
|
1.40e-03
|
Influenza-Viral-RNA-Transcription-and-Replication
|
118
|
8.50e-24
|
8.40e-22
|
0.71100
|
4.89e-01
|
-0.516000
|
4.21e-20
|
3.11e-22
|
Mitochondrial-tRNA-aminoacylation
|
18
|
3.13e-04
|
2.97e-03
|
0.70500
|
-5.26e-01
|
0.468000
|
1.10e-04
|
5.79e-04
|
Alpha-protein-kinase-1-signaling-pathway
|
10
|
8.73e-03
|
4.27e-02
|
0.70300
|
4.27e-01
|
-0.559000
|
1.93e-02
|
2.20e-03
|
Glutamate-and-glutamine-metabolism
|
12
|
4.90e-03
|
2.72e-02
|
0.70000
|
4.63e-01
|
-0.525000
|
5.49e-03
|
1.65e-03
|
Interleukin-2-signaling
|
11
|
8.99e-03
|
4.37e-02
|
0.68700
|
-5.18e-01
|
0.451000
|
2.94e-03
|
9.61e-03
|
Respiratory-electron-transport
|
99
|
3.24e-19
|
2.19e-17
|
0.68100
|
4.30e-01
|
-0.527000
|
1.31e-13
|
1.07e-19
|
IRF3-mediated-induction-of-type-I-IFN
|
10
|
9.15e-03
|
4.42e-02
|
0.67500
|
-3.77e-01
|
0.559000
|
3.89e-02
|
2.19e-03
|
Regulation-of-KIT-signaling
|
16
|
1.06e-03
|
7.88e-03
|
0.67100
|
-4.12e-01
|
0.530000
|
4.28e-03
|
2.42e-04
|
tRNA-processing-in-the-mitochondrion
|
16
|
2.12e-03
|
1.36e-02
|
0.65700
|
4.74e-01
|
-0.455000
|
1.04e-03
|
1.62e-03
|
Basigin-interactions
|
24
|
1.55e-05
|
2.74e-04
|
0.65500
|
5.53e-01
|
-0.351000
|
2.67e-06
|
2.93e-03
|
HS-GAG-degradation
|
20
|
1.79e-04
|
1.82e-03
|
0.65100
|
-3.70e-01
|
0.536000
|
4.19e-03
|
3.27e-05
|
Respiratory-electron-transport,-ATP-synthesis-by-chemiosmotic-coupling,-and-heat-production-by-uncoupling-proteins.
|
107
|
1.42e-18
|
9.15e-17
|
0.64300
|
4.06e-01
|
-0.499000
|
3.53e-13
|
4.52e-19
|
Bicarbonate-transporters
|
10
|
1.09e-06
|
3.36e-05
|
0.63100
|
6.22e-01
|
0.104000
|
6.55e-04
|
5.69e-01
|
Influenza-Infection
|
134
|
1.07e-20
|
7.91e-19
|
0.62000
|
4.23e-01
|
-0.454000
|
2.72e-17
|
1.05e-19
|
Regulation-of-expression-of-SLITs-and-ROBOs
|
149
|
4.28e-23
|
3.97e-21
|
0.60800
|
3.79e-01
|
-0.475000
|
1.18e-15
|
1.16e-23
|
Metabolism-of-Angiotensinogen-to-Angiotensins
|
12
|
2.00e-02
|
8.22e-02
|
0.60400
|
4.15e-01
|
-0.439000
|
1.28e-02
|
8.44e-03
|
A-tetrasaccharide-linker-sequence-is-required-for-GAG-synthesis
|
24
|
6.79e-06
|
1.55e-04
|
0.59800
|
-2.44e-01
|
0.547000
|
3.87e-02
|
3.54e-06
|
Generation-of-second-messenger-molecules
|
29
|
9.31e-05
|
1.07e-03
|
0.59800
|
-4.05e-01
|
0.440000
|
1.61e-04
|
4.15e-05
|
Passive-transport-by-Aquaporins
|
11
|
2.29e-02
|
9.03e-02
|
0.58300
|
4.78e-01
|
-0.334000
|
6.01e-03
|
5.52e-02
|
TICAM1,TRAF6-dependent-induction-of-TAK1-complex
|
10
|
4.43e-02
|
1.44e-01
|
0.58300
|
3.76e-01
|
-0.445000
|
3.97e-02
|
1.47e-02
|
Amino-acid-transport-across-the-plasma-membrane
|
33
|
2.84e-05
|
4.29e-04
|
0.58000
|
4.55e-01
|
-0.360000
|
5.94e-06
|
3.45e-04
|
Interaction-between-L1-and-Ankyrins
|
26
|
7.45e-05
|
8.83e-04
|
0.57700
|
4.92e-01
|
-0.302000
|
1.42e-05
|
7.58e-03
|
tRNA-Aminoacylation
|
23
|
1.44e-03
|
1.01e-02
|
0.56500
|
-4.10e-01
|
0.388000
|
6.68e-04
|
1.26e-03
|
Glutathione-synthesis-and-recycling
|
12
|
2.30e-02
|
9.03e-02
|
0.56200
|
-4.58e-01
|
0.327000
|
6.05e-03
|
4.99e-02
|
FCGR-activation
|
24
|
8.93e-04
|
6.82e-03
|
0.56200
|
-4.34e-01
|
0.357000
|
2.32e-04
|
2.43e-03
|
Defective-GALNT3-causes-familial-hyperphosphatemic-tumoral-calcinosis-(HFTC)
|
12
|
2.02e-02
|
8.29e-02
|
0.55900
|
4.65e-01
|
-0.309000
|
5.24e-03
|
6.35e-02
|
The-citric-acid-(TCA)-cycle-and-respiratory-electron-transport
|
155
|
3.99e-20
|
2.82e-18
|
0.55400
|
3.44e-01
|
-0.434000
|
1.30e-13
|
8.78e-21
|
TICAM1,-RIP1-mediated-IKK-complex-recruitment
|
17
|
2.54e-04
|
2.52e-03
|
0.54800
|
1.80e-01
|
-0.518000
|
1.98e-01
|
2.19e-04
|
ATF6-(ATF6-alpha)-activates-chaperones
|
12
|
1.39e-02
|
6.27e-02
|
0.54600
|
-4.79e-01
|
0.262000
|
4.05e-03
|
1.16e-01
|
BBSome-mediated-cargo-targeting-to-cilium
|
21
|
3.65e-03
|
2.15e-02
|
0.54100
|
-4.11e-01
|
0.352000
|
1.11e-03
|
5.27e-03
|
Cristae-formation
|
13
|
1.72e-02
|
7.34e-02
|
0.53400
|
4.55e-01
|
-0.281000
|
4.54e-03
|
7.96e-02
|
Defective-pyroptosis
|
13
|
3.52e-02
|
1.25e-01
|
0.53400
|
-3.98e-01
|
0.356000
|
1.30e-02
|
2.61e-02
|
PRC2-methylates-histones-and-DNA
|
14
|
1.42e-02
|
6.39e-02
|
0.52900
|
-4.49e-01
|
0.279000
|
3.65e-03
|
7.02e-02
|
Defective-C1GALT1C1-causes-Tn-polyagglutination-syndrome-(TNPS)
|
13
|
4.01e-02
|
1.34e-01
|
0.52700
|
3.67e-01
|
-0.378000
|
2.20e-02
|
1.81e-02
|
Defective-B3GALT6-causes-EDSP2-and-SEMDJL1
|
18
|
7.95e-04
|
6.27e-03
|
0.52500
|
-2.03e-01
|
0.484000
|
1.35e-01
|
3.81e-04
|
Defective-B3GAT3-causes-JDSSDHD
|
18
|
6.49e-04
|
5.31e-03
|
0.52400
|
-1.95e-01
|
0.486000
|
1.51e-01
|
3.54e-04
|
Keratan-sulfate-degradation
|
10
|
8.60e-02
|
2.15e-01
|
0.52200
|
-3.50e-01
|
0.388000
|
5.54e-02
|
3.38e-02
|
Interleukin-35-Signalling
|
12
|
4.29e-02
|
1.40e-01
|
0.52100
|
-4.16e-01
|
0.314000
|
1.25e-02
|
5.98e-02
|
Elevation-of-cytosolic-Ca2+-levels
|
15
|
1.71e-03
|
1.15e-02
|
0.51900
|
4.87e-01
|
-0.177000
|
1.08e-03
|
2.34e-01
|
Acetylcholine-Neurotransmitter-Release-Cycle
|
14
|
2.15e-02
|
8.70e-02
|
0.51500
|
4.28e-01
|
-0.288000
|
5.60e-03
|
6.24e-02
|
Dermatan-sulfate-biosynthesis
|
10
|
3.78e-02
|
1.30e-01
|
0.51300
|
-2.35e-01
|
0.455000
|
1.97e-01
|
1.26e-02
|
Sodium/Calcium-exchangers
|
10
|
3.58e-02
|
1.26e-01
|
0.51000
|
4.57e-01
|
-0.227000
|
1.24e-02
|
2.14e-01
|
Insulin-receptor-recycling
|
25
|
1.02e-04
|
1.15e-03
|
0.50800
|
4.67e-01
|
-0.200000
|
5.22e-05
|
8.30e-02
|
Interleukin-27-signaling
|
11
|
3.97e-02
|
1.34e-01
|
0.50400
|
-4.37e-01
|
0.250000
|
1.20e-02
|
1.51e-01
|
MASTL-Facilitates-Mitotic-Progression
|
10
|
9.71e-02
|
2.34e-01
|
0.50200
|
3.87e-01
|
-0.320000
|
3.41e-02
|
7.96e-02
|
Fertilization
|
19
|
1.03e-02
|
4.92e-02
|
0.50000
|
3.99e-01
|
-0.302000
|
2.62e-03
|
2.26e-02
|
N-glycan-trimming-in-the-ER-and-Calnexin/Calreticulin-cycle
|
33
|
1.54e-04
|
1.60e-03
|
0.49900
|
-4.20e-01
|
0.268000
|
2.89e-05
|
7.69e-03
|
NOTCH2-intracellular-domain-regulates-transcription
|
11
|
8.14e-02
|
2.07e-01
|
0.49800
|
-3.21e-01
|
0.381000
|
6.50e-02
|
2.86e-02
|
Major-pathway-of-rRNA-processing-in-the-nucleolus-and-cytosol
|
162
|
6.41e-17
|
3.65e-15
|
0.49200
|
3.00e-01
|
-0.390000
|
4.39e-11
|
9.57e-18
|
Defective-B4GALT7-causes-EDS,-progeroid-type
|
18
|
1.40e-03
|
1.00e-02
|
0.48800
|
-1.74e-01
|
0.456000
|
2.00e-01
|
8.11e-04
|
Assembly-Of-The-HIV-Virion
|
14
|
3.56e-02
|
1.26e-01
|
0.48600
|
2.78e-01
|
-0.399000
|
7.22e-02
|
9.81e-03
|
IKK-complex-recruitment-mediated-by-RIP1
|
21
|
1.56e-04
|
1.61e-03
|
0.48600
|
1.38e-01
|
-0.466000
|
2.74e-01
|
2.20e-04
|
Calnexin/calreticulin-cycle
|
24
|
1.91e-03
|
1.25e-02
|
0.48500
|
-4.15e-01
|
0.251000
|
4.36e-04
|
3.35e-02
|
Aspartate-and-asparagine-metabolism
|
11
|
6.37e-02
|
1.79e-01
|
0.48300
|
2.59e-01
|
-0.408000
|
1.37e-01
|
1.92e-02
|
ATF6-(ATF6-alpha)-activates-chaperone-genes
|
10
|
3.66e-02
|
1.27e-01
|
0.48200
|
-4.43e-01
|
0.190000
|
1.52e-02
|
2.98e-01
|
NOTCH3-Intracellular-Domain-Regulates-Transcription
|
25
|
3.41e-03
|
2.03e-02
|
0.48100
|
-2.84e-01
|
0.389000
|
1.39e-02
|
7.67e-04
|
Signaling-by-ROBO-receptors
|
192
|
3.39e-18
|
2.10e-16
|
0.47800
|
3.06e-01
|
-0.367000
|
2.26e-13
|
1.58e-18
|
Regulation-of-signaling-by-CBL
|
18
|
2.06e-02
|
8.40e-02
|
0.47800
|
-2.95e-01
|
0.376000
|
3.01e-02
|
5.77e-03
|
Condensation-of-Prometaphase-Chromosomes
|
11
|
9.68e-02
|
2.34e-01
|
0.47400
|
3.73e-01
|
-0.293000
|
3.23e-02
|
9.26e-02
|
alpha-linolenic-(omega3)-and-linoleic-(omega6)-acid-metabolism
|
12
|
2.91e-03
|
1.79e-02
|
0.47200
|
7.89e-02
|
-0.465000
|
6.36e-01
|
5.25e-03
|
alpha-linolenic-acid-(ALA)-metabolism
|
12
|
2.91e-03
|
1.79e-02
|
0.47200
|
7.89e-02
|
-0.465000
|
6.36e-01
|
5.25e-03
|
Membrane-binding-and-targetting-of-GAG-proteins
|
12
|
6.65e-02
|
1.85e-01
|
0.46700
|
2.59e-01
|
-0.388000
|
1.20e-01
|
1.99e-02
|
Synthesis-And-Processing-Of-GAG,-GAGPOL-Polyproteins
|
12
|
6.65e-02
|
1.85e-01
|
0.46700
|
2.59e-01
|
-0.388000
|
1.20e-01
|
1.99e-02
|
ABC-transporters-in-lipid-homeostasis
|
17
|
1.85e-02
|
7.74e-02
|
0.45400
|
2.29e-01
|
-0.392000
|
1.02e-01
|
5.13e-03
|
RMTs-methylate-histone-arginines
|
29
|
3.44e-03
|
2.04e-02
|
0.45400
|
-2.78e-01
|
0.358000
|
9.50e-03
|
8.32e-04
|
Chondroitin-sulfate/dermatan-sulfate-metabolism
|
48
|
3.46e-05
|
4.88e-04
|
0.45300
|
-2.50e-01
|
0.378000
|
2.71e-03
|
5.89e-06
|
TRAF6-mediated-NF-kB-activation
|
21
|
2.22e-02
|
8.83e-02
|
0.44900
|
3.02e-01
|
-0.333000
|
1.66e-02
|
8.30e-03
|
Other-semaphorin-interactions
|
19
|
1.00e-03
|
7.51e-03
|
0.44800
|
-1.22e-01
|
0.431000
|
3.57e-01
|
1.13e-03
|
Transferrin-endocytosis-and-recycling
|
29
|
1.98e-04
|
2.00e-03
|
0.44500
|
4.13e-01
|
-0.166000
|
1.18e-04
|
1.21e-01
|
Formation-of-the-beta-catenin:TCF-transactivating-complex
|
32
|
5.96e-04
|
4.96e-03
|
0.44400
|
-2.17e-01
|
0.388000
|
3.36e-02
|
1.46e-04
|
rRNA-processing-in-the-nucleus-and-cytosol
|
172
|
6.74e-15
|
3.22e-13
|
0.44400
|
2.66e-01
|
-0.355000
|
1.75e-09
|
8.42e-16
|
WNT-ligand-biogenesis-and-trafficking
|
23
|
1.16e-02
|
5.41e-02
|
0.44100
|
2.56e-01
|
-0.359000
|
3.38e-02
|
2.84e-03
|
Glutamate-Neurotransmitter-Release-Cycle
|
24
|
1.05e-02
|
4.97e-02
|
0.43900
|
3.55e-01
|
-0.258000
|
2.57e-03
|
2.88e-02
|
Activation-of-the-TFAP2-(AP-2)-family-of-transcription-factors
|
10
|
5.10e-02
|
1.55e-01
|
0.43800
|
4.10e-01
|
-0.154000
|
2.47e-02
|
4.00e-01
|
Signal-regulatory-protein-family-interactions
|
11
|
1.12e-01
|
2.55e-01
|
0.43700
|
-2.40e-01
|
0.364000
|
1.67e-01
|
3.63e-02
|
Budding-and-maturation-of-HIV-virion
|
25
|
1.47e-02
|
6.58e-02
|
0.43500
|
3.15e-01
|
-0.300000
|
6.39e-03
|
9.48e-03
|
rRNA-processing
|
191
|
1.49e-15
|
7.91e-14
|
0.43400
|
2.65e-01
|
-0.344000
|
2.63e-10
|
2.28e-16
|
Na+/Cl–dependent-neurotransmitter-transporters
|
18
|
4.01e-02
|
1.34e-01
|
0.43300
|
2.64e-01
|
-0.343000
|
5.26e-02
|
1.18e-02
|
Signaling-by-FGFR4-in-disease
|
11
|
2.85e-02
|
1.06e-01
|
0.43000
|
1.25e-01
|
-0.412000
|
4.72e-01
|
1.80e-02
|
Plasma-lipoprotein-remodeling
|
30
|
3.18e-04
|
2.98e-03
|
0.43000
|
1.65e-01
|
-0.397000
|
1.18e-01
|
1.67e-04
|
GPVI-mediated-activation-cascade
|
31
|
5.70e-03
|
3.08e-02
|
0.43000
|
-2.85e-01
|
0.321000
|
6.04e-03
|
1.94e-03
|
Regulation-of-IFNA-signaling
|
12
|
8.88e-02
|
2.18e-01
|
0.42700
|
-2.22e-01
|
0.365000
|
1.83e-01
|
2.86e-02
|
Interleukin-6-signaling
|
11
|
1.67e-01
|
3.35e-01
|
0.42700
|
-2.91e-01
|
0.312000
|
9.49e-02
|
7.30e-02
|
Synaptic-adhesion-like-molecules
|
21
|
1.05e-03
|
7.80e-03
|
0.42600
|
4.10e-01
|
-0.117000
|
1.15e-03
|
3.52e-01
|
Interleukin-3,-Interleukin-5-and-GM-CSF-signaling
|
40
|
1.54e-03
|
1.05e-02
|
0.42600
|
-2.93e-01
|
0.310000
|
1.36e-03
|
7.02e-04
|
Defective-EXT1-causes-exostoses-1,-TRPS2-and-CHDS
|
13
|
7.71e-03
|
3.85e-02
|
0.42600
|
-8.49e-02
|
0.417000
|
5.96e-01
|
9.22e-03
|
Defective-EXT2-causes-exostoses-2
|
13
|
7.71e-03
|
3.85e-02
|
0.42600
|
-8.49e-02
|
0.417000
|
5.96e-01
|
9.22e-03
|
Signaling-by-Leptin
|
10
|
8.67e-02
|
2.15e-01
|
0.42400
|
1.76e-01
|
-0.385000
|
3.35e-01
|
3.48e-02
|
Crosslinking-of-collagen-fibrils
|
10
|
2.40e-04
|
2.41e-03
|
0.42300
|
3.44e-01
|
0.247000
|
5.98e-02
|
1.76e-01
|
ERCC6-(CSB)-and-EHMT2-(G9a)-positively-regulate-rRNA-expression
|
16
|
5.06e-02
|
1.55e-01
|
0.42300
|
-2.34e-01
|
0.353000
|
1.05e-01
|
1.46e-02
|
Regulation-of-TLR-by-endogenous-ligand
|
16
|
6.47e-02
|
1.81e-01
|
0.42300
|
2.57e-01
|
-0.336000
|
7.48e-02
|
2.01e-02
|
Regulation-of-innate-immune-responses-to-cytosolic-DNA
|
12
|
1.11e-01
|
2.55e-01
|
0.42100
|
-3.49e-01
|
0.236000
|
3.61e-02
|
1.57e-01
|
Translesion-synthesis-by-REV1
|
15
|
5.68e-02
|
1.68e-01
|
0.42100
|
3.56e-01
|
-0.225000
|
1.69e-02
|
1.32e-01
|
Translesion-synthesis-by-POLK
|
16
|
2.37e-02
|
9.27e-02
|
0.42100
|
3.80e-01
|
-0.181000
|
8.48e-03
|
2.09e-01
|
NOTCH4-Intracellular-Domain-Regulates-Transcription
|
20
|
2.79e-02
|
1.05e-01
|
0.42000
|
-2.40e-01
|
0.345000
|
6.34e-02
|
7.48e-03
|
RUNX3-regulates-NOTCH-signaling
|
14
|
1.04e-01
|
2.44e-01
|
0.42000
|
-3.21e-01
|
0.270000
|
3.74e-02
|
7.98e-02
|
Immunoregulatory-interactions-between-a-Lymphoid-and-a-non-Lymphoid-cell
|
94
|
1.69e-07
|
5.69e-06
|
0.41900
|
-2.58e-01
|
0.330000
|
1.50e-05
|
3.11e-08
|
Norepinephrine-Neurotransmitter-Release-Cycle
|
18
|
1.98e-02
|
8.16e-02
|
0.41800
|
3.72e-01
|
-0.192000
|
6.33e-03
|
1.58e-01
|
eNOS-activation
|
11
|
7.46e-02
|
1.98e-01
|
0.41500
|
-3.78e-01
|
0.171000
|
2.99e-02
|
3.25e-01
|
Signaling-by-PDGF
|
53
|
5.19e-05
|
6.52e-04
|
0.41300
|
-2.18e-01
|
0.351000
|
6.10e-03
|
9.66e-06
|
Pyrimidine-salvage
|
10
|
2.10e-01
|
3.83e-01
|
0.41300
|
3.14e-01
|
-0.268000
|
8.55e-02
|
1.42e-01
|
RUNX1-interacts-with-co-factors-whose-precise-effect-on-RUNX1-targets-is-not-known
|
36
|
2.77e-03
|
1.73e-02
|
0.41100
|
-3.29e-01
|
0.246000
|
6.28e-04
|
1.06e-02
|
Interleukin-2-family-signaling
|
40
|
1.94e-03
|
1.26e-02
|
0.41100
|
-2.61e-01
|
0.317000
|
4.26e-03
|
5.16e-04
|
Deregulated-CDK5-triggers-multiple-neurodegenerative-pathways-in-Alzheimer’s-disease-models
|
22
|
3.81e-02
|
1.30e-01
|
0.40700
|
3.00e-01
|
-0.274000
|
1.47e-02
|
2.60e-02
|
Neurodegenerative-Diseases
|
22
|
3.81e-02
|
1.30e-01
|
0.40700
|
3.00e-01
|
-0.274000
|
1.47e-02
|
2.60e-02
|
Plasma-lipoprotein-assembly
|
17
|
4.75e-03
|
2.67e-02
|
0.40600
|
9.87e-02
|
-0.394000
|
4.81e-01
|
4.94e-03
|
Regulation-of-gene-expression-in-late-stage-(branching-morphogenesis)-pancreatic-bud-precursor-cells
|
14
|
1.29e-01
|
2.82e-01
|
0.40500
|
-2.92e-01
|
0.281000
|
5.84e-02
|
6.87e-02
|
RHOBTB2-GTPase-cycle
|
20
|
1.09e-02
|
5.16e-02
|
0.40500
|
-3.69e-01
|
0.166000
|
4.22e-03
|
1.98e-01
|
Lysine-catabolism
|
12
|
1.46e-01
|
3.06e-01
|
0.40500
|
-3.26e-01
|
0.240000
|
5.04e-02
|
1.50e-01
|
Synthesis,-secretion,-and-deacylation-of-Ghrelin
|
15
|
1.28e-02
|
5.88e-02
|
0.40400
|
1.13e-01
|
-0.388000
|
4.47e-01
|
9.33e-03
|
Endosomal-Sorting-Complex-Required-For-Transport-(ESCRT)
|
28
|
1.56e-02
|
6.84e-02
|
0.40300
|
3.07e-01
|
-0.260000
|
4.88e-03
|
1.70e-02
|
RHO-GTPases-Activate-ROCKs
|
18
|
4.10e-02
|
1.36e-01
|
0.40200
|
3.43e-01
|
-0.211000
|
1.18e-02
|
1.21e-01
|
Cargo-trafficking-to-the-periciliary-membrane
|
49
|
8.08e-04
|
6.34e-03
|
0.40200
|
-2.68e-01
|
0.299000
|
1.18e-03
|
2.87e-04
|
Receptor-type-tyrosine-protein-phosphatases
|
19
|
9.92e-04
|
7.46e-03
|
0.40100
|
3.97e-01
|
-0.058200
|
2.76e-03
|
6.60e-01
|
APC/C:Cdc20-mediated-degradation-of-Cyclin-B
|
23
|
3.67e-02
|
1.27e-01
|
0.40100
|
2.73e-01
|
-0.293000
|
2.34e-02
|
1.49e-02
|
MET-receptor-recycling
|
10
|
7.04e-02
|
1.91e-01
|
0.39900
|
-3.79e-01
|
0.126000
|
3.80e-02
|
4.89e-01
|
Abacavir-transport-and-metabolism
|
10
|
1.35e-01
|
2.94e-01
|
0.39900
|
-1.81e-01
|
0.355000
|
3.22e-01
|
5.17e-02
|
Josephin-domain-DUBs
|
10
|
1.65e-01
|
3.33e-01
|
0.39700
|
-3.43e-01
|
0.200000
|
6.01e-02
|
2.73e-01
|
Platelet-calcium-homeostasis
|
27
|
3.67e-04
|
3.32e-03
|
0.39700
|
3.84e-01
|
-0.103000
|
5.57e-04
|
3.56e-01
|
Mitotic-Telophase/Cytokinesis
|
13
|
1.17e-02
|
5.45e-02
|
0.39700
|
6.79e-02
|
-0.391000
|
6.72e-01
|
1.46e-02
|
Termination-of-O-glycan-biosynthesis
|
19
|
7.35e-03
|
3.73e-02
|
0.39500
|
3.74e-01
|
-0.125000
|
4.72e-03
|
3.45e-01
|
Mitochondrial-protein-import
|
60
|
9.07e-05
|
1.05e-03
|
0.39500
|
2.29e-01
|
-0.322000
|
2.17e-03
|
1.62e-05
|
Cohesin-Loading-onto-Chromatin
|
10
|
1.54e-03
|
1.05e-02
|
0.39500
|
-1.47e-01
|
-0.366000
|
4.21e-01
|
4.49e-02
|
Ras-activation-upon-Ca2+-influx-through-NMDA-receptor
|
20
|
5.11e-02
|
1.55e-01
|
0.39000
|
3.14e-01
|
-0.231000
|
1.50e-02
|
7.36e-02
|
Pyruvate-metabolism-and-Citric-Acid-(TCA)-cycle
|
52
|
3.74e-04
|
3.36e-03
|
0.38900
|
2.23e-01
|
-0.318000
|
5.34e-03
|
7.15e-05
|
Heparan-sulfate/heparin-(HS-GAG)-metabolism
|
50
|
2.92e-06
|
8.01e-05
|
0.38900
|
-1.20e-01
|
0.370000
|
1.43e-01
|
6.04e-06
|
IRAK2-mediated-activation-of-TAK1-complex-upon-TLR7/8-or-9-stimulation
|
14
|
8.70e-02
|
2.15e-01
|
0.38600
|
1.89e-01
|
-0.336000
|
2.21e-01
|
2.93e-02
|
Pyrimidine-catabolism
|
12
|
1.38e-01
|
2.95e-01
|
0.38500
|
1.99e-01
|
-0.330000
|
2.32e-01
|
4.80e-02
|
Adenylate-cyclase-activating-pathway
|
10
|
1.67e-01
|
3.35e-01
|
0.38500
|
-1.83e-01
|
0.339000
|
3.17e-01
|
6.35e-02
|
Antigen-activates-B-Cell-Receptor-(BCR)-leading-to-generation-of-second-messengers
|
42
|
4.05e-03
|
2.34e-02
|
0.38300
|
-2.79e-01
|
0.263000
|
1.74e-03
|
3.22e-03
|
Prolactin-receptor-signaling
|
10
|
2.13e-02
|
8.64e-02
|
0.38000
|
-3.80e-01
|
0.015500
|
3.76e-02
|
9.32e-01
|
N-Glycan-antennae-elongation
|
14
|
4.76e-02
|
1.49e-01
|
0.37900
|
3.53e-01
|
-0.138000
|
2.21e-02
|
3.71e-01
|
Mucopolysaccharidoses
|
11
|
1.36e-01
|
2.94e-01
|
0.37900
|
-3.38e-01
|
0.172000
|
5.24e-02
|
3.24e-01
|
Biotin-transport-and-metabolism
|
11
|
2.45e-01
|
4.21e-01
|
0.37800
|
-2.62e-01
|
0.273000
|
1.32e-01
|
1.17e-01
|
Heme-biosynthesis
|
14
|
1.67e-01
|
3.35e-01
|
0.37800
|
-2.75e-01
|
0.259000
|
7.48e-02
|
9.28e-02
|
Neurotoxicity-of-clostridium-toxins
|
10
|
2.38e-01
|
4.14e-01
|
0.37600
|
2.15e-01
|
-0.309000
|
2.40e-01
|
9.03e-02
|
Condensation-of-Prophase-Chromosomes
|
14
|
1.34e-01
|
2.91e-01
|
0.37600
|
3.10e-01
|
-0.213000
|
4.48e-02
|
1.68e-01
|
Synthesis,-secretion,-and-inactivation-of-Glucose-dependent-Insulinotropic-Polypeptide-(GIP)
|
11
|
6.34e-03
|
3.32e-02
|
0.37500
|
-4.45e-02
|
-0.372000
|
7.98e-01
|
3.26e-02
|
Beta-oxidation-of-very-long-chain-fatty-acids
|
11
|
1.12e-03
|
8.23e-03
|
0.37200
|
-1.81e-01
|
-0.325000
|
2.98e-01
|
6.20e-02
|
Aberrant-regulation-of-mitotic-G1/S-transition-in-cancer-due-to-RB1-defects
|
17
|
2.20e-02
|
8.79e-02
|
0.36900
|
3.50e-01
|
-0.119000
|
1.25e-02
|
3.97e-01
|
Defective-binding-of-RB1-mutants-to-E2F1,(E2F2,-E2F3)
|
17
|
2.20e-02
|
8.79e-02
|
0.36900
|
3.50e-01
|
-0.119000
|
1.25e-02
|
3.97e-01
|
Synthesis-of-very-long-chain-fatty-acyl-CoAs
|
21
|
5.50e-02
|
1.64e-01
|
0.36900
|
2.09e-01
|
-0.304000
|
9.73e-02
|
1.60e-02
|
Cytosolic-iron-sulfur-cluster-assembly
|
11
|
3.53e-03
|
2.09e-02
|
0.36800
|
3.56e-01
|
0.094800
|
4.09e-02
|
5.86e-01
|
The-role-of-Nef-in-HIV-1-replication-and-disease-pathogenesis
|
27
|
7.75e-03
|
3.85e-02
|
0.36800
|
-1.58e-01
|
0.333000
|
1.56e-01
|
2.75e-03
|
Chemokine-receptors-bind-chemokines
|
42
|
6.12e-03
|
3.22e-02
|
0.36800
|
-2.49e-01
|
0.271000
|
5.17e-03
|
2.39e-03
|
G1/S-DNA-Damage-Checkpoints
|
64
|
3.19e-06
|
8.58e-05
|
0.36700
|
1.39e-01
|
-0.340000
|
5.40e-02
|
2.51e-06
|
Gamma-carboxylation-of-protein-precursors
|
10
|
8.13e-02
|
2.07e-01
|
0.36700
|
-9.38e-02
|
0.354000
|
6.07e-01
|
5.22e-02
|
Translation
|
255
|
1.99e-15
|
1.02e-13
|
0.36700
|
2.13e-01
|
-0.298000
|
4.53e-09
|
2.01e-16
|
Disorders-of-Developmental-Biology
|
11
|
1.69e-01
|
3.37e-01
|
0.36600
|
-3.22e-01
|
0.174000
|
6.45e-02
|
3.18e-01
|
Disorders-of-Nervous-System-Development
|
11
|
1.69e-01
|
3.37e-01
|
0.36600
|
-3.22e-01
|
0.174000
|
6.45e-02
|
3.18e-01
|
Loss-of-function-of-MECP2-in-Rett-syndrome
|
11
|
1.69e-01
|
3.37e-01
|
0.36600
|
-3.22e-01
|
0.174000
|
6.45e-02
|
3.18e-01
|
Pervasive-developmental-disorders
|
11
|
1.69e-01
|
3.37e-01
|
0.36600
|
-3.22e-01
|
0.174000
|
6.45e-02
|
3.18e-01
|
CDT1-association-with-the-CDC6:ORC:origin-complex
|
57
|
1.85e-06
|
5.37e-05
|
0.36300
|
1.04e-01
|
-0.348000
|
1.73e-01
|
5.49e-06
|
Regulation-of-FOXO-transcriptional-activity-by-acetylation
|
10
|
5.92e-02
|
1.73e-01
|
0.36200
|
6.31e-02
|
-0.356000
|
7.30e-01
|
5.10e-02
|
Interleukin-receptor-SHC-signaling
|
25
|
3.03e-02
|
1.12e-01
|
0.36100
|
-1.93e-01
|
0.305000
|
9.41e-02
|
8.35e-03
|
Signaling-by-SCF-KIT
|
42
|
5.16e-03
|
2.84e-02
|
0.36000
|
-2.17e-01
|
0.288000
|
1.52e-02
|
1.23e-03
|
Cyclin-A/B1/B2-associated-events-during-G2/M-transition
|
24
|
3.83e-02
|
1.30e-01
|
0.36000
|
3.01e-01
|
-0.198000
|
1.07e-02
|
9.32e-02
|
Phosphorylation-of-the-APC/C
|
20
|
9.91e-02
|
2.37e-01
|
0.36000
|
2.61e-01
|
-0.248000
|
4.33e-02
|
5.51e-02
|
TRAF6-mediated-induction-of-TAK1-complex-within-TLR4-complex
|
15
|
1.15e-01
|
2.60e-01
|
0.36000
|
1.85e-01
|
-0.308000
|
2.14e-01
|
3.87e-02
|
TP53-Regulates-Transcription-of-Caspase-Activators-and-Caspases
|
11
|
2.80e-01
|
4.59e-01
|
0.35900
|
-2.63e-01
|
0.245000
|
1.31e-01
|
1.59e-01
|
Activation-of-APC/C-and-APC/C:Cdc20-mediated-degradation-of-mitotic-proteins
|
74
|
1.69e-05
|
2.95e-04
|
0.35700
|
1.76e-01
|
-0.311000
|
8.95e-03
|
3.73e-06
|
Digestion-and-absorption
|
15
|
1.71e-01
|
3.39e-01
|
0.35600
|
2.76e-01
|
-0.226000
|
6.45e-02
|
1.30e-01
|
p53-Dependent-G1-DNA-Damage-Response
|
62
|
7.35e-06
|
1.56e-04
|
0.35600
|
1.30e-01
|
-0.331000
|
7.61e-02
|
6.34e-06
|
p53-Dependent-G1/S-DNA-damage-checkpoint
|
62
|
7.35e-06
|
1.56e-04
|
0.35600
|
1.30e-01
|
-0.331000
|
7.61e-02
|
6.34e-06
|
Negative-regulation-of-NOTCH4-signaling
|
51
|
4.08e-05
|
5.65e-04
|
0.35500
|
1.22e-01
|
-0.333000
|
1.31e-01
|
3.78e-05
|
mitochondrial-fatty-acid-beta-oxidation-of-saturated-fatty-acids
|
10
|
2.56e-03
|
1.61e-02
|
0.35400
|
-2.52e-01
|
-0.249000
|
1.68e-01
|
1.72e-01
|
APC/C:Cdc20-mediated-degradation-of-mitotic-proteins
|
73
|
1.85e-05
|
3.13e-04
|
0.35400
|
1.70e-01
|
-0.310000
|
1.19e-02
|
4.44e-06
|
CREB1-phosphorylation-through-NMDA-receptor-mediated-activation-of-RAS-signaling
|
28
|
2.93e-02
|
1.09e-01
|
0.35300
|
2.90e-01
|
-0.202000
|
7.88e-03
|
6.46e-02
|
Serotonin-Neurotransmitter-Release-Cycle
|
18
|
1.72e-02
|
7.33e-02
|
0.35300
|
3.39e-01
|
-0.095100
|
1.26e-02
|
4.85e-01
|
Glucose-metabolism
|
85
|
3.13e-05
|
4.63e-04
|
0.35200
|
2.85e-01
|
-0.206000
|
5.39e-06
|
1.03e-03
|
Assembly-of-active-LPL-and-LIPC-lipase-complexes
|
18
|
3.59e-02
|
1.26e-01
|
0.35100
|
1.29e-01
|
-0.326000
|
3.43e-01
|
1.65e-02
|
Cholesterol-biosynthesis
|
23
|
3.37e-02
|
1.22e-01
|
0.35000
|
1.67e-01
|
-0.308000
|
1.64e-01
|
1.06e-02
|
Recognition-of-DNA-damage-by-PCNA-containing-replication-complex
|
29
|
2.63e-02
|
1.01e-01
|
0.35000
|
2.89e-01
|
-0.197000
|
6.99e-03
|
6.63e-02
|
Ubiquitin-Mediated-Degradation-of-Phosphorylated-Cdc25A
|
50
|
7.30e-06
|
1.56e-04
|
0.35000
|
8.23e-02
|
-0.340000
|
3.14e-01
|
3.21e-05
|
p53-Independent-DNA-Damage-Response
|
50
|
7.30e-06
|
1.56e-04
|
0.35000
|
8.23e-02
|
-0.340000
|
3.14e-01
|
3.21e-05
|
p53-Independent-G1/S-DNA-damage-checkpoint
|
50
|
7.30e-06
|
1.56e-04
|
0.35000
|
8.23e-02
|
-0.340000
|
3.14e-01
|
3.21e-05
|
rRNA-processing-in-the-mitochondrion
|
19
|
1.29e-01
|
2.83e-01
|
0.34700
|
2.53e-01
|
-0.237000
|
5.58e-02
|
7.36e-02
|
Role-of-LAT2/NTAL/LAB-on-calcium-mobilization
|
24
|
5.47e-02
|
1.63e-01
|
0.34700
|
-2.84e-01
|
0.199000
|
1.60e-02
|
9.13e-02
|
Polo-like-kinase-mediated-events
|
16
|
1.80e-01
|
3.51e-01
|
0.34700
|
2.50e-01
|
-0.241000
|
8.36e-02
|
9.57e-02
|
Apoptotic-cleavage-of-cell-adhesion–proteins
|
10
|
6.09e-02
|
1.74e-01
|
0.34600
|
3.43e-01
|
-0.044100
|
6.00e-02
|
8.09e-01
|
APC/C:Cdc20-mediated-degradation-of-Securin
|
66
|
7.58e-06
|
1.58e-04
|
0.34600
|
1.28e-01
|
-0.321000
|
7.30e-02
|
6.27e-06
|
GRB2-events-in-EGFR-signaling
|
12
|
2.43e-01
|
4.19e-01
|
0.34500
|
2.02e-01
|
-0.280000
|
2.25e-01
|
9.31e-02
|
Chk1/Chk2(Cds1)-mediated-inactivation-of-Cyclin-B:Cdk1-complex
|
12
|
2.80e-01
|
4.58e-01
|
0.34400
|
2.34e-01
|
-0.253000
|
1.61e-01
|
1.29e-01
|
Inflammasomes
|
21
|
6.76e-02
|
1.87e-01
|
0.34400
|
-1.83e-01
|
0.292000
|
1.47e-01
|
2.07e-02
|
Vif-mediated-degradation-of-APOBEC3G
|
49
|
5.56e-06
|
1.35e-04
|
0.34400
|
6.67e-02
|
-0.338000
|
4.19e-01
|
4.31e-05
|
SCF(Skp2)-mediated-degradation-of-p27/p21
|
57
|
6.08e-05
|
7.51e-04
|
0.34300
|
1.33e-01
|
-0.317000
|
8.32e-02
|
3.48e-05
|
Triglyceride-biosynthesis
|
11
|
2.03e-01
|
3.77e-01
|
0.34300
|
1.60e-01
|
-0.304000
|
3.58e-01
|
8.10e-02
|
Acyl-chain-remodelling-of-PS
|
18
|
1.52e-01
|
3.14e-01
|
0.34300
|
2.42e-01
|
-0.243000
|
7.51e-02
|
7.45e-02
|
Gamma-carboxylation,-transport,-and-amino-terminal-cleavage-of-proteins
|
11
|
1.06e-01
|
2.47e-01
|
0.34300
|
-1.01e-01
|
0.328000
|
5.62e-01
|
5.98e-02
|
Intraflagellar-transport
|
34
|
1.65e-02
|
7.15e-02
|
0.34200
|
-1.91e-01
|
0.284000
|
5.39e-02
|
4.19e-03
|
Signaling-by-Hippo
|
20
|
4.95e-04
|
4.26e-03
|
0.34100
|
-3.39e-01
|
-0.040300
|
8.75e-03
|
7.55e-01
|
Transport-of-inorganic-cations/anions-and-amino-acids/oligopeptides
|
103
|
6.82e-07
|
2.15e-05
|
0.34100
|
2.99e-01
|
-0.164000
|
1.60e-07
|
3.92e-03
|
Receptor-Mediated-Mitophagy
|
11
|
1.39e-01
|
2.95e-01
|
0.33900
|
1.18e-01
|
-0.318000
|
4.99e-01
|
6.79e-02
|
Glucuronidation
|
13
|
2.61e-01
|
4.39e-01
|
0.33800
|
2.25e-01
|
-0.252000
|
1.60e-01
|
1.15e-01
|
Ketone-body-metabolism
|
10
|
1.45e-01
|
3.06e-01
|
0.33800
|
-3.21e-01
|
0.104000
|
7.85e-02
|
5.70e-01
|
APC/C:Cdh1-mediated-degradation-of-Cdc20-and-other-APC/C:Cdh1-targeted-proteins-in-late-mitosis/early-G1
|
72
|
1.34e-05
|
2.41e-04
|
0.33800
|
1.39e-01
|
-0.308000
|
4.12e-02
|
6.34e-06
|
APC:Cdc20-mediated-degradation-of-cell-cycle-proteins-prior-to-satisfation-of-the-cell-cycle-checkpoint
|
71
|
3.41e-05
|
4.87e-04
|
0.33700
|
1.50e-01
|
-0.301000
|
2.85e-02
|
1.11e-05
|
Stabilization-of-p53
|
54
|
8.61e-06
|
1.77e-04
|
0.33600
|
8.14e-02
|
-0.326000
|
3.00e-01
|
3.36e-05
|
SLBP-Dependent-Processing-of-Replication-Dependent-Histone-Pre-mRNAs
|
10
|
2.81e-01
|
4.59e-01
|
0.33600
|
-2.89e-01
|
0.171000
|
1.14e-01
|
3.48e-01
|
Regulation-of-RUNX1-Expression-and-Activity
|
17
|
1.37e-01
|
2.94e-01
|
0.33600
|
-1.86e-01
|
0.279000
|
1.84e-01
|
4.62e-02
|
Regulation-of-activated-PAK-2p34-by-proteasome-mediated-degradation
|
48
|
9.92e-06
|
1.94e-04
|
0.33500
|
6.03e-02
|
-0.330000
|
4.70e-01
|
7.68e-05
|
Signaling-by-NTRK3-(TRKC)
|
17
|
5.04e-04
|
4.32e-03
|
0.33500
|
3.18e-01
|
0.106000
|
2.33e-02
|
4.49e-01
|
MAP3K8-(TPL2)-dependent-MAPK1/3-activation
|
15
|
6.54e-02
|
1.83e-01
|
0.33500
|
1.10e-01
|
-0.316000
|
4.61e-01
|
3.40e-02
|
Scavenging-of-heme-from-plasma
|
23
|
3.02e-02
|
1.12e-01
|
0.33400
|
-3.04e-01
|
0.138000
|
1.16e-02
|
2.50e-01
|
Autodegradation-of-the-E3-ubiquitin-ligase-COP1
|
50
|
1.48e-05
|
2.64e-04
|
0.33200
|
7.11e-02
|
-0.325000
|
3.84e-01
|
7.05e-05
|
CDK-mediated-phosphorylation-and-removal-of-Cdc6
|
70
|
9.40e-06
|
1.88e-04
|
0.33200
|
1.22e-01
|
-0.309000
|
7.74e-02
|
7.76e-06
|
APC-Cdc20-mediated-degradation-of-Nek2A
|
25
|
8.47e-02
|
2.13e-01
|
0.33200
|
2.44e-01
|
-0.224000
|
3.43e-02
|
5.21e-02
|
Degradation-of-DVL
|
55
|
6.51e-06
|
1.51e-04
|
0.33100
|
7.41e-02
|
-0.323000
|
3.42e-01
|
3.39e-05
|
Processing-of-Intronless-Pre-mRNAs
|
17
|
4.21e-02
|
1.38e-01
|
0.33100
|
-3.16e-01
|
0.101000
|
2.43e-02
|
4.70e-01
|
TP53-Regulates-Transcription-of-Genes-Involved-in-G2-Cell-Cycle-Arrest
|
18
|
3.47e-02
|
1.23e-01
|
0.33100
|
3.15e-01
|
-0.100000
|
2.06e-02
|
4.63e-01
|
Autodegradation-of-Cdh1-by-Cdh1:APC/C
|
62
|
2.93e-05
|
4.38e-04
|
0.33000
|
1.16e-01
|
-0.309000
|
1.15e-01
|
2.61e-05
|
Branched-chain-amino-acid-catabolism
|
21
|
8.81e-03
|
4.29e-02
|
0.32900
|
-3.23e-01
|
0.064100
|
1.05e-02
|
6.11e-01
|
PI3K-events-in-ERBB4-signaling
|
10
|
2.33e-01
|
4.10e-01
|
0.32800
|
1.38e-01
|
-0.298000
|
4.51e-01
|
1.03e-01
|
HIV-elongation-arrest-and-recovery
|
29
|
3.43e-02
|
1.23e-01
|
0.32700
|
2.78e-01
|
-0.173000
|
9.66e-03
|
1.08e-01
|
Pausing-and-recovery-of-HIV-elongation
|
29
|
3.43e-02
|
1.23e-01
|
0.32700
|
2.78e-01
|
-0.173000
|
9.66e-03
|
1.08e-01
|
PIWI-interacting-RNA-(piRNA)-biogenesis
|
27
|
6.83e-02
|
1.88e-01
|
0.32700
|
2.54e-01
|
-0.206000
|
2.24e-02
|
6.41e-02
|
Cdc20:Phospho-APC/C-mediated-degradation-of-Cyclin-A
|
70
|
4.96e-05
|
6.34e-04
|
0.32700
|
1.39e-01
|
-0.295000
|
4.36e-02
|
1.92e-05
|
Translesion-synthesis-by-POLI
|
16
|
1.47e-01
|
3.07e-01
|
0.32600
|
2.81e-01
|
-0.166000
|
5.19e-02
|
2.50e-01
|
RA-biosynthesis-pathway
|
19
|
1.38e-01
|
2.95e-01
|
0.32600
|
-2.63e-01
|
0.192000
|
4.72e-02
|
1.47e-01
|
APC-truncation-mutants-have-impaired-AXIN-binding
|
14
|
6.08e-02
|
1.74e-01
|
0.32500
|
3.15e-01
|
-0.081200
|
4.11e-02
|
5.99e-01
|
AXIN-missense-mutants-destabilize-the-destruction-complex
|
14
|
6.08e-02
|
1.74e-01
|
0.32500
|
3.15e-01
|
-0.081200
|
4.11e-02
|
5.99e-01
|
Signaling-by-AMER1-mutants
|
14
|
6.08e-02
|
1.74e-01
|
0.32500
|
3.15e-01
|
-0.081200
|
4.11e-02
|
5.99e-01
|
Signaling-by-APC-mutants
|
14
|
6.08e-02
|
1.74e-01
|
0.32500
|
3.15e-01
|
-0.081200
|
4.11e-02
|
5.99e-01
|
Signaling-by-AXIN-mutants
|
14
|
6.08e-02
|
1.74e-01
|
0.32500
|
3.15e-01
|
-0.081200
|
4.11e-02
|
5.99e-01
|
Truncations-of-AMER1-destabilize-the-destruction-complex
|
14
|
6.08e-02
|
1.74e-01
|
0.32500
|
3.15e-01
|
-0.081200
|
4.11e-02
|
5.99e-01
|
ERBB2-Regulates-Cell-Motility
|
14
|
6.13e-02
|
1.75e-01
|
0.32500
|
8.05e-02
|
-0.314000
|
6.02e-01
|
4.16e-02
|
Degradation-of-AXIN
|
53
|
4.69e-05
|
6.10e-04
|
0.32300
|
8.81e-02
|
-0.311000
|
2.67e-01
|
9.12e-05
|
The-NLRP3-inflammasome
|
16
|
9.31e-02
|
2.27e-01
|
0.32000
|
-1.24e-01
|
0.295000
|
3.92e-01
|
4.07e-02
|
Mitochondrial-Fatty-Acid-Beta-Oxidation
|
34
|
1.63e-03
|
1.11e-02
|
0.32000
|
8.39e-02
|
-0.309000
|
3.97e-01
|
1.83e-03
|
Diseases-associated-with-glycosaminoglycan-metabolism
|
36
|
8.05e-03
|
3.97e-02
|
0.32000
|
-1.39e-01
|
0.288000
|
1.50e-01
|
2.78e-03
|
SUMOylation-of-DNA-methylation-proteins
|
16
|
1.80e-01
|
3.52e-01
|
0.31800
|
-2.67e-01
|
0.173000
|
6.46e-02
|
2.32e-01
|
Mitochondrial-translation-initiation
|
86
|
4.64e-04
|
4.05e-03
|
0.31700
|
2.24e-01
|
-0.224000
|
3.22e-04
|
3.24e-04
|
RHO-GTPases-Activate-NADPH-Oxidases
|
23
|
1.26e-01
|
2.77e-01
|
0.31600
|
-2.10e-01
|
0.236000
|
8.06e-02
|
5.02e-02
|
AUF1-(hnRNP-D0)-binds-and-destabilizes-mRNA
|
53
|
9.72e-06
|
1.92e-04
|
0.31600
|
5.29e-02
|
-0.312000
|
5.05e-01
|
8.68e-05
|
NIK–>noncanonical-NF-kB-signaling
|
57
|
4.48e-06
|
1.16e-04
|
0.31600
|
5.42e-02
|
-0.311000
|
4.79e-01
|
4.79e-05
|
KSRP-(KHSRP)-binds-and-destabilizes-mRNA
|
15
|
2.48e-01
|
4.25e-01
|
0.31600
|
-2.45e-01
|
0.199000
|
1.00e-01
|
1.82e-01
|
Collagen-chain-trimerization
|
43
|
1.52e-03
|
1.05e-02
|
0.31500
|
-1.13e-01
|
0.294000
|
1.98e-01
|
8.58e-04
|
RHOBTB1-GTPase-cycle
|
22
|
1.30e-04
|
1.40e-03
|
0.31400
|
-2.93e-01
|
-0.113000
|
1.73e-02
|
3.58e-01
|
Mitochondrial-translation-termination
|
86
|
5.32e-04
|
4.51e-03
|
0.31400
|
2.20e-01
|
-0.224000
|
4.06e-04
|
3.31e-04
|
FOXO-mediated-transcription-of-cell-cycle-genes
|
15
|
2.62e-01
|
4.41e-01
|
0.31400
|
2.36e-01
|
-0.207000
|
1.14e-01
|
1.65e-01
|
Dectin-1-mediated-noncanonical-NF-kB-signaling
|
60
|
5.21e-06
|
1.31e-04
|
0.31300
|
6.14e-02
|
-0.306000
|
4.11e-01
|
3.98e-05
|
p130Cas-linkage-to-MAPK-signaling-for-integrins
|
15
|
2.64e-01
|
4.43e-01
|
0.31200
|
2.36e-01
|
-0.203000
|
1.13e-01
|
1.72e-01
|
GRB2:SOS-provides-linkage-to-MAPK-signaling-for-Integrins
|
15
|
1.68e-01
|
3.35e-01
|
0.31200
|
2.76e-01
|
-0.146000
|
6.45e-02
|
3.28e-01
|
Regulation-of-MECP2-expression-and-activity
|
28
|
8.36e-02
|
2.11e-01
|
0.31100
|
-2.38e-01
|
0.200000
|
2.94e-02
|
6.67e-02
|
Pyruvate-metabolism
|
28
|
2.74e-02
|
1.04e-01
|
0.31100
|
1.32e-01
|
-0.281000
|
2.25e-01
|
1.00e-02
|
Transcriptional-regulation-of-testis-differentiation
|
12
|
1.88e-01
|
3.60e-01
|
0.31000
|
2.86e-01
|
-0.120000
|
8.57e-02
|
4.72e-01
|
APC/C-mediated-degradation-of-cell-cycle-proteins
|
85
|
6.82e-05
|
8.29e-04
|
0.31000
|
1.52e-01
|
-0.271000
|
1.56e-02
|
1.57e-05
|
Regulation-of-mitotic-cell-cycle
|
85
|
6.82e-05
|
8.29e-04
|
0.31000
|
1.52e-01
|
-0.271000
|
1.56e-02
|
1.57e-05
|
Amino-acids-regulate-mTORC1
|
53
|
1.65e-03
|
1.11e-02
|
0.31000
|
2.76e-01
|
-0.141000
|
5.01e-04
|
7.65e-02
|
Unblocking-of-NMDA-receptors,-glutamate-binding-and-activation
|
21
|
6.01e-02
|
1.74e-01
|
0.31000
|
2.84e-01
|
-0.125000
|
2.45e-02
|
3.21e-01
|
NF-kB-activation-through-FADD/RIP-1-pathway-mediated-by-caspase-8-and–10
|
11
|
1.81e-02
|
7.63e-02
|
0.31000
|
-8.18e-02
|
-0.299000
|
6.39e-01
|
8.64e-02
|
FCERI-mediated-Ca+2-mobilization
|
39
|
3.51e-02
|
1.24e-01
|
0.31000
|
-2.09e-01
|
0.228000
|
2.38e-02
|
1.36e-02
|
Mitochondrial-translation-elongation
|
86
|
6.76e-04
|
5.50e-03
|
0.30900
|
2.21e-01
|
-0.217000
|
4.03e-04
|
5.13e-04
|
ER-Quality-Control-Compartment-(ERQC)
|
19
|
7.63e-02
|
1.98e-01
|
0.30900
|
-2.84e-01
|
0.122000
|
3.22e-02
|
3.56e-01
|
Downstream-signal-transduction
|
29
|
8.25e-02
|
2.09e-01
|
0.30900
|
-2.06e-01
|
0.230000
|
5.48e-02
|
3.19e-02
|
TRP-channels
|
24
|
2.23e-02
|
8.86e-02
|
0.30900
|
2.93e-01
|
-0.097400
|
1.30e-02
|
4.09e-01
|
Removal-of-aminoterminal-propeptides-from-gamma-carboxylated-proteins
|
10
|
9.01e-02
|
2.21e-01
|
0.30800
|
-2.34e-02
|
0.308000
|
8.98e-01
|
9.21e-02
|
Signaling-by-NOTCH3
|
48
|
1.73e-02
|
7.35e-02
|
0.30800
|
-2.13e-01
|
0.222000
|
1.06e-02
|
7.67e-03
|
Pausing-and-recovery-of-Tat-mediated-HIV-elongation
|
27
|
4.46e-02
|
1.44e-01
|
0.30700
|
2.71e-01
|
-0.144000
|
1.46e-02
|
1.94e-01
|
Tat-mediated-HIV-elongation-arrest-and-recovery
|
27
|
4.46e-02
|
1.44e-01
|
0.30700
|
2.71e-01
|
-0.144000
|
1.46e-02
|
1.94e-01
|
LGI-ADAM-interactions
|
13
|
5.83e-03
|
3.10e-02
|
0.30700
|
1.18e-01
|
0.284000
|
4.61e-01
|
7.64e-02
|
FBXL7-down-regulates-AURKA-during-mitotic-entry-and-in-early-mitosis
|
53
|
2.54e-05
|
3.92e-04
|
0.30700
|
5.64e-02
|
-0.302000
|
4.78e-01
|
1.45e-04
|
FCGR3A-mediated-IL10-synthesis
|
49
|
1.43e-02
|
6.41e-02
|
0.30600
|
-1.94e-01
|
0.237000
|
1.89e-02
|
4.16e-03
|
RNA-Polymerase-III-Chain-Elongation
|
18
|
2.21e-01
|
3.95e-01
|
0.30600
|
2.26e-01
|
-0.205000
|
9.65e-02
|
1.31e-01
|
TBC/RABGAPs
|
43
|
2.38e-02
|
9.30e-02
|
0.30500
|
2.38e-01
|
-0.192000
|
7.02e-03
|
2.97e-02
|
IL-6-type-cytokine-receptor-ligand-interactions
|
16
|
2.06e-01
|
3.79e-01
|
0.30400
|
-2.56e-01
|
0.164000
|
7.59e-02
|
2.55e-01
|
NF-kB-is-activated-and-signals-survival
|
12
|
2.89e-01
|
4.65e-01
|
0.30400
|
1.56e-01
|
-0.261000
|
3.50e-01
|
1.17e-01
|
Vpu-mediated-degradation-of-CD4
|
50
|
4.41e-05
|
5.89e-04
|
0.30400
|
5.13e-02
|
-0.299000
|
5.30e-01
|
2.50e-04
|
DCC-mediated-attractive-signaling
|
13
|
3.17e-01
|
4.96e-01
|
0.30300
|
-1.83e-01
|
0.241000
|
2.53e-01
|
1.32e-01
|
CLEC7A-(Dectin-1)-induces-NFAT-activation
|
11
|
3.28e-01
|
5.04e-01
|
0.30300
|
2.59e-01
|
-0.158000
|
1.37e-01
|
3.65e-01
|
Ubiquitin-dependent-degradation-of-Cyclin-D
|
50
|
3.08e-04
|
2.96e-03
|
0.30300
|
8.63e-02
|
-0.290000
|
2.91e-01
|
3.83e-04
|
The-role-of-GTSE1-in-G2/M-progression-after-G2-checkpoint
|
58
|
1.64e-04
|
1.69e-03
|
0.30300
|
9.75e-02
|
-0.286000
|
1.99e-01
|
1.60e-04
|
SEMA3A-Plexin-repulsion-signaling-by-inhibiting-Integrin-adhesion
|
14
|
7.60e-03
|
3.84e-02
|
0.30200
|
8.07e-02
|
0.291000
|
6.01e-01
|
5.91e-02
|
Early-Phase-of-HIV-Life-Cycle
|
13
|
1.02e-01
|
2.43e-01
|
0.30100
|
2.93e-01
|
-0.071000
|
6.77e-02
|
6.57e-01
|
Regulation-of-APC/C-activators-between-G1/S-and-early-anaphase
|
78
|
1.29e-04
|
1.39e-03
|
0.30100
|
1.35e-01
|
-0.269000
|
3.94e-02
|
4.03e-05
|
Mitophagy
|
28
|
5.65e-02
|
1.67e-01
|
0.30000
|
1.51e-01
|
-0.259000
|
1.66e-01
|
1.76e-02
|
SCF-beta-TrCP-mediated-degradation-of-Emi1
|
53
|
5.03e-05
|
6.37e-04
|
0.29900
|
5.79e-02
|
-0.294000
|
4.66e-01
|
2.16e-04
|
DAP12-interactions
|
33
|
4.40e-02
|
1.43e-01
|
0.29800
|
-1.60e-01
|
0.251000
|
1.11e-01
|
1.26e-02
|
Regulation-of-TP53-Degradation
|
33
|
7.42e-02
|
1.98e-01
|
0.29800
|
2.09e-01
|
-0.212000
|
3.78e-02
|
3.49e-02
|
RAS-processing
|
18
|
1.11e-01
|
2.54e-01
|
0.29700
|
1.21e-01
|
-0.271000
|
3.74e-01
|
4.62e-02
|
PKA-activation-in-glucagon-signalling
|
16
|
1.79e-01
|
3.51e-01
|
0.29600
|
-1.39e-01
|
0.262000
|
3.36e-01
|
6.97e-02
|
Binding-and-Uptake-of-Ligands-by-Scavenger-Receptors
|
50
|
7.74e-03
|
3.85e-02
|
0.29600
|
-1.53e-01
|
0.253000
|
6.04e-02
|
1.94e-03
|
Costimulation-by-the-CD28-family
|
63
|
3.81e-03
|
2.22e-02
|
0.29500
|
-1.67e-01
|
0.243000
|
2.15e-02
|
8.44e-04
|
RIPK1-mediated-regulated-necrosis
|
26
|
5.72e-02
|
1.68e-01
|
0.29500
|
1.33e-01
|
-0.263000
|
2.42e-01
|
2.02e-02
|
Regulation-of-necroptotic-cell-death
|
26
|
5.72e-02
|
1.68e-01
|
0.29500
|
1.33e-01
|
-0.263000
|
2.42e-01
|
2.02e-02
|
Erythropoietin-activates-Phosphoinositide-3-kinase-(PI3K)
|
12
|
1.74e-02
|
7.39e-02
|
0.29400
|
-2.81e-01
|
-0.085800
|
9.14e-02
|
6.07e-01
|
Interleukin-15-signaling
|
13
|
3.37e-01
|
5.13e-01
|
0.29400
|
-2.35e-01
|
0.177000
|
1.42e-01
|
2.70e-01
|
Pentose-phosphate-pathway
|
12
|
1.61e-02
|
7.06e-02
|
0.29400
|
2.79e-01
|
0.093200
|
9.47e-02
|
5.76e-01
|
Long-term-potentiation
|
23
|
4.59e-02
|
1.45e-01
|
0.29200
|
2.74e-01
|
-0.101000
|
2.28e-02
|
4.02e-01
|
Transport-of-nucleosides-and-free-purine-and-pyrimidine-bases-across-the-plasma-membrane
|
10
|
4.22e-01
|
5.90e-01
|
0.29200
|
2.40e-01
|
-0.166000
|
1.89e-01
|
3.62e-01
|
Establishment-of-Sister-Chromatid-Cohesion
|
11
|
2.13e-02
|
8.63e-02
|
0.29200
|
-1.05e-01
|
-0.272000
|
5.46e-01
|
1.18e-01
|
Senescence-Associated-Secretory-Phenotype-(SASP)
|
48
|
2.29e-02
|
9.03e-02
|
0.29100
|
2.25e-01
|
-0.185000
|
6.93e-03
|
2.65e-02
|
Separation-of-Sister-Chromatids
|
167
|
5.39e-07
|
1.74e-05
|
0.29100
|
1.64e-01
|
-0.241000
|
2.46e-04
|
7.75e-08
|
Resolution-of-Sister-Chromatid-Cohesion
|
104
|
4.25e-04
|
3.77e-03
|
0.29000
|
2.09e-01
|
-0.201000
|
2.30e-04
|
3.99e-04
|
ROS-sensing-by-NFE2L2
|
55
|
7.11e-05
|
8.50e-04
|
0.29000
|
5.73e-02
|
-0.284000
|
4.62e-01
|
2.68e-04
|
Formation-of-tubulin-folding-intermediates-by-CCT/TriC
|
20
|
5.73e-02
|
1.68e-01
|
0.28900
|
-2.76e-01
|
0.087100
|
3.28e-02
|
5.00e-01
|
Interleukin-1-signaling
|
96
|
2.11e-05
|
3.44e-04
|
0.28800
|
1.21e-01
|
-0.262000
|
4.08e-02
|
9.14e-06
|
Amplification–of-signal-from-unattached–kinetochores-via-a-MAD2–inhibitory-signal
|
91
|
9.22e-04
|
6.97e-03
|
0.28600
|
2.24e-01
|
-0.179000
|
2.21e-04
|
3.20e-03
|
Amplification-of-signal-from-the-kinetochores
|
91
|
9.22e-04
|
6.97e-03
|
0.28600
|
2.24e-01
|
-0.179000
|
2.21e-04
|
3.20e-03
|
Activation-of-SMO
|
17
|
2.73e-01
|
4.52e-01
|
0.28600
|
-2.23e-01
|
0.179000
|
1.11e-01
|
2.02e-01
|
SUMOylation-of-immune-response-proteins
|
11
|
4.46e-01
|
6.16e-01
|
0.28600
|
2.11e-01
|
-0.192000
|
2.25e-01
|
2.70e-01
|
SHC1-events-in-ERBB4-signaling
|
14
|
3.41e-01
|
5.15e-01
|
0.28500
|
1.77e-01
|
-0.224000
|
2.52e-01
|
1.47e-01
|
PINK1-PRKN-Mediated-Mitophagy
|
21
|
1.53e-01
|
3.15e-01
|
0.28500
|
1.49e-01
|
-0.243000
|
2.37e-01
|
5.36e-02
|
DAP12-signaling
|
28
|
1.26e-01
|
2.77e-01
|
0.28400
|
-1.83e-01
|
0.217000
|
9.32e-02
|
4.66e-02
|
RNA-Polymerase-III-Transcription-Initiation-From-Type-3-Promoter
|
28
|
4.53e-02
|
1.44e-01
|
0.28400
|
1.17e-01
|
-0.259000
|
2.84e-01
|
1.78e-02
|
Metabolism-of-amino-acids-and-derivatives
|
335
|
1.35e-13
|
6.06e-12
|
0.28400
|
1.47e-01
|
-0.243000
|
3.54e-06
|
1.94e-14
|
Mitotic-Spindle-Checkpoint
|
108
|
3.62e-04
|
3.29e-03
|
0.28300
|
2.16e-01
|
-0.183000
|
1.03e-04
|
9.83e-04
|
RHO-GTPases-Activate-WASPs-and-WAVEs
|
35
|
3.99e-02
|
1.34e-01
|
0.28300
|
1.41e-01
|
-0.245000
|
1.48e-01
|
1.20e-02
|
Collagen-biosynthesis-and-modifying-enzymes
|
66
|
1.14e-04
|
1.27e-03
|
0.28300
|
-8.43e-02
|
0.270000
|
2.36e-01
|
1.48e-04
|
VxPx-cargo-targeting-to-cilium
|
20
|
1.31e-01
|
2.85e-01
|
0.28300
|
-1.27e-01
|
0.253000
|
3.27e-01
|
5.04e-02
|
Regulation-of-Apoptosis
|
51
|
5.54e-05
|
6.90e-04
|
0.28200
|
2.97e-02
|
-0.281000
|
7.13e-01
|
5.24e-04
|
Metalloprotease-DUBs
|
19
|
2.32e-01
|
4.08e-01
|
0.28200
|
1.69e-01
|
-0.226000
|
2.01e-01
|
8.87e-02
|
Phospholipase-C-mediated-cascade;-FGFR2
|
13
|
2.67e-01
|
4.45e-01
|
0.28200
|
1.26e-01
|
-0.252000
|
4.33e-01
|
1.15e-01
|
EPHB-mediated-forward-signaling
|
32
|
1.03e-01
|
2.44e-01
|
0.28200
|
2.05e-01
|
-0.193000
|
4.45e-02
|
5.86e-02
|
Keratinization
|
59
|
1.50e-02
|
6.66e-02
|
0.28200
|
2.09e-01
|
-0.189000
|
5.52e-03
|
1.21e-02
|
RHOBTB-GTPase-Cycle
|
32
|
1.52e-03
|
1.05e-02
|
0.28100
|
-2.80e-01
|
0.018400
|
6.02e-03
|
8.57e-01
|
Regulation-of-ornithine-decarboxylase-(ODC)
|
50
|
7.66e-05
|
9.01e-04
|
0.28100
|
3.01e-02
|
-0.279000
|
7.12e-01
|
6.38e-04
|
Kinesins
|
40
|
1.47e-03
|
1.03e-02
|
0.27900
|
2.74e-01
|
-0.053500
|
2.71e-03
|
5.58e-01
|
MET-activates-PTK2-signaling
|
18
|
3.18e-02
|
1.16e-01
|
0.27800
|
-2.50e-02
|
0.277000
|
8.55e-01
|
4.18e-02
|
Synthesis-of-PA
|
34
|
8.60e-02
|
2.15e-01
|
0.27800
|
2.16e-01
|
-0.175000
|
2.90e-02
|
7.76e-02
|
Telomere-C-strand-synthesis-initiation
|
13
|
4.10e-01
|
5.80e-01
|
0.27700
|
-2.01e-01
|
0.190000
|
2.08e-01
|
2.34e-01
|
DSCAM-interactions
|
10
|
3.18e-01
|
4.97e-01
|
0.27700
|
-1.03e-01
|
0.257000
|
5.74e-01
|
1.59e-01
|
Nicotinamide-salvaging
|
18
|
2.73e-01
|
4.53e-01
|
0.27700
|
1.72e-01
|
-0.217000
|
2.06e-01
|
1.11e-01
|
Assembly-of-the-pre-replicative-complex
|
66
|
5.28e-04
|
4.50e-03
|
0.27500
|
1.00e-01
|
-0.256000
|
1.58e-01
|
3.13e-04
|
MET-activates-RAP1-and-RAC1
|
11
|
1.43e-01
|
3.03e-01
|
0.27400
|
-2.72e-01
|
0.033700
|
1.18e-01
|
8.46e-01
|
Interleukin-6-family-signaling
|
23
|
2.16e-01
|
3.88e-01
|
0.27400
|
-1.93e-01
|
0.194000
|
1.10e-01
|
1.07e-01
|
Cross-presentation-of-soluble-exogenous-antigens-(endosomes)
|
48
|
3.35e-04
|
3.08e-03
|
0.27400
|
4.25e-02
|
-0.270000
|
6.10e-01
|
1.19e-03
|
Synthesis,-secretion,-and-inactivation-of-Glucagon-like-Peptide-1-(GLP-1)
|
15
|
3.03e-02
|
1.12e-01
|
0.27300
|
-2.20e-02
|
-0.272000
|
8.83e-01
|
6.82e-02
|
Downstream-signaling-events-of-B-Cell-Receptor-(BCR)
|
79
|
3.30e-06
|
8.74e-05
|
0.27300
|
4.77e-02
|
-0.268000
|
4.63e-01
|
3.70e-05
|
Dopamine-Neurotransmitter-Release-Cycle
|
23
|
6.85e-02
|
1.88e-01
|
0.27100
|
2.55e-01
|
-0.092400
|
3.42e-02
|
4.43e-01
|
Glycosaminoglycan-metabolism
|
113
|
2.12e-06
|
6.04e-05
|
0.27000
|
-9.19e-02
|
0.254000
|
9.13e-02
|
2.97e-06
|
Activation-of-NF-kappaB-in-B-cells
|
65
|
1.80e-05
|
3.10e-04
|
0.26900
|
3.46e-02
|
-0.267000
|
6.29e-01
|
1.99e-04
|
Transcriptional-Regulation-by-MECP2
|
55
|
1.18e-02
|
5.46e-02
|
0.26900
|
-2.31e-01
|
0.138000
|
3.08e-03
|
7.68e-02
|
RNA-Polymerase-I-Transcription-Initiation
|
44
|
2.64e-02
|
1.01e-01
|
0.26800
|
-1.34e-01
|
0.232000
|
1.24e-01
|
7.64e-03
|
Negative-regulation-of-FLT3
|
14
|
1.43e-01
|
3.04e-01
|
0.26800
|
-2.60e-01
|
0.063400
|
9.17e-02
|
6.81e-01
|
Processing-of-Capped-Intronless-Pre-mRNA
|
25
|
3.47e-02
|
1.23e-01
|
0.26800
|
-2.59e-01
|
0.067900
|
2.49e-02
|
5.57e-01
|
Regulation-of-beta-cell-development
|
35
|
1.04e-01
|
2.44e-01
|
0.26700
|
-2.01e-01
|
0.175000
|
3.91e-02
|
7.25e-02
|
E2F-mediated-regulation-of-DNA-replication
|
22
|
2.48e-01
|
4.24e-01
|
0.26500
|
1.97e-01
|
-0.178000
|
1.10e-01
|
1.48e-01
|
Trafficking-and-processing-of-endosomal-TLR
|
12
|
2.74e-01
|
4.53e-01
|
0.26500
|
9.51e-02
|
-0.248000
|
5.68e-01
|
1.37e-01
|
SUMOylation-of-intracellular-receptors
|
30
|
5.80e-03
|
3.10e-02
|
0.26500
|
-2.64e-01
|
0.026300
|
1.23e-02
|
8.03e-01
|
Peroxisomal-lipid-metabolism
|
29
|
1.07e-04
|
1.19e-03
|
0.26500
|
-2.30e-01
|
-0.132000
|
3.21e-02
|
2.19e-01
|
Processing-and-activation-of-SUMO
|
10
|
5.02e-01
|
6.62e-01
|
0.26500
|
-2.14e-01
|
0.155000
|
2.41e-01
|
3.95e-01
|
GRB2-events-in-ERBB2-signaling
|
16
|
2.39e-01
|
4.15e-01
|
0.26400
|
1.18e-01
|
-0.237000
|
4.14e-01
|
1.01e-01
|
Lysosphingolipid-and-LPA-receptors
|
14
|
1.81e-02
|
7.63e-02
|
0.26400
|
2.47e-01
|
0.093400
|
1.09e-01
|
5.45e-01
|
Regulation-of-RAS-by-GAPs
|
66
|
4.45e-05
|
5.89e-04
|
0.26400
|
4.42e-02
|
-0.260000
|
5.34e-01
|
2.55e-04
|
Rap1-signalling
|
14
|
1.21e-01
|
2.71e-01
|
0.26400
|
-2.60e-01
|
0.045400
|
9.22e-02
|
7.68e-01
|
EML4-and-NUDC-in-mitotic-spindle-formation
|
95
|
1.93e-03
|
1.26e-02
|
0.26300
|
2.08e-01
|
-0.161000
|
4.50e-04
|
6.53e-03
|
Gamma-carboxylation,-hypusine-formation-and-arylsulfatase-activation
|
37
|
2.60e-02
|
1.01e-01
|
0.26300
|
-1.04e-01
|
0.242000
|
2.75e-01
|
1.08e-02
|
JNK-(c-Jun-kinases)-phosphorylation-and–activation-mediated-by-activated-human-TAK1
|
17
|
3.51e-01
|
5.27e-01
|
0.26300
|
1.83e-01
|
-0.189000
|
1.92e-01
|
1.78e-01
|
Orc1-removal-from-chromatin
|
68
|
2.65e-04
|
2.61e-03
|
0.26300
|
7.53e-02
|
-0.252000
|
2.83e-01
|
3.33e-04
|
Sema3A-PAK-dependent-Axon-repulsion
|
16
|
3.82e-02
|
1.30e-01
|
0.26200
|
1.06e-02
|
0.262000
|
9.42e-01
|
6.99e-02
|
GLI3-is-processed-to-GLI3R-by-the-proteasome
|
57
|
8.46e-05
|
9.87e-04
|
0.26100
|
2.78e-02
|
-0.260000
|
7.16e-01
|
6.87e-04
|
Switching-of-origins-to-a-post-replicative-state
|
88
|
1.42e-04
|
1.51e-03
|
0.26100
|
9.72e-02
|
-0.242000
|
1.15e-01
|
8.68e-05
|
COPI-independent-Golgi-to-ER-retrograde-traffic
|
31
|
9.84e-02
|
2.36e-01
|
0.26100
|
2.22e-01
|
-0.136000
|
3.21e-02
|
1.91e-01
|
Pregnenolone-biosynthesis
|
12
|
4.02e-01
|
5.72e-01
|
0.26000
|
1.34e-01
|
-0.223000
|
4.23e-01
|
1.80e-01
|
Triglyceride-metabolism
|
31
|
1.53e-01
|
3.15e-01
|
0.26000
|
1.91e-01
|
-0.176000
|
6.52e-02
|
8.95e-02
|
PKA-activation
|
17
|
1.28e-01
|
2.82e-01
|
0.26000
|
-7.19e-02
|
0.249000
|
6.08e-01
|
7.50e-02
|
HS-GAG-biosynthesis
|
28
|
8.13e-04
|
6.34e-03
|
0.25900
|
6.70e-02
|
0.250000
|
5.40e-01
|
2.18e-02
|
Downregulation-of-ERBB2:ERBB3-signaling
|
12
|
3.92e-01
|
5.67e-01
|
0.25900
|
1.27e-01
|
-0.225000
|
4.44e-01
|
1.77e-01
|
Lewis-blood-group-biosynthesis
|
15
|
1.18e-01
|
2.66e-01
|
0.25800
|
-4.65e-02
|
0.254000
|
7.55e-01
|
8.82e-02
|
Nuclear-events-stimulated-by-ALK-signaling-in-cancer
|
17
|
3.64e-01
|
5.42e-01
|
0.25800
|
1.83e-01
|
-0.182000
|
1.90e-01
|
1.94e-01
|
PKA-mediated-phosphorylation-of-CREB
|
19
|
1.02e-01
|
2.43e-01
|
0.25700
|
-6.93e-02
|
0.248000
|
6.01e-01
|
6.16e-02
|
Zinc-influx-into-cells-by-the-SLC39-gene-family
|
10
|
1.75e-01
|
3.45e-01
|
0.25700
|
1.23e-02
|
-0.257000
|
9.46e-01
|
1.60e-01
|
Regulation-of-RUNX3-expression-and-activity
|
52
|
6.40e-04
|
5.27e-03
|
0.25700
|
4.53e-02
|
-0.253000
|
5.72e-01
|
1.62e-03
|
Free-fatty-acids-regulate-insulin-secretion
|
11
|
5.04e-01
|
6.64e-01
|
0.25600
|
-2.02e-01
|
0.157000
|
2.46e-01
|
3.67e-01
|
CRMPs-in-Sema3A-signaling
|
16
|
6.97e-03
|
3.56e-02
|
0.25600
|
1.90e-01
|
0.171000
|
1.88e-01
|
2.36e-01
|
Fanconi-Anemia-Pathway
|
34
|
1.12e-01
|
2.55e-01
|
0.25500
|
2.07e-01
|
-0.149000
|
3.66e-02
|
1.32e-01
|
Diseases-associated-with-glycosylation-precursor-biosynthesis
|
17
|
1.54e-01
|
3.17e-01
|
0.25500
|
2.43e-01
|
-0.078200
|
8.33e-02
|
5.76e-01
|
Degradation-of-GLI2-by-the-proteasome
|
57
|
3.27e-05
|
4.76e-04
|
0.25500
|
1.88e-03
|
-0.255000
|
9.80e-01
|
8.68e-04
|
Role-of-phospholipids-in-phagocytosis
|
36
|
1.20e-01
|
2.70e-01
|
0.25500
|
-1.68e-01
|
0.192000
|
8.15e-02
|
4.64e-02
|
Adherens-junctions-interactions
|
23
|
4.94e-02
|
1.52e-01
|
0.25500
|
-5.42e-02
|
0.249000
|
6.53e-01
|
3.89e-02
|
Constitutive-Signaling-by-NOTCH1-HD-Domain-Mutants
|
14
|
1.89e-01
|
3.60e-01
|
0.25500
|
-2.46e-01
|
0.067300
|
1.12e-01
|
6.63e-01
|
Signaling-by-NOTCH1-HD-Domain-Mutants-in-Cancer
|
14
|
1.89e-01
|
3.60e-01
|
0.25500
|
-2.46e-01
|
0.067300
|
1.12e-01
|
6.63e-01
|
Diseases-associated-with-visual-transduction
|
12
|
4.83e-01
|
6.48e-01
|
0.25400
|
1.59e-01
|
-0.199000
|
3.41e-01
|
2.33e-01
|
Diseases-of-the-neuronal-system
|
12
|
4.83e-01
|
6.48e-01
|
0.25400
|
1.59e-01
|
-0.199000
|
3.41e-01
|
2.33e-01
|
Retinoid-cycle-disease-events
|
12
|
4.83e-01
|
6.48e-01
|
0.25400
|
1.59e-01
|
-0.199000
|
3.41e-01
|
2.33e-01
|
Inactivation-of-APC/C-via-direct-inhibition-of-the-APC/C-complex
|
21
|
2.50e-01
|
4.26e-01
|
0.25400
|
2.10e-01
|
-0.143000
|
9.58e-02
|
2.55e-01
|
Inhibition-of-the-proteolytic-activity-of-APC/C-required-for-the-onset-of-anaphase-by-mitotic-spindle-checkpoint-components
|
21
|
2.50e-01
|
4.26e-01
|
0.25400
|
2.10e-01
|
-0.143000
|
9.58e-02
|
2.55e-01
|
Laminin-interactions
|
23
|
8.65e-04
|
6.64e-03
|
0.25400
|
1.83e-01
|
0.176000
|
1.29e-01
|
1.43e-01
|
Translation-of-Replicase-and-Assembly-of-the-Replication-Transcription-Complex
|
12
|
3.21e-01
|
5.00e-01
|
0.25400
|
2.35e-01
|
-0.096100
|
1.58e-01
|
5.64e-01
|
Signaling-by-FGFR2-in-disease
|
38
|
8.65e-02
|
2.15e-01
|
0.25400
|
1.47e-01
|
-0.207000
|
1.17e-01
|
2.70e-02
|
Reduction-of-cytosolic-Ca++-levels
|
12
|
1.25e-01
|
2.76e-01
|
0.25400
|
2.54e-01
|
-0.008870
|
1.28e-01
|
9.58e-01
|
Defects-in-vitamin-and-cofactor-metabolism
|
20
|
2.32e-01
|
4.08e-01
|
0.25400
|
-2.19e-01
|
0.128000
|
9.01e-02
|
3.21e-01
|
Classical-antibody-mediated-complement-activation
|
18
|
1.20e-01
|
2.70e-01
|
0.25300
|
-2.44e-01
|
0.067200
|
7.26e-02
|
6.22e-01
|
Signaling-by-Activin
|
13
|
4.50e-01
|
6.20e-01
|
0.25300
|
2.01e-01
|
-0.154000
|
2.09e-01
|
3.37e-01
|
Glycerophospholipid-biosynthesis
|
114
|
1.43e-03
|
1.01e-02
|
0.25300
|
1.87e-01
|
-0.171000
|
5.46e-04
|
1.64e-03
|
Golgi-Associated-Vesicle-Biogenesis
|
55
|
2.37e-02
|
9.27e-02
|
0.25300
|
1.37e-01
|
-0.213000
|
7.82e-02
|
6.30e-03
|
Cellular-hexose-transport
|
19
|
9.40e-03
|
4.52e-02
|
0.25300
|
2.43e-01
|
0.069400
|
6.64e-02
|
6.01e-01
|
CD28-dependent-Vav1-pathway
|
12
|
5.05e-01
|
6.64e-01
|
0.25300
|
-1.73e-01
|
0.184000
|
2.99e-01
|
2.70e-01
|
RHO-GTPases-activate-PKNs
|
32
|
1.25e-01
|
2.77e-01
|
0.25200
|
2.08e-01
|
-0.143000
|
4.16e-02
|
1.62e-01
|
RNA-Polymerase-III-Transcription-Initiation-From-Type-2-Promoter
|
27
|
2.07e-01
|
3.80e-01
|
0.25200
|
1.93e-01
|
-0.163000
|
8.29e-02
|
1.43e-01
|
Regulation-of-PTEN-gene-transcription
|
59
|
2.17e-02
|
8.75e-02
|
0.25200
|
-1.42e-01
|
0.208000
|
5.85e-02
|
5.65e-03
|
Oxygen-dependent-proline-hydroxylation-of-Hypoxia-inducible-Factor-Alpha
|
62
|
2.43e-05
|
3.81e-04
|
0.25200
|
7.08e-03
|
-0.251000
|
9.23e-01
|
6.14e-04
|
Deactivation-of-the-beta-catenin-transactivating-complex
|
38
|
6.35e-02
|
1.79e-01
|
0.25100
|
-1.26e-01
|
0.218000
|
1.80e-01
|
2.02e-02
|
Integrin-cell-surface-interactions
|
64
|
7.60e-04
|
6.05e-03
|
0.25100
|
-6.97e-02
|
0.241000
|
3.35e-01
|
8.62e-04
|
Blood-group-systems-biosynthesis
|
17
|
1.16e-01
|
2.62e-01
|
0.25000
|
-5.29e-02
|
0.245000
|
7.06e-01
|
8.07e-02
|
Glycolysis
|
66
|
5.74e-03
|
3.08e-02
|
0.24900
|
2.22e-01
|
-0.113000
|
1.79e-03
|
1.12e-01
|
CLEC7A-(Dectin-1)-signaling
|
97
|
3.29e-04
|
3.05e-03
|
0.24800
|
1.05e-01
|
-0.225000
|
7.42e-02
|
1.25e-04
|
Late-endosomal-microautophagy
|
29
|
1.95e-01
|
3.69e-01
|
0.24800
|
1.59e-01
|
-0.190000
|
1.37e-01
|
7.72e-02
|
Regulation-of-TP53-Expression-and-Degradation
|
34
|
1.57e-01
|
3.21e-01
|
0.24700
|
1.73e-01
|
-0.177000
|
8.01e-02
|
7.47e-02
|
Aberrant-regulation-of-mitotic-cell-cycle-due-to-RB1-defects
|
36
|
7.21e-02
|
1.94e-01
|
0.24700
|
2.17e-01
|
-0.119000
|
2.42e-02
|
2.17e-01
|
Listeria-monocytogenes-entry-into-host-cells
|
18
|
3.67e-01
|
5.43e-01
|
0.24700
|
-1.87e-01
|
0.162000
|
1.70e-01
|
2.34e-01
|
RNA-Polymerase-I-Transcription
|
48
|
2.98e-02
|
1.11e-01
|
0.24700
|
-1.18e-01
|
0.217000
|
1.57e-01
|
9.25e-03
|
Mitochondrial-translation
|
92
|
6.59e-03
|
3.40e-02
|
0.24700
|
1.67e-01
|
-0.182000
|
5.68e-03
|
2.51e-03
|
Asymmetric-localization-of-PCP-proteins
|
62
|
1.22e-04
|
1.34e-03
|
0.24700
|
2.77e-02
|
-0.245000
|
7.06e-01
|
8.37e-04
|
Class-I-peroxisomal-membrane-protein-import
|
20
|
6.67e-02
|
1.85e-01
|
0.24600
|
3.74e-02
|
-0.243000
|
7.72e-01
|
5.99e-02
|
Tight-junction-interactions
|
28
|
2.15e-01
|
3.88e-01
|
0.24600
|
1.61e-01
|
-0.186000
|
1.40e-01
|
8.88e-02
|
PI3K-events-in-ERBB2-signaling
|
16
|
8.69e-02
|
2.15e-01
|
0.24500
|
1.80e-02
|
-0.245000
|
9.01e-01
|
9.02e-02
|
Cyclin-E-associated-events-during-G1/S-transition
|
80
|
1.26e-03
|
9.09e-03
|
0.24500
|
9.84e-02
|
-0.224000
|
1.28e-01
|
5.34e-04
|
Hh-mutants-abrogate-ligand-secretion
|
57
|
3.42e-05
|
4.87e-04
|
0.24400
|
-1.29e-02
|
-0.244000
|
8.66e-01
|
1.43e-03
|
TP53-Regulates-Transcription-of-Genes-Involved-in-G1-Cell-Cycle-Arrest
|
13
|
3.67e-01
|
5.43e-01
|
0.24400
|
2.19e-01
|
-0.107000
|
1.71e-01
|
5.02e-01
|
Negative-regulation-of-TCF-dependent-signaling-by-WNT-ligand-antagonists
|
14
|
3.34e-01
|
5.12e-01
|
0.24400
|
-1.05e-01
|
0.220000
|
4.96e-01
|
1.54e-01
|
Regulation-of-glycolysis-by-fructose-2,6-bisphosphate-metabolism
|
11
|
2.30e-01
|
4.06e-01
|
0.24300
|
2.40e-01
|
-0.035100
|
1.68e-01
|
8.40e-01
|
ECM-proteoglycans
|
51
|
1.87e-03
|
1.23e-02
|
0.24300
|
-4.67e-02
|
0.238000
|
5.64e-01
|
3.23e-03
|
Regulation-of-PTEN-stability-and-activity
|
66
|
6.16e-04
|
5.10e-03
|
0.24200
|
5.86e-02
|
-0.235000
|
4.10e-01
|
9.61e-04
|
Metabolism-of-folate-and-pterines
|
15
|
2.00e-01
|
3.75e-01
|
0.24200
|
2.33e-01
|
-0.063600
|
1.18e-01
|
6.70e-01
|
Signaling-by-ERBB2-in-Cancer
|
25
|
1.34e-02
|
6.13e-02
|
0.24100
|
-8.99e-03
|
-0.241000
|
9.38e-01
|
3.69e-02
|
RAF-activation
|
34
|
1.58e-01
|
3.22e-01
|
0.24100
|
1.52e-01
|
-0.188000
|
1.26e-01
|
5.82e-02
|
Diseases-of-mitotic-cell-cycle
|
38
|
7.53e-02
|
1.98e-01
|
0.24100
|
2.10e-01
|
-0.118000
|
2.49e-02
|
2.08e-01
|
RNA-Polymerase-I-Transcription-Termination
|
28
|
1.15e-01
|
2.60e-01
|
0.24000
|
-1.02e-01
|
0.218000
|
3.52e-01
|
4.61e-02
|
Degradation-of-GLI1-by-the-proteasome
|
57
|
4.28e-05
|
5.82e-04
|
0.24000
|
-1.51e-02
|
-0.240000
|
8.43e-01
|
1.74e-03
|
SHC1-events-in-EGFR-signaling
|
13
|
4.55e-01
|
6.25e-01
|
0.24000
|
1.31e-01
|
-0.201000
|
4.13e-01
|
2.10e-01
|
Neurotransmitter-clearance
|
10
|
4.79e-01
|
6.45e-01
|
0.24000
|
2.15e-01
|
-0.107000
|
2.40e-01
|
5.58e-01
|
Positive-epigenetic-regulation-of-rRNA-expression
|
43
|
1.04e-01
|
2.45e-01
|
0.23900
|
-1.54e-01
|
0.183000
|
8.12e-02
|
3.74e-02
|
p75NTR-signals-via-NF-kB
|
15
|
2.51e-01
|
4.27e-01
|
0.23900
|
7.94e-02
|
-0.226000
|
5.94e-01
|
1.30e-01
|
Degradation-of-beta-catenin-by-the-destruction-complex
|
82
|
4.80e-03
|
2.69e-02
|
0.23900
|
1.20e-01
|
-0.207000
|
5.93e-02
|
1.21e-03
|
Hh-mutants-are-degraded-by-ERAD
|
54
|
4.76e-05
|
6.13e-04
|
0.23900
|
-2.54e-02
|
-0.238000
|
7.46e-01
|
2.51e-03
|
Heme-signaling
|
45
|
6.95e-03
|
3.56e-02
|
0.23900
|
-2.32e-01
|
0.056300
|
7.03e-03
|
5.13e-01
|
Signaling-by-FGFR3-fusions-in-cancer
|
10
|
2.86e-01
|
4.62e-01
|
0.23800
|
3.85e-02
|
-0.235000
|
8.33e-01
|
1.98e-01
|
Deadenylation-of-mRNA
|
24
|
1.89e-02
|
7.85e-02
|
0.23800
|
-2.38e-01
|
-0.005810
|
4.34e-02
|
9.61e-01
|
Non-integrin-membrane-ECM-interactions
|
42
|
1.42e-02
|
6.40e-02
|
0.23800
|
-6.61e-02
|
0.229000
|
4.58e-01
|
1.04e-02
|
Activation-of-Matrix-Metalloproteinases
|
25
|
8.97e-02
|
2.20e-01
|
0.23800
|
-7.19e-02
|
0.227000
|
5.33e-01
|
4.98e-02
|
RHO-GTPases-Activate-Formins
|
115
|
3.07e-03
|
1.88e-02
|
0.23800
|
1.73e-01
|
-0.163000
|
1.35e-03
|
2.50e-03
|
ER-Phagosome-pathway
|
81
|
4.43e-05
|
5.89e-04
|
0.23800
|
3.89e-02
|
-0.234000
|
5.45e-01
|
2.63e-04
|
Metabolism-of-cofactors
|
19
|
3.19e-01
|
4.98e-01
|
0.23700
|
-2.00e-01
|
0.127000
|
1.31e-01
|
3.37e-01
|
EPHA-mediated-growth-cone-collapse
|
14
|
4.32e-01
|
6.02e-01
|
0.23700
|
2.00e-01
|
-0.128000
|
1.96e-01
|
4.08e-01
|
Cellular-response-to-hypoxia
|
71
|
3.70e-05
|
5.18e-04
|
0.23700
|
1.55e-02
|
-0.236000
|
8.21e-01
|
5.73e-04
|
RORA-activates-gene-expression
|
17
|
1.12e-02
|
5.28e-02
|
0.23600
|
-1.75e-01
|
-0.158000
|
2.12e-01
|
2.58e-01
|
RNA-Polymerase-I-Promoter-Clearance
|
47
|
4.65e-02
|
1.46e-01
|
0.23500
|
-1.14e-01
|
0.205000
|
1.77e-01
|
1.48e-02
|
Protein-methylation
|
14
|
5.03e-01
|
6.63e-01
|
0.23500
|
1.65e-01
|
-0.167000
|
2.84e-01
|
2.80e-01
|
Regulation-of-HMOX1-expression-and-activity
|
63
|
4.11e-05
|
5.65e-04
|
0.23400
|
-6.36e-03
|
-0.234000
|
9.30e-01
|
1.30e-03
|
Regulation-of-BACH1-activity
|
10
|
9.18e-02
|
2.24e-01
|
0.23400
|
-1.04e-01
|
-0.210000
|
5.70e-01
|
2.50e-01
|
Signaling-by-ERBB2-KD-Mutants
|
24
|
3.62e-02
|
1.26e-01
|
0.23400
|
1.81e-02
|
-0.233000
|
8.78e-01
|
4.77e-02
|
Apoptotic-factor-mediated-response
|
15
|
3.24e-02
|
1.18e-01
|
0.23400
|
8.88e-02
|
0.216000
|
5.51e-01
|
1.47e-01
|
TAK1-activates-NFkB-by-phosphorylation-and-activation-of-IKKs-complex
|
24
|
2.88e-01
|
4.65e-01
|
0.23400
|
1.44e-01
|
-0.184000
|
2.23e-01
|
1.18e-01
|
Triglyceride-catabolism
|
20
|
2.52e-01
|
4.27e-01
|
0.23400
|
2.08e-01
|
-0.106000
|
1.07e-01
|
4.12e-01
|
Signaling-by-ALK
|
26
|
2.66e-01
|
4.44e-01
|
0.23300
|
-1.82e-01
|
0.146000
|
1.08e-01
|
1.97e-01
|
Formation-of-the-cornified-envelope
|
35
|
1.80e-01
|
3.51e-01
|
0.23300
|
1.56e-01
|
-0.173000
|
1.10e-01
|
7.57e-02
|
Mitotic-Anaphase
|
222
|
1.86e-05
|
3.13e-04
|
0.23300
|
1.53e-01
|
-0.176000
|
8.08e-05
|
6.17e-06
|
Regulation-of-FZD-by-ubiquitination
|
19
|
3.78e-01
|
5.53e-01
|
0.23300
|
1.44e-01
|
-0.183000
|
2.77e-01
|
1.67e-01
|
Signaling-by-ERBB2-TMD/JMD-mutants
|
21
|
1.36e-01
|
2.94e-01
|
0.23300
|
6.73e-02
|
-0.223000
|
5.94e-01
|
7.70e-02
|
VEGFR2-mediated-cell-proliferation
|
19
|
2.81e-01
|
4.59e-01
|
0.23200
|
2.06e-01
|
-0.107000
|
1.20e-01
|
4.20e-01
|
Phase-2—plateau-phase
|
15
|
2.28e-02
|
9.03e-02
|
0.23100
|
1.80e-01
|
0.145000
|
2.28e-01
|
3.29e-01
|
S33-mutants-of-beta-catenin-aren’t-phosphorylated
|
15
|
1.22e-01
|
2.71e-01
|
0.23100
|
2.31e-01
|
-0.012000
|
1.21e-01
|
9.36e-01
|
S37-mutants-of-beta-catenin-aren’t-phosphorylated
|
15
|
1.22e-01
|
2.71e-01
|
0.23100
|
2.31e-01
|
-0.012000
|
1.21e-01
|
9.36e-01
|
S45-mutants-of-beta-catenin-aren’t-phosphorylated
|
15
|
1.22e-01
|
2.71e-01
|
0.23100
|
2.31e-01
|
-0.012000
|
1.21e-01
|
9.36e-01
|
Signaling-by-CTNNB1-phospho-site-mutants
|
15
|
1.22e-01
|
2.71e-01
|
0.23100
|
2.31e-01
|
-0.012000
|
1.21e-01
|
9.36e-01
|
Signaling-by-GSK3beta-mutants
|
15
|
1.22e-01
|
2.71e-01
|
0.23100
|
2.31e-01
|
-0.012000
|
1.21e-01
|
9.36e-01
|
T41-mutants-of-beta-catenin-aren’t-phosphorylated
|
15
|
1.22e-01
|
2.71e-01
|
0.23100
|
2.31e-01
|
-0.012000
|
1.21e-01
|
9.36e-01
|
Signaling-by-NOTCH2
|
31
|
2.11e-01
|
3.83e-01
|
0.23100
|
-1.81e-01
|
0.144000
|
8.08e-02
|
1.67e-01
|
Iron-uptake-and-transport
|
55
|
4.77e-02
|
1.49e-01
|
0.23100
|
1.92e-01
|
-0.128000
|
1.37e-02
|
1.00e-01
|
CS/DS-degradation
|
13
|
4.77e-01
|
6.45e-01
|
0.23100
|
-1.24e-01
|
0.195000
|
4.39e-01
|
2.25e-01
|
Synthesis-of-bile-acids-and-bile-salts
|
31
|
8.13e-02
|
2.07e-01
|
0.23000
|
8.25e-02
|
-0.215000
|
4.27e-01
|
3.83e-02
|
Mitotic-Metaphase-and-Anaphase
|
223
|
2.44e-05
|
3.81e-04
|
0.23000
|
1.52e-01
|
-0.173000
|
9.34e-05
|
8.34e-06
|
HuR-(ELAVL1)-binds-and-stabilizes-mRNA
|
10
|
6.24e-01
|
7.57e-01
|
0.23000
|
1.57e-01
|
-0.168000
|
3.91e-01
|
3.58e-01
|
Signaling-by-EGFR-in-Cancer
|
23
|
4.49e-02
|
1.44e-01
|
0.22800
|
1.38e-02
|
-0.228000
|
9.09e-01
|
5.84e-02
|
MHC-class-II-antigen-presentation
|
95
|
3.33e-03
|
2.00e-02
|
0.22800
|
1.98e-01
|
-0.114000
|
8.40e-04
|
5.56e-02
|
Signaling-by-FLT3-fusion-proteins
|
19
|
8.65e-02
|
2.15e-01
|
0.22800
|
2.03e-02
|
-0.227000
|
8.78e-01
|
8.65e-02
|
Synthesis-of-PIPs-at-the-late-endosome-membrane
|
11
|
2.26e-01
|
4.02e-01
|
0.22800
|
-1.25e-02
|
0.227000
|
9.43e-01
|
1.92e-01
|
Cell-Cycle-Checkpoints
|
249
|
1.04e-05
|
1.97e-04
|
0.22700
|
1.53e-01
|
-0.168000
|
3.01e-05
|
4.81e-06
|
PCNA-Dependent-Long-Patch-Base-Excision-Repair
|
21
|
7.36e-02
|
1.97e-01
|
0.22700
|
2.26e-01
|
-0.024600
|
7.30e-02
|
8.45e-01
|
Prefoldin-mediated-transfer-of-substrate–to-CCT/TriC
|
24
|
6.05e-03
|
3.20e-02
|
0.22700
|
-2.12e-01
|
-0.082100
|
7.23e-02
|
4.86e-01
|
Defective-CFTR-causes-cystic-fibrosis
|
59
|
5.49e-06
|
1.35e-04
|
0.22700
|
-7.31e-02
|
-0.215000
|
3.31e-01
|
4.35e-03
|
Zinc-transporters
|
17
|
2.57e-02
|
9.95e-02
|
0.22700
|
-8.74e-02
|
-0.209000
|
5.33e-01
|
1.36e-01
|
Activated-NOTCH1-Transmits-Signal-to-the-Nucleus
|
30
|
1.88e-01
|
3.60e-01
|
0.22600
|
-1.92e-01
|
0.120000
|
6.85e-02
|
2.56e-01
|
Phase-0—rapid-depolarisation
|
29
|
2.75e-02
|
1.04e-01
|
0.22600
|
2.25e-01
|
-0.023000
|
3.62e-02
|
8.30e-01
|
G0-and-Early-G1
|
26
|
2.99e-01
|
4.76e-01
|
0.22500
|
1.71e-01
|
-0.147000
|
1.31e-01
|
1.96e-01
|
Acyl-chain-remodelling-of-PE
|
21
|
3.67e-01
|
5.43e-01
|
0.22500
|
1.77e-01
|
-0.140000
|
1.61e-01
|
2.67e-01
|
Presynaptic-depolarization-and-calcium-channel-opening
|
12
|
2.37e-01
|
4.14e-01
|
0.22500
|
2.24e-01
|
-0.026900
|
1.80e-01
|
8.72e-01
|
Diseases-associated-with-the-TLR-signaling-cascade
|
29
|
2.04e-01
|
3.77e-01
|
0.22500
|
1.20e-01
|
-0.191000
|
2.64e-01
|
7.54e-02
|
Diseases-of-Immune-System
|
29
|
2.04e-01
|
3.77e-01
|
0.22500
|
1.20e-01
|
-0.191000
|
2.64e-01
|
7.54e-02
|
IRAK4-deficiency-(TLR2/4)
|
17
|
3.82e-01
|
5.58e-01
|
0.22500
|
1.16e-01
|
-0.193000
|
4.08e-01
|
1.68e-01
|
Glucagon-signaling-in-metabolic-regulation
|
30
|
6.25e-02
|
1.77e-01
|
0.22500
|
-5.99e-02
|
0.217000
|
5.70e-01
|
3.99e-02
|
Cyclin-A:Cdk2-associated-events-at-S-phase-entry
|
82
|
4.69e-03
|
2.65e-02
|
0.22500
|
9.87e-02
|
-0.202000
|
1.22e-01
|
1.56e-03
|
RAC2-GTPase-cycle
|
86
|
5.11e-03
|
2.82e-02
|
0.22400
|
-1.05e-01
|
0.198000
|
9.34e-02
|
1.49e-03
|
Synthesis-of-IP2,-IP,-and-Ins-in-the-cytosol
|
14
|
7.43e-02
|
1.98e-01
|
0.22400
|
5.27e-02
|
0.218000
|
7.33e-01
|
1.59e-01
|
Deposition-of-new-CENPA-containing-nucleosomes-at-the-centromere
|
25
|
3.28e-01
|
5.04e-01
|
0.22400
|
1.53e-01
|
-0.163000
|
1.84e-01
|
1.59e-01
|
Nucleosome-assembly
|
25
|
3.28e-01
|
5.04e-01
|
0.22400
|
1.53e-01
|
-0.163000
|
1.84e-01
|
1.59e-01
|
Metal-ion-SLC-transporters
|
26
|
4.68e-02
|
1.47e-01
|
0.22100
|
2.41e-02
|
-0.220000
|
8.32e-01
|
5.21e-02
|
NRIF-signals-cell-death-from-the-nucleus
|
15
|
4.66e-01
|
6.37e-01
|
0.22100
|
1.22e-01
|
-0.184000
|
4.13e-01
|
2.17e-01
|
Post-NMDA-receptor-activation-events
|
61
|
7.76e-03
|
3.85e-02
|
0.22000
|
2.09e-01
|
-0.070800
|
4.83e-03
|
3.38e-01
|
Stimuli-sensing-channels
|
93
|
3.27e-05
|
4.76e-04
|
0.22000
|
2.18e-01
|
-0.030200
|
2.76e-04
|
6.15e-01
|
Transport-of-bile-salts-and-organic-acids,-metal-ions-and-amine-compounds
|
80
|
2.72e-02
|
1.04e-01
|
0.22000
|
1.39e-01
|
-0.171000
|
3.21e-02
|
8.16e-03
|
RHOD-GTPase-cycle
|
53
|
4.53e-02
|
1.44e-01
|
0.22000
|
-1.04e-01
|
0.194000
|
1.89e-01
|
1.47e-02
|
cGMP-effects
|
15
|
5.01e-01
|
6.62e-01
|
0.22000
|
1.74e-01
|
-0.135000
|
2.44e-01
|
3.66e-01
|
Synthesis-of-active-ubiquitin:-roles-of-E1-and-E2-enzymes
|
29
|
3.71e-02
|
1.28e-01
|
0.22000
|
2.67e-02
|
-0.218000
|
8.03e-01
|
4.21e-02
|
Signalling-to-RAS
|
20
|
1.45e-01
|
3.06e-01
|
0.22000
|
-4.79e-02
|
0.214000
|
7.11e-01
|
9.69e-02
|
Peroxisomal-protein-import
|
62
|
2.78e-05
|
4.25e-04
|
0.22000
|
-2.16e-01
|
-0.039900
|
3.25e-03
|
5.86e-01
|
RNA-Polymerase-III-Transcription-Initiation-From-Type-1-Promoter
|
28
|
2.58e-01
|
4.36e-01
|
0.21900
|
1.80e-01
|
-0.126000
|
9.99e-02
|
2.48e-01
|
Incretin-synthesis,-secretion,-and-inactivation
|
17
|
4.81e-02
|
1.49e-01
|
0.21900
|
-5.22e-02
|
-0.213000
|
7.09e-01
|
1.28e-01
|
Adrenaline,noradrenaline-inhibits-insulin-secretion
|
27
|
5.38e-02
|
1.61e-01
|
0.21900
|
2.16e-01
|
-0.031800
|
5.17e-02
|
7.75e-01
|
TGF-beta-receptor-signaling-in-EMT-(epithelial-to-mesenchymal-transition)
|
14
|
5.40e-01
|
6.91e-01
|
0.21800
|
1.68e-01
|
-0.140000
|
2.77e-01
|
3.66e-01
|
Glucagon-like-Peptide-1-(GLP1)-regulates-insulin-secretion
|
39
|
3.10e-02
|
1.13e-01
|
0.21700
|
2.10e-01
|
-0.053300
|
2.32e-02
|
5.65e-01
|
TP53-Regulates-Transcription-of-Cell-Cycle-Genes
|
46
|
4.69e-02
|
1.47e-01
|
0.21700
|
1.99e-01
|
-0.085600
|
1.95e-02
|
3.15e-01
|
Extracellular-matrix-organization
|
274
|
3.06e-12
|
1.26e-10
|
0.21700
|
-4.23e-02
|
0.212000
|
2.27e-01
|
1.35e-09
|
Mismatch-repair-(MMR)-directed-by-MSH2:MSH3-(MutSbeta)
|
13
|
8.71e-02
|
2.15e-01
|
0.21600
|
2.04e-01
|
0.070600
|
2.02e-01
|
6.59e-01
|
Cytoprotection-by-HMOX1
|
118
|
6.40e-06
|
1.51e-04
|
0.21600
|
3.58e-02
|
-0.213000
|
5.02e-01
|
6.57e-05
|
Bile-acid-and-bile-salt-metabolism
|
39
|
4.46e-02
|
1.44e-01
|
0.21500
|
6.44e-02
|
-0.206000
|
4.86e-01
|
2.63e-02
|
SLC-mediated-transmembrane-transport
|
232
|
1.26e-05
|
2.32e-04
|
0.21500
|
1.81e-01
|
-0.117000
|
2.09e-06
|
2.09e-03
|
Golgi-Cisternae-Pericentriolar-Stack-Reorganization
|
14
|
5.60e-01
|
7.05e-01
|
0.21400
|
1.43e-01
|
-0.160000
|
3.53e-01
|
3.01e-01
|
NCAM1-interactions
|
36
|
9.52e-03
|
4.55e-02
|
0.21400
|
-3.90e-04
|
0.214000
|
9.97e-01
|
2.59e-02
|
FGFR1-ligand-binding-and-activation
|
10
|
6.07e-01
|
7.44e-01
|
0.21400
|
-1.82e-01
|
0.114000
|
3.20e-01
|
5.34e-01
|
Sema4D-induced-cell-migration-and-growth-cone-collapse
|
19
|
1.52e-01
|
3.15e-01
|
0.21400
|
2.11e-01
|
-0.037400
|
1.11e-01
|
7.78e-01
|
Protein-protein-interactions-at-synapses
|
82
|
9.40e-06
|
1.88e-04
|
0.21400
|
2.14e-01
|
0.014400
|
8.11e-04
|
8.21e-01
|
DARPP-32-events
|
23
|
3.35e-01
|
5.13e-01
|
0.21400
|
1.78e-01
|
-0.119000
|
1.39e-01
|
3.24e-01
|
Metabolism-of-polyamines
|
58
|
8.28e-04
|
6.43e-03
|
0.21300
|
7.34e-03
|
-0.213000
|
9.23e-01
|
4.93e-03
|
Synthesis-of-bile-acids-and-bile-salts-via-7alpha-hydroxycholesterol
|
21
|
7.52e-02
|
1.98e-01
|
0.21300
|
6.25e-03
|
-0.213000
|
9.60e-01
|
9.07e-02
|
Beta-catenin-phosphorylation-cascade
|
17
|
1.38e-01
|
2.95e-01
|
0.21300
|
2.12e-01
|
-0.013600
|
1.29e-01
|
9.23e-01
|
Aberrant-regulation-of-mitotic-exit-in-cancer-due-to-RB1-defects
|
20
|
4.42e-01
|
6.12e-01
|
0.21300
|
1.42e-01
|
-0.158000
|
2.71e-01
|
2.20e-01
|
Nucleotide-salvage
|
22
|
3.98e-01
|
5.70e-01
|
0.21300
|
1.35e-01
|
-0.164000
|
2.72e-01
|
1.83e-01
|
Circadian-Clock
|
64
|
7.07e-05
|
8.50e-04
|
0.21300
|
-2.71e-02
|
-0.211000
|
7.08e-01
|
3.51e-03
|
Regulation-of-pyruvate-dehydrogenase-(PDH)-complex
|
15
|
4.18e-01
|
5.87e-01
|
0.21100
|
9.24e-02
|
-0.190000
|
5.35e-01
|
2.02e-01
|
Inactivation-of-CSF3-(G-CSF)-signaling
|
22
|
1.64e-02
|
7.11e-02
|
0.21100
|
-1.94e-01
|
-0.082800
|
1.16e-01
|
5.01e-01
|
RND2-GTPase-cycle
|
42
|
4.51e-02
|
1.44e-01
|
0.21000
|
-6.59e-02
|
0.200000
|
4.60e-01
|
2.52e-02
|
Interleukin-1-family-signaling
|
130
|
6.94e-04
|
5.62e-03
|
0.21000
|
9.43e-02
|
-0.188000
|
6.33e-02
|
2.16e-04
|
RHOF-GTPase-cycle
|
41
|
2.00e-01
|
3.75e-01
|
0.21000
|
-1.49e-01
|
0.148000
|
9.93e-02
|
1.00e-01
|
Signaling-by-FGFR3-in-disease
|
20
|
2.40e-01
|
4.16e-01
|
0.21000
|
6.89e-02
|
-0.198000
|
5.94e-01
|
1.25e-01
|
Signaling-by-FGFR3-point-mutants-in-cancer
|
20
|
2.40e-01
|
4.16e-01
|
0.21000
|
6.89e-02
|
-0.198000
|
5.94e-01
|
1.25e-01
|
DNA-Damage-Bypass
|
46
|
1.38e-01
|
2.95e-01
|
0.21000
|
1.69e-01
|
-0.124000
|
4.70e-02
|
1.47e-01
|
Nucleobase-biosynthesis
|
15
|
1.61e-01
|
3.27e-01
|
0.21000
|
2.10e-01
|
-0.002590
|
1.60e-01
|
9.86e-01
|
ROS-and-RNS-production-in-phagocytes
|
35
|
1.85e-02
|
7.74e-02
|
0.20900
|
2.09e-01
|
-0.011000
|
3.27e-02
|
9.10e-01
|
Mismatch-repair-(MMR)-directed-by-MSH2:MSH6-(MutSalpha)
|
13
|
9.75e-02
|
2.35e-01
|
0.20900
|
1.95e-01
|
0.074800
|
2.24e-01
|
6.40e-01
|
Epigenetic-regulation-of-gene-expression
|
85
|
3.65e-02
|
1.27e-01
|
0.20900
|
-1.41e-01
|
0.154000
|
2.50e-02
|
1.41e-02
|
p75NTR-recruits-signalling-complexes
|
12
|
1.99e-01
|
3.75e-01
|
0.20800
|
-1.47e-02
|
-0.208000
|
9.30e-01
|
2.12e-01
|
ERBB2-Activates-PTK6-Signaling
|
13
|
2.04e-01
|
3.77e-01
|
0.20800
|
-3.85e-04
|
-0.208000
|
9.98e-01
|
1.94e-01
|
Activation-of-RAC1
|
13
|
3.06e-01
|
4.84e-01
|
0.20800
|
-2.04e-01
|
0.038800
|
2.03e-01
|
8.09e-01
|
Gap-filling-DNA-repair-synthesis-and-ligation-in-GG-NER
|
24
|
5.95e-02
|
1.74e-01
|
0.20700
|
2.07e-01
|
-0.004800
|
7.85e-02
|
9.68e-01
|
DNA-Replication-Pre-Initiation
|
82
|
4.15e-03
|
2.38e-02
|
0.20700
|
7.24e-02
|
-0.194000
|
2.57e-01
|
2.33e-03
|
Aflatoxin-activation-and-detoxification
|
16
|
4.95e-01
|
6.57e-01
|
0.20700
|
-1.17e-01
|
0.171000
|
4.19e-01
|
2.36e-01
|
Regulation-of-mRNA-stability-by-proteins-that-bind-AU-rich-elements
|
85
|
1.45e-04
|
1.53e-03
|
0.20700
|
2.11e-02
|
-0.206000
|
7.36e-01
|
1.02e-03
|
Synthesis-of-DNA
|
117
|
2.91e-03
|
1.79e-02
|
0.20700
|
1.01e-01
|
-0.180000
|
5.79e-02
|
7.49e-04
|
Dual-Incision-in-GG-NER
|
40
|
7.17e-03
|
3.65e-02
|
0.20700
|
2.07e-01
|
0.003680
|
2.36e-02
|
9.68e-01
|
Resolution-of-Abasic-Sites-(AP-sites)
|
37
|
1.07e-02
|
5.06e-02
|
0.20700
|
2.07e-01
|
0.002800
|
2.95e-02
|
9.77e-01
|
Regulated-proteolysis-of-p75NTR
|
11
|
5.09e-01
|
6.66e-01
|
0.20700
|
1.90e-01
|
-0.080400
|
2.74e-01
|
6.44e-01
|
MAPK6/MAPK4-signaling
|
85
|
7.64e-04
|
6.05e-03
|
0.20600
|
4.56e-02
|
-0.201000
|
4.67e-01
|
1.33e-03
|
Netrin-1-signaling
|
48
|
5.52e-02
|
1.64e-01
|
0.20600
|
-8.06e-02
|
0.189000
|
3.34e-01
|
2.33e-02
|
DNA-Replication
|
124
|
3.76e-03
|
2.20e-02
|
0.20500
|
1.09e-01
|
-0.173000
|
3.55e-02
|
8.59e-04
|
Assembly-of-collagen-fibrils-and-other-multimeric-structures
|
56
|
1.50e-04
|
1.57e-03
|
0.20400
|
5.22e-02
|
0.197000
|
4.99e-01
|
1.06e-02
|
Growth-hormone-receptor-signaling
|
19
|
6.19e-02
|
1.76e-01
|
0.20400
|
-3.75e-02
|
-0.201000
|
7.77e-01
|
1.30e-01
|
Elastic-fibre-formation
|
39
|
1.63e-03
|
1.11e-02
|
0.20400
|
6.35e-02
|
0.194000
|
4.93e-01
|
3.62e-02
|
TNF-receptor-superfamily-(TNFSF)-members-mediating-non-canonical-NF-kB-pathway
|
17
|
4.05e-01
|
5.76e-01
|
0.20400
|
-9.06e-02
|
0.182000
|
5.18e-01
|
1.93e-01
|
Peptide-hormone-metabolism
|
69
|
7.58e-02
|
1.98e-01
|
0.20400
|
1.35e-01
|
-0.152000
|
5.18e-02
|
2.87e-02
|
tRNA-modification-in-the-nucleus-and-cytosol
|
41
|
2.12e-01
|
3.86e-01
|
0.20400
|
-1.32e-01
|
0.155000
|
1.42e-01
|
8.68e-02
|
Ovarian-tumor-domain-proteases
|
35
|
2.20e-01
|
3.94e-01
|
0.20300
|
1.12e-01
|
-0.170000
|
2.51e-01
|
8.20e-02
|
Interleukin-10-signaling
|
39
|
2.37e-01
|
4.14e-01
|
0.20300
|
-1.41e-01
|
0.147000
|
1.27e-01
|
1.13e-01
|
Translesion-Synthesis-by-POLH
|
18
|
5.03e-01
|
6.63e-01
|
0.20300
|
1.57e-01
|
-0.130000
|
2.50e-01
|
3.40e-01
|
Synthesis-of-PC
|
27
|
3.69e-01
|
5.45e-01
|
0.20300
|
1.48e-01
|
-0.140000
|
1.84e-01
|
2.08e-01
|
Plasma-lipoprotein-assembly,-remodeling,-and-clearance
|
68
|
3.89e-03
|
2.26e-02
|
0.20300
|
4.55e-02
|
-0.198000
|
5.16e-01
|
4.70e-03
|
Chondroitin-sulfate-biosynthesis
|
19
|
4.80e-01
|
6.46e-01
|
0.20300
|
-1.27e-01
|
0.159000
|
3.38e-01
|
2.32e-01
|
Ion-channel-transport
|
167
|
1.65e-07
|
5.67e-06
|
0.20200
|
2.00e-01
|
-0.027600
|
7.78e-06
|
5.38e-01
|
Regulation-of-TP53-Activity-through-Acetylation
|
30
|
3.25e-01
|
5.04e-01
|
0.20200
|
-1.30e-01
|
0.155000
|
2.17e-01
|
1.43e-01
|
C-type-lectin-receptors-(CLRs)
|
129
|
2.16e-03
|
1.38e-02
|
0.20200
|
9.86e-02
|
-0.176000
|
5.29e-02
|
5.52e-04
|
Negative-regulation-of-MAPK-pathway
|
42
|
1.56e-01
|
3.20e-01
|
0.20100
|
1.06e-01
|
-0.171000
|
2.34e-01
|
5.48e-02
|
Infection-with-Mycobacterium-tuberculosis
|
25
|
3.92e-01
|
5.67e-01
|
0.20100
|
1.28e-01
|
-0.155000
|
2.67e-01
|
1.79e-01
|
RNA-Polymerase-III-Transcription-Initiation
|
36
|
2.46e-01
|
4.21e-01
|
0.20100
|
1.21e-01
|
-0.161000
|
2.08e-01
|
9.54e-02
|
SUMOylation-of-transcription-cofactors
|
41
|
1.45e-01
|
3.06e-01
|
0.20100
|
-1.75e-01
|
0.099200
|
5.24e-02
|
2.72e-01
|
Regulation-of-PTEN-mRNA-translation
|
11
|
6.73e-01
|
7.97e-01
|
0.20100
|
-1.38e-01
|
0.146000
|
4.27e-01
|
4.03e-01
|
Repression-of-WNT-target-genes
|
13
|
1.68e-01
|
3.35e-01
|
0.20000
|
1.98e-01
|
0.031600
|
2.17e-01
|
8.43e-01
|
Glycogen-synthesis
|
14
|
6.00e-01
|
7.38e-01
|
0.20000
|
1.31e-01
|
-0.151000
|
3.94e-01
|
3.28e-01
|
Resolution-of-AP-sites-via-the-multiple-nucleotide-patch-replacement-pathway
|
24
|
1.05e-01
|
2.47e-01
|
0.20000
|
1.98e-01
|
-0.024600
|
9.25e-02
|
8.34e-01
|
L1CAM-interactions
|
95
|
4.64e-04
|
4.05e-03
|
0.20000
|
1.95e-01
|
-0.041900
|
9.90e-04
|
4.80e-01
|
FCERI-mediated-NF-kB-activation
|
86
|
1.18e-05
|
2.21e-04
|
0.19900
|
-2.64e-02
|
-0.198000
|
6.73e-01
|
1.52e-03
|
Activated-point-mutants-of-FGFR2
|
12
|
4.22e-01
|
5.90e-01
|
0.19900
|
5.42e-02
|
-0.192000
|
7.45e-01
|
2.50e-01
|
Trafficking-of-GluR2-containing-AMPA-receptors
|
17
|
5.04e-02
|
1.55e-01
|
0.19900
|
1.75e-01
|
0.094200
|
2.10e-01
|
5.01e-01
|
RHOC-GTPase-cycle
|
71
|
4.91e-03
|
2.72e-02
|
0.19900
|
-4.93e-02
|
0.193000
|
4.73e-01
|
4.94e-03
|
HCMV-Late-Events
|
52
|
8.19e-02
|
2.07e-01
|
0.19800
|
1.75e-01
|
-0.092600
|
2.87e-02
|
2.48e-01
|
PTK6-Regulates-RHO-GTPases,-RAS-GTPase-and-MAP-kinases
|
13
|
3.58e-01
|
5.34e-01
|
0.19800
|
-4.22e-02
|
0.193000
|
7.92e-01
|
2.27e-01
|
HDR-through-MMEJ-(alt-NHEJ)
|
10
|
1.57e-01
|
3.21e-01
|
0.19700
|
1.36e-01
|
0.143000
|
4.56e-01
|
4.34e-01
|
Mitotic-Prometaphase
|
182
|
1.75e-03
|
1.16e-02
|
0.19700
|
1.48e-01
|
-0.130000
|
5.81e-04
|
2.43e-03
|
HDR-through-Single-Strand-Annealing-(SSA)
|
37
|
1.88e-02
|
7.84e-02
|
0.19700
|
1.97e-01
|
-0.002210
|
3.84e-02
|
9.81e-01
|
M-Phase
|
339
|
1.01e-05
|
1.95e-04
|
0.19600
|
1.37e-01
|
-0.140000
|
1.33e-05
|
8.80e-06
|
CaM-pathway
|
33
|
7.22e-02
|
1.94e-01
|
0.19600
|
-3.90e-02
|
0.192000
|
6.98e-01
|
5.58e-02
|
Calmodulin-induced-events
|
33
|
7.22e-02
|
1.94e-01
|
0.19600
|
-3.90e-02
|
0.192000
|
6.98e-01
|
5.58e-02
|
Signal-transduction-by-L1
|
21
|
4.37e-01
|
6.08e-01
|
0.19600
|
1.10e-01
|
-0.162000
|
3.82e-01
|
1.98e-01
|
Regulation-of-TP53-Activity-through-Association-with-Co-factors
|
13
|
5.18e-01
|
6.75e-01
|
0.19600
|
1.77e-01
|
-0.084300
|
2.70e-01
|
5.98e-01
|
Regulated-Necrosis
|
47
|
1.65e-01
|
3.33e-01
|
0.19500
|
1.12e-01
|
-0.160000
|
1.83e-01
|
5.79e-02
|
NoRC-negatively-regulates-rRNA-expression
|
44
|
1.99e-01
|
3.75e-01
|
0.19500
|
-1.17e-01
|
0.156000
|
1.80e-01
|
7.36e-02
|
Adenylate-cyclase-inhibitory-pathway
|
13
|
6.34e-01
|
7.67e-01
|
0.19500
|
-1.24e-01
|
0.150000
|
4.39e-01
|
3.49e-01
|
Gene-and-protein-expression-by-JAK-STAT-signaling-after-Interleukin-12-stimulation
|
35
|
7.78e-02
|
2.00e-01
|
0.19400
|
4.61e-02
|
-0.189000
|
6.37e-01
|
5.30e-02
|
Toll-Like-Receptor-7/8-(TLR7/8)-Cascade
|
86
|
5.15e-02
|
1.56e-01
|
0.19400
|
1.26e-01
|
-0.148000
|
4.39e-02
|
1.75e-02
|
CDC6-association-with-the-ORC:origin-complex
|
11
|
6.91e-01
|
8.09e-01
|
0.19400
|
1.41e-01
|
-0.133000
|
4.18e-01
|
4.44e-01
|
Abortive-elongation-of-HIV-1-transcript-in-the-absence-of-Tat
|
23
|
8.86e-02
|
2.18e-01
|
0.19400
|
1.94e-01
|
-0.000422
|
1.08e-01
|
9.97e-01
|
Nuclear-signaling-by-ERBB4
|
31
|
3.46e-01
|
5.22e-01
|
0.19400
|
1.47e-01
|
-0.126000
|
1.56e-01
|
2.25e-01
|
Scavenging-by-Class-A-Receptors
|
18
|
1.38e-01
|
2.95e-01
|
0.19300
|
6.55e-03
|
0.193000
|
9.62e-01
|
1.56e-01
|
MyD88-cascade-initiated-on-plasma-membrane
|
78
|
7.59e-02
|
1.98e-01
|
0.19300
|
1.33e-01
|
-0.139000
|
4.19e-02
|
3.33e-02
|
Toll-Like-Receptor-10-(TLR10)-Cascade
|
78
|
7.59e-02
|
1.98e-01
|
0.19300
|
1.33e-01
|
-0.139000
|
4.19e-02
|
3.33e-02
|
Toll-Like-Receptor-5-(TLR5)-Cascade
|
78
|
7.59e-02
|
1.98e-01
|
0.19300
|
1.33e-01
|
-0.139000
|
4.19e-02
|
3.33e-02
|
Vitamin-B5-(pantothenate)-metabolism
|
16
|
7.53e-02
|
1.98e-01
|
0.19200
|
-1.72e-01
|
-0.086100
|
2.33e-01
|
5.51e-01
|
Recycling-of-bile-acids-and-salts
|
15
|
3.25e-01
|
5.04e-01
|
0.19200
|
4.04e-02
|
-0.188000
|
7.86e-01
|
2.07e-01
|
Transport-of-organic-anions
|
10
|
4.07e-01
|
5.78e-01
|
0.19200
|
-1.91e-01
|
0.019000
|
2.96e-01
|
9.17e-01
|
Downregulation-of-ERBB2-signaling
|
27
|
4.91e-02
|
1.52e-01
|
0.19100
|
-1.13e-02
|
-0.191000
|
9.19e-01
|
8.57e-02
|
MAPK3-(ERK1)-activation
|
10
|
7.22e-01
|
8.25e-01
|
0.19100
|
-1.34e-01
|
0.137000
|
4.64e-01
|
4.53e-01
|
Keratan-sulfate-biosynthesis
|
24
|
1.94e-01
|
3.67e-01
|
0.19100
|
-4.87e-02
|
0.185000
|
6.80e-01
|
1.17e-01
|
MyD88:MAL(TIRAP)-cascade-initiated-on-plasma-membrane
|
95
|
4.55e-02
|
1.44e-01
|
0.19100
|
1.30e-01
|
-0.140000
|
2.81e-02
|
1.87e-02
|
Toll-Like-Receptor-2-(TLR2)-Cascade
|
95
|
4.55e-02
|
1.44e-01
|
0.19100
|
1.30e-01
|
-0.140000
|
2.81e-02
|
1.87e-02
|
Toll-Like-Receptor-TLR1:TLR2-Cascade
|
95
|
4.55e-02
|
1.44e-01
|
0.19100
|
1.30e-01
|
-0.140000
|
2.81e-02
|
1.87e-02
|
Toll-Like-Receptor-TLR6:TLR2-Cascade
|
95
|
4.55e-02
|
1.44e-01
|
0.19100
|
1.30e-01
|
-0.140000
|
2.81e-02
|
1.87e-02
|
ABC-family-proteins-mediated-transport
|
97
|
1.05e-04
|
1.18e-03
|
0.19100
|
1.10e-02
|
-0.191000
|
8.52e-01
|
1.17e-03
|
ABC-transporter-disorders
|
76
|
1.93e-05
|
3.22e-04
|
0.19100
|
-5.76e-02
|
-0.182000
|
3.85e-01
|
6.09e-03
|
HDACs-deacetylate-histones
|
31
|
2.48e-01
|
4.24e-01
|
0.19000
|
-1.69e-01
|
0.086700
|
1.04e-01
|
4.03e-01
|
FGFR2-mutant-receptor-activation
|
28
|
4.01e-01
|
5.72e-01
|
0.18900
|
1.24e-01
|
-0.143000
|
2.57e-01
|
1.90e-01
|
Erythrocytes-take-up-carbon-dioxide-and-release-oxygen
|
12
|
2.38e-01
|
4.14e-01
|
0.18900
|
2.57e-02
|
0.187000
|
8.78e-01
|
2.61e-01
|
O2/CO2-exchange-in-erythrocytes
|
12
|
2.38e-01
|
4.14e-01
|
0.18900
|
2.57e-02
|
0.187000
|
8.78e-01
|
2.61e-01
|
Creation-of-C4-and-C2-activators
|
23
|
2.02e-01
|
3.76e-01
|
0.18900
|
-1.84e-01
|
0.044200
|
1.27e-01
|
7.13e-01
|
Regulation-of-gene-expression-by-Hypoxia-inducible-Factor
|
11
|
6.33e-01
|
7.67e-01
|
0.18900
|
9.34e-02
|
-0.164000
|
5.92e-01
|
3.45e-01
|
Nef-mediates-down-modulation-of-cell-surface-receptors-by-recruiting-them-to-clathrin-adapters
|
20
|
8.70e-02
|
2.15e-01
|
0.18900
|
3.00e-02
|
0.186000
|
8.17e-01
|
1.49e-01
|
Tetrahydrobiopterin-(BH4)-synthesis,-recycling,-salvage-and-regulation
|
10
|
2.30e-01
|
4.06e-01
|
0.18900
|
-1.75e-01
|
-0.069100
|
3.37e-01
|
7.05e-01
|
mRNA-3’-end-processing
|
54
|
4.12e-02
|
1.37e-01
|
0.18800
|
-1.79e-01
|
0.059400
|
2.30e-02
|
4.50e-01
|
Axon-guidance
|
493
|
4.10e-08
|
1.45e-06
|
0.18800
|
1.53e-01
|
-0.109000
|
5.64e-09
|
2.99e-05
|
Pre-NOTCH-Transcription-and-Translation
|
34
|
2.02e-01
|
3.76e-01
|
0.18700
|
-7.93e-02
|
0.170000
|
4.24e-01
|
8.64e-02
|
DDX58/IFIH1-mediated-induction-of-interferon-alpha/beta
|
61
|
8.70e-03
|
4.27e-02
|
0.18700
|
2.89e-02
|
-0.185000
|
6.96e-01
|
1.26e-02
|
PERK-regulates-gene-expression
|
29
|
1.37e-01
|
2.95e-01
|
0.18700
|
4.27e-02
|
-0.182000
|
6.91e-01
|
8.99e-02
|
Transcriptional-regulation-of-pluripotent-stem-cells
|
24
|
3.25e-01
|
5.04e-01
|
0.18600
|
7.83e-02
|
-0.169000
|
5.06e-01
|
1.51e-01
|
Nuclear-Receptor-transcription-pathway
|
51
|
7.66e-02
|
1.98e-01
|
0.18600
|
-1.72e-01
|
0.071100
|
3.36e-02
|
3.80e-01
|
MET-promotes-cell-motility
|
29
|
2.30e-01
|
4.06e-01
|
0.18600
|
-7.01e-02
|
0.172000
|
5.13e-01
|
1.09e-01
|
WNT5A-dependent-internalization-of-FZD2,-FZD5-and-ROR2
|
13
|
6.59e-01
|
7.87e-01
|
0.18600
|
-1.17e-01
|
0.144000
|
4.64e-01
|
3.69e-01
|
Downregulation-of-SMAD2/3:SMAD4-transcriptional-activity
|
22
|
8.03e-02
|
2.05e-01
|
0.18600
|
-1.84e-01
|
-0.024500
|
1.35e-01
|
8.42e-01
|
Purine-ribonucleoside-monophosphate-biosynthesis
|
12
|
3.41e-01
|
5.15e-01
|
0.18500
|
1.85e-01
|
-0.009460
|
2.68e-01
|
9.55e-01
|
MyD88-dependent-cascade-initiated-on-endosome
|
85
|
7.09e-02
|
1.91e-01
|
0.18500
|
1.20e-01
|
-0.141000
|
5.62e-02
|
2.49e-02
|
PCP/CE-pathway
|
88
|
4.54e-04
|
4.00e-03
|
0.18400
|
1.15e-02
|
-0.184000
|
8.52e-01
|
2.84e-03
|
MyD88-deficiency-(TLR2/4)
|
16
|
4.56e-01
|
6.26e-01
|
0.18400
|
7.12e-02
|
-0.170000
|
6.22e-01
|
2.39e-01
|
Diseases-associated-with-N-glycosylation-of-proteins
|
16
|
4.55e-01
|
6.25e-01
|
0.18400
|
-1.70e-01
|
0.070800
|
2.39e-01
|
6.24e-01
|
Translation-of-Structural-Proteins
|
28
|
4.21e-01
|
5.90e-01
|
0.18400
|
-1.20e-01
|
0.140000
|
2.72e-01
|
2.00e-01
|
Hedgehog-ligand-biogenesis
|
63
|
3.59e-04
|
3.28e-03
|
0.18400
|
-4.42e-02
|
-0.179000
|
5.44e-01
|
1.41e-02
|
VEGFR2-mediated-vascular-permeability
|
26
|
4.33e-01
|
6.02e-01
|
0.18400
|
-1.46e-01
|
0.112000
|
1.99e-01
|
3.21e-01
|
E3-ubiquitin-ligases-ubiquitinate-target-proteins
|
40
|
1.26e-01
|
2.77e-01
|
0.18400
|
-1.72e-01
|
0.065500
|
5.99e-02
|
4.73e-01
|
Nonhomologous-End-Joining-(NHEJ)
|
34
|
3.14e-01
|
4.93e-01
|
0.18400
|
-1.05e-01
|
0.151000
|
2.88e-01
|
1.28e-01
|
EPH-Ephrin-signaling
|
85
|
3.60e-02
|
1.26e-01
|
0.18400
|
1.60e-01
|
-0.090800
|
1.09e-02
|
1.48e-01
|
Constitutive-Signaling-by-Overexpressed-ERBB2
|
10
|
2.10e-01
|
3.83e-01
|
0.18300
|
-1.07e-01
|
-0.149000
|
5.60e-01
|
4.15e-01
|
Metabolic-disorders-of-biological-oxidation-enzymes
|
32
|
1.15e-01
|
2.61e-01
|
0.18300
|
3.89e-02
|
-0.179000
|
7.03e-01
|
7.99e-02
|
Dissolution-of-Fibrin-Clot
|
12
|
1.63e-01
|
3.30e-01
|
0.18300
|
-1.57e-01
|
-0.094400
|
3.48e-01
|
5.71e-01
|
Mismatch-Repair
|
14
|
1.09e-01
|
2.52e-01
|
0.18300
|
1.32e-01
|
0.127000
|
3.93e-01
|
4.12e-01
|
Signaling-by-Erythropoietin
|
25
|
1.54e-01
|
3.17e-01
|
0.18200
|
-1.80e-01
|
0.026800
|
1.19e-01
|
8.17e-01
|
SUMOylation-of-chromatin-organization-proteins
|
54
|
1.97e-01
|
3.72e-01
|
0.18200
|
-1.18e-01
|
0.138000
|
1.33e-01
|
7.94e-02
|
Notch-HLH-transcription-pathway
|
27
|
3.52e-01
|
5.27e-01
|
0.18100
|
-8.84e-02
|
0.158000
|
4.26e-01
|
1.54e-01
|
N-glycan-antennae-elongation-in-the-medial/trans-Golgi
|
23
|
2.44e-01
|
4.21e-01
|
0.18100
|
1.75e-01
|
-0.046500
|
1.46e-01
|
7.00e-01
|
RNA-Polymerase-II-Transcription-Termination
|
62
|
2.73e-02
|
1.04e-01
|
0.18100
|
-1.74e-01
|
0.051400
|
1.79e-02
|
4.84e-01
|
SHC-mediated-cascade:FGFR2
|
18
|
4.95e-01
|
6.57e-01
|
0.18100
|
8.71e-02
|
-0.159000
|
5.22e-01
|
2.44e-01
|
Signaling-by-ERBB2-ECD-mutants
|
15
|
1.02e-01
|
2.43e-01
|
0.18100
|
-1.06e-01
|
-0.146000
|
4.77e-01
|
3.27e-01
|
Constitutive-Signaling-by-Aberrant-PI3K-in-Cancer
|
71
|
1.09e-01
|
2.52e-01
|
0.18000
|
-1.44e-01
|
0.108000
|
3.60e-02
|
1.14e-01
|
Myogenesis
|
24
|
4.77e-01
|
6.45e-01
|
0.18000
|
-1.10e-01
|
0.142000
|
3.51e-01
|
2.27e-01
|
RIP-mediated-NFkB-activation-via-ZBP1
|
17
|
5.48e-01
|
6.93e-01
|
0.18000
|
1.53e-01
|
-0.094400
|
2.75e-01
|
5.00e-01
|
Negative-regulation-of-NMDA-receptor-mediated-neuronal-transmission
|
21
|
1.06e-01
|
2.47e-01
|
0.17900
|
1.78e-01
|
0.023700
|
1.59e-01
|
8.51e-01
|
Neurotransmitter-release-cycle
|
46
|
1.75e-01
|
3.45e-01
|
0.17900
|
1.57e-01
|
-0.086900
|
6.59e-02
|
3.07e-01
|
Protein-localization
|
156
|
6.46e-06
|
1.51e-04
|
0.17900
|
1.96e-02
|
-0.178000
|
6.73e-01
|
1.23e-04
|
Signaling-by-Hedgehog
|
132
|
1.86e-03
|
1.23e-02
|
0.17900
|
-1.66e-01
|
0.065800
|
9.76e-04
|
1.91e-01
|
Viral-Messenger-RNA-Synthesis
|
42
|
1.31e-01
|
2.85e-01
|
0.17900
|
1.67e-01
|
-0.064400
|
6.17e-02
|
4.70e-01
|
Constitutive-Signaling-by-NOTCH1-HD+PEST-Domain-Mutants
|
56
|
1.88e-01
|
3.60e-01
|
0.17900
|
-1.39e-01
|
0.112000
|
7.12e-02
|
1.48e-01
|
Constitutive-Signaling-by-NOTCH1-PEST-Domain-Mutants
|
56
|
1.88e-01
|
3.60e-01
|
0.17900
|
-1.39e-01
|
0.112000
|
7.12e-02
|
1.48e-01
|
Signaling-by-NOTCH1-HD+PEST-Domain-Mutants-in-Cancer
|
56
|
1.88e-01
|
3.60e-01
|
0.17900
|
-1.39e-01
|
0.112000
|
7.12e-02
|
1.48e-01
|
Signaling-by-NOTCH1-PEST-Domain-Mutants-in-Cancer
|
56
|
1.88e-01
|
3.60e-01
|
0.17900
|
-1.39e-01
|
0.112000
|
7.12e-02
|
1.48e-01
|
Signaling-by-NOTCH1-in-Cancer
|
56
|
1.88e-01
|
3.60e-01
|
0.17900
|
-1.39e-01
|
0.112000
|
7.12e-02
|
1.48e-01
|
Conversion-from-APC/C:Cdc20-to-APC/C:Cdh1-in-late-anaphase
|
20
|
5.47e-01
|
6.93e-01
|
0.17800
|
1.41e-01
|
-0.110000
|
2.76e-01
|
3.95e-01
|
Synthesis-of-PIPs-at-the-early-endosome-membrane
|
16
|
5.26e-01
|
6.79e-01
|
0.17800
|
-8.06e-02
|
0.159000
|
5.77e-01
|
2.71e-01
|
Antigen-processing-Cross-presentation
|
95
|
5.64e-04
|
4.72e-03
|
0.17800
|
1.53e-02
|
-0.177000
|
7.97e-01
|
2.79e-03
|
TNFR1-induced-proapoptotic-signaling
|
13
|
6.31e-01
|
7.65e-01
|
0.17700
|
-1.53e-01
|
0.090700
|
3.41e-01
|
5.71e-01
|
RND1-GTPase-cycle
|
41
|
1.42e-01
|
3.02e-01
|
0.17700
|
-6.45e-02
|
0.165000
|
4.75e-01
|
6.71e-02
|
Signaling-by-FLT3-ITD-and-TKD-mutants
|
16
|
5.58e-01
|
7.04e-01
|
0.17700
|
8.76e-02
|
-0.154000
|
5.44e-01
|
2.86e-01
|
Defective-B3GALTL-causes-Peters-plus-syndrome-(PpS)
|
37
|
1.50e-02
|
6.67e-02
|
0.17700
|
3.81e-02
|
0.173000
|
6.89e-01
|
6.91e-02
|
Paradoxical-activation-of-RAF-signaling-by-kinase-inactive-BRAF
|
43
|
2.82e-01
|
4.59e-01
|
0.17700
|
1.10e-01
|
-0.139000
|
2.14e-01
|
1.16e-01
|
Signaling-by-RAS-mutants
|
43
|
2.82e-01
|
4.59e-01
|
0.17700
|
1.10e-01
|
-0.139000
|
2.14e-01
|
1.16e-01
|
Signaling-by-moderate-kinase-activity-BRAF-mutants
|
43
|
2.82e-01
|
4.59e-01
|
0.17700
|
1.10e-01
|
-0.139000
|
2.14e-01
|
1.16e-01
|
Signaling-downstream-of-RAS-mutants
|
43
|
2.82e-01
|
4.59e-01
|
0.17700
|
1.10e-01
|
-0.139000
|
2.14e-01
|
1.16e-01
|
RHO-GTPases-activate-KTN1
|
10
|
7.42e-01
|
8.41e-01
|
0.17700
|
1.40e-01
|
-0.107000
|
4.42e-01
|
5.57e-01
|
Nervous-system-development
|
517
|
2.12e-07
|
6.99e-06
|
0.17600
|
1.42e-01
|
-0.104000
|
3.20e-08
|
4.78e-05
|
Sensory-processing-of-sound
|
69
|
4.17e-02
|
1.38e-01
|
0.17600
|
1.63e-01
|
-0.064900
|
1.90e-02
|
3.51e-01
|
Cellular-response-to-chemical-stress
|
151
|
1.27e-05
|
2.32e-04
|
0.17600
|
1.77e-02
|
-0.175000
|
7.07e-01
|
2.09e-04
|
Transcriptional-regulation-by-the-AP-2-(TFAP2)-family-of-transcription-factors
|
32
|
4.12e-01
|
5.82e-01
|
0.17600
|
1.18e-01
|
-0.130000
|
2.48e-01
|
2.03e-01
|
Smooth-Muscle-Contraction
|
36
|
2.34e-01
|
4.11e-01
|
0.17500
|
-7.62e-02
|
0.158000
|
4.29e-01
|
1.01e-01
|
Mitochondrial-iron-sulfur-cluster-biogenesis
|
13
|
4.90e-01
|
6.54e-01
|
0.17500
|
1.68e-01
|
-0.049100
|
2.93e-01
|
7.59e-01
|
Fatty-acyl-CoA-biosynthesis
|
32
|
2.01e-01
|
3.76e-01
|
0.17400
|
5.60e-02
|
-0.165000
|
5.83e-01
|
1.06e-01
|
Interactions-of-Vpr-with-host-cellular-proteins
|
34
|
2.41e-01
|
4.17e-01
|
0.17400
|
1.59e-01
|
-0.070800
|
1.09e-01
|
4.75e-01
|
Collagen-degradation
|
36
|
2.40e-01
|
4.16e-01
|
0.17400
|
-7.51e-02
|
0.157000
|
4.36e-01
|
1.04e-01
|
FLT3-Signaling
|
37
|
1.56e-01
|
3.20e-01
|
0.17300
|
-1.65e-01
|
0.054600
|
8.30e-02
|
5.66e-01
|
RHO-GTPase-Effectors
|
236
|
1.15e-03
|
8.47e-03
|
0.17300
|
1.38e-01
|
-0.105000
|
2.54e-04
|
5.39e-03
|
RHOG-GTPase-cycle
|
72
|
7.89e-02
|
2.02e-01
|
0.17300
|
-8.47e-02
|
0.151000
|
2.14e-01
|
2.63e-02
|
RAC3-GTPase-cycle
|
90
|
6.29e-02
|
1.78e-01
|
0.17300
|
-9.73e-02
|
0.143000
|
1.10e-01
|
1.87e-02
|
Molecules-associated-with-elastic-fibres
|
29
|
1.09e-01
|
2.52e-01
|
0.17300
|
-1.14e-02
|
0.172000
|
9.16e-01
|
1.08e-01
|
p38MAPK-events
|
13
|
3.52e-01
|
5.27e-01
|
0.17300
|
1.72e-01
|
-0.005500
|
2.82e-01
|
9.73e-01
|
Negative-epigenetic-regulation-of-rRNA-expression
|
47
|
2.43e-01
|
4.19e-01
|
0.17200
|
-9.81e-02
|
0.142000
|
2.44e-01
|
9.24e-02
|
Collagen-formation
|
88
|
2.66e-04
|
2.61e-03
|
0.17100
|
1.65e-02
|
0.171000
|
7.89e-01
|
5.63e-03
|
RNA-Polymerase-III-Transcription-Termination
|
23
|
3.20e-01
|
4.99e-01
|
0.17100
|
5.27e-02
|
-0.163000
|
6.62e-01
|
1.76e-01
|
FGFR2-ligand-binding-and-activation
|
14
|
4.74e-01
|
6.42e-01
|
0.17100
|
4.54e-02
|
-0.165000
|
7.69e-01
|
2.86e-01
|
RNA-Polymerase-I-Promoter-Escape
|
28
|
2.35e-01
|
4.11e-01
|
0.17100
|
-4.80e-02
|
0.164000
|
6.60e-01
|
1.34e-01
|
TRAF6-mediated-induction-of-NFkB-and-MAP-kinases-upon-TLR7/8-or-9-activation
|
84
|
1.07e-01
|
2.48e-01
|
0.17000
|
1.09e-01
|
-0.131000
|
8.28e-02
|
3.84e-02
|
Signaling-by-high-kinase-activity-BRAF-mutants
|
34
|
3.57e-01
|
5.33e-01
|
0.17000
|
1.42e-01
|
-0.093900
|
1.51e-01
|
3.43e-01
|
PI-3K-cascade:FGFR2
|
18
|
2.85e-01
|
4.62e-01
|
0.17000
|
1.82e-02
|
-0.169000
|
8.94e-01
|
2.14e-01
|
Unwinding-of-DNA
|
12
|
2.14e-01
|
3.88e-01
|
0.17000
|
1.49e-01
|
0.081800
|
3.71e-01
|
6.24e-01
|
RET-signaling
|
40
|
3.26e-01
|
5.04e-01
|
0.17000
|
-1.36e-01
|
0.101000
|
1.35e-01
|
2.68e-01
|
TP53-Regulates-Metabolic-Genes
|
83
|
9.15e-02
|
2.24e-01
|
0.17000
|
9.78e-02
|
-0.139000
|
1.23e-01
|
2.88e-02
|
Transcriptional-activity-of-SMAD2/SMAD3:SMAD4-heterotrimer
|
43
|
1.90e-02
|
7.88e-02
|
0.16900
|
-1.69e-01
|
-0.017300
|
5.58e-02
|
8.44e-01
|
Activation-of-gene-expression-by-SREBF-(SREBP)
|
40
|
2.81e-02
|
1.06e-01
|
0.16900
|
-1.31e-02
|
-0.169000
|
8.86e-01
|
6.47e-02
|
Cellular-responses-to-stress
|
635
|
5.02e-09
|
2.01e-07
|
0.16900
|
9.05e-02
|
-0.143000
|
9.39e-05
|
6.95e-10
|
Signaling-by-FGFR-in-disease
|
57
|
3.22e-02
|
1.17e-01
|
0.16900
|
3.17e-02
|
-0.166000
|
6.79e-01
|
3.00e-02
|
TNFR1-induced-NFkappaB-signaling-pathway
|
25
|
5.23e-01
|
6.78e-01
|
0.16800
|
1.28e-01
|
-0.108000
|
2.66e-01
|
3.48e-01
|
Activation-of-NMDA-receptors-and-postsynaptic-events
|
74
|
7.78e-03
|
3.85e-02
|
0.16800
|
1.67e-01
|
-0.021400
|
1.32e-02
|
7.50e-01
|
Constitutive-Signaling-by-EGFRvIII
|
15
|
2.15e-01
|
3.88e-01
|
0.16800
|
-1.64e-01
|
-0.036400
|
2.72e-01
|
8.07e-01
|
Signaling-by-EGFRvIII-in-Cancer
|
15
|
2.15e-01
|
3.88e-01
|
0.16800
|
-1.64e-01
|
-0.036400
|
2.72e-01
|
8.07e-01
|
Miscellaneous-transport-and-binding-events
|
23
|
4.10e-01
|
5.80e-01
|
0.16700
|
-6.81e-02
|
0.153000
|
5.72e-01
|
2.05e-01
|
Prolonged-ERK-activation-events
|
14
|
4.93e-01
|
6.56e-01
|
0.16700
|
-1.61e-01
|
0.045500
|
2.98e-01
|
7.68e-01
|
MAP2K-and-MAPK-activation
|
38
|
3.36e-01
|
5.13e-01
|
0.16700
|
1.38e-01
|
-0.093000
|
1.40e-01
|
3.21e-01
|
Activated-NTRK2-signals-through-FRS2-and-FRS3
|
11
|
4.50e-01
|
6.20e-01
|
0.16600
|
-8.58e-03
|
0.166000
|
9.61e-01
|
3.40e-01
|
Cellular-responses-to-stimuli
|
639
|
8.37e-09
|
3.18e-07
|
0.16600
|
8.91e-02
|
-0.141000
|
1.14e-04
|
1.17e-09
|
Platelet-Adhesion-to-exposed-collagen
|
13
|
3.94e-01
|
5.68e-01
|
0.16600
|
8.99e-03
|
-0.165000
|
9.55e-01
|
3.02e-01
|
Signaling-by-NOTCH1
|
72
|
1.72e-01
|
3.40e-01
|
0.16500
|
-1.12e-01
|
0.122000
|
1.00e-01
|
7.41e-02
|
Phospholipase-C-mediated-cascade;-FGFR4
|
12
|
3.65e-01
|
5.42e-01
|
0.16500
|
-1.15e-02
|
-0.165000
|
9.45e-01
|
3.24e-01
|
DNA-strand-elongation
|
32
|
1.67e-02
|
7.19e-02
|
0.16500
|
1.29e-01
|
0.103000
|
2.08e-01
|
3.13e-01
|
TP53-Regulates-Transcription-of-DNA-Repair-Genes
|
57
|
2.45e-02
|
9.51e-02
|
0.16500
|
1.64e-01
|
-0.017900
|
3.24e-02
|
8.15e-01
|
Cleavage-of-the-damaged-purine
|
11
|
7.20e-01
|
8.25e-01
|
0.16400
|
-8.54e-02
|
0.140000
|
6.24e-01
|
4.20e-01
|
Depurination
|
11
|
7.20e-01
|
8.25e-01
|
0.16400
|
-8.54e-02
|
0.140000
|
6.24e-01
|
4.20e-01
|
Recognition-and-association-of-DNA-glycosylase-with-site-containing-an-affected-purine
|
11
|
7.20e-01
|
8.25e-01
|
0.16400
|
-8.54e-02
|
0.140000
|
6.24e-01
|
4.20e-01
|
Lagging-Strand-Synthesis
|
20
|
7.73e-02
|
2.00e-01
|
0.16400
|
1.16e-01
|
0.116000
|
3.68e-01
|
3.70e-01
|
Keratan-sulfate/keratin-metabolism
|
29
|
3.29e-01
|
5.05e-01
|
0.16400
|
-6.44e-02
|
0.151000
|
5.48e-01
|
1.60e-01
|
RHOV-GTPase-cycle
|
37
|
1.82e-01
|
3.54e-01
|
0.16400
|
4.88e-02
|
-0.156000
|
6.07e-01
|
9.99e-02
|
Synthesis-of-bile-acids-and-bile-salts-via-24-hydroxycholesterol
|
11
|
6.78e-01
|
8.00e-01
|
0.16300
|
6.96e-02
|
-0.147000
|
6.89e-01
|
3.97e-01
|
Activation-of-HOX-genes-during-differentiation
|
61
|
2.21e-01
|
3.95e-01
|
0.16300
|
-1.02e-01
|
0.127000
|
1.66e-01
|
8.69e-02
|
Activation-of-anterior-HOX-genes-in-hindbrain-development-during-early-embryogenesis
|
61
|
2.21e-01
|
3.95e-01
|
0.16300
|
-1.02e-01
|
0.127000
|
1.66e-01
|
8.69e-02
|
Constitutive-Signaling-by-Ligand-Responsive-EGFR-Cancer-Variants
|
18
|
1.10e-01
|
2.53e-01
|
0.16300
|
-9.24e-02
|
-0.134000
|
4.97e-01
|
3.25e-01
|
Signaling-by-Ligand-Responsive-EGFR-Variants-in-Cancer
|
18
|
1.10e-01
|
2.53e-01
|
0.16300
|
-9.24e-02
|
-0.134000
|
4.97e-01
|
3.25e-01
|
Regulation-of-insulin-secretion
|
75
|
6.07e-03
|
3.20e-02
|
0.16300
|
1.62e-01
|
-0.010300
|
1.50e-02
|
8.77e-01
|
Cilium-Assembly
|
174
|
5.33e-03
|
2.92e-02
|
0.16300
|
-8.18e-02
|
0.141000
|
6.26e-02
|
1.36e-03
|
Vitamin-D-(calciferol)-metabolism
|
11
|
7.21e-01
|
8.25e-01
|
0.16300
|
8.30e-02
|
-0.140000
|
6.33e-01
|
4.22e-01
|
Initiation-of-Nuclear-Envelope-(NE)-Reformation
|
19
|
1.05e-01
|
2.47e-01
|
0.16300
|
1.41e-01
|
0.080700
|
2.87e-01
|
5.42e-01
|
Butyrate-Response-Factor-1-(BRF1)-binds-and-destabilizes-mRNA
|
16
|
5.82e-01
|
7.25e-01
|
0.16200
|
-1.45e-01
|
0.072400
|
3.14e-01
|
6.16e-01
|
UCH-proteinases
|
83
|
1.53e-03
|
1.05e-02
|
0.16200
|
-6.30e-03
|
-0.162000
|
9.21e-01
|
1.06e-02
|
Downstream-signaling-of-activated-FGFR2
|
25
|
2.65e-01
|
4.43e-01
|
0.16200
|
3.37e-02
|
-0.158000
|
7.70e-01
|
1.71e-01
|
O-glycosylation-of-TSR-domain-containing-proteins
|
38
|
1.86e-02
|
7.76e-02
|
0.16100
|
5.34e-02
|
0.152000
|
5.69e-01
|
1.04e-01
|
RUNX1-regulates-transcription-of-genes-involved-in-differentiation-of-HSCs
|
69
|
5.56e-03
|
3.03e-02
|
0.16100
|
-3.07e-03
|
-0.161000
|
9.65e-01
|
2.04e-02
|
Autophagy
|
125
|
5.26e-02
|
1.58e-01
|
0.16100
|
1.22e-01
|
-0.106000
|
1.85e-02
|
4.12e-02
|
Cooperation-of-Prefoldin-and-TriC/CCT–in-actin-and-tubulin-folding
|
27
|
5.05e-02
|
1.55e-01
|
0.16100
|
-1.46e-01
|
-0.066800
|
1.88e-01
|
5.48e-01
|
Leading-Strand-Synthesis
|
14
|
2.15e-01
|
3.88e-01
|
0.16100
|
1.47e-01
|
0.065400
|
3.42e-01
|
6.72e-01
|
Polymerase-switching
|
14
|
2.15e-01
|
3.88e-01
|
0.16100
|
1.47e-01
|
0.065400
|
3.42e-01
|
6.72e-01
|
Sealing-of-the-nuclear-envelope-(NE)-by-ESCRT-III
|
24
|
6.89e-02
|
1.88e-01
|
0.16100
|
1.45e-01
|
0.069300
|
2.19e-01
|
5.57e-01
|
Mitochondrial-calcium-ion-transport
|
22
|
5.24e-01
|
6.78e-01
|
0.16100
|
8.09e-02
|
-0.139000
|
5.11e-01
|
2.60e-01
|
S-Phase
|
159
|
1.13e-02
|
5.32e-02
|
0.16100
|
8.40e-02
|
-0.137000
|
6.72e-02
|
2.89e-03
|
Oncogenic-MAPK-signaling
|
79
|
8.72e-02
|
2.15e-01
|
0.16000
|
7.64e-02
|
-0.141000
|
2.40e-01
|
3.02e-02
|
FRS-mediated-FGFR2-signaling
|
20
|
5.45e-01
|
6.92e-01
|
0.16000
|
7.79e-02
|
-0.140000
|
5.46e-01
|
2.78e-01
|
Ub-specific-processing-proteases
|
158
|
3.16e-03
|
1.92e-02
|
0.16000
|
6.26e-02
|
-0.147000
|
1.74e-01
|
1.39e-03
|
Metabolism-of-steroids
|
139
|
1.25e-03
|
9.03e-03
|
0.16000
|
3.99e-02
|
-0.155000
|
4.17e-01
|
1.60e-03
|
TNFR2-non-canonical-NF-kB-pathway
|
94
|
4.01e-03
|
2.32e-02
|
0.16000
|
2.17e-02
|
-0.158000
|
7.16e-01
|
7.90e-03
|
Cytochrome-c-mediated-apoptotic-response
|
11
|
3.17e-01
|
4.96e-01
|
0.16000
|
5.63e-02
|
0.150000
|
7.46e-01
|
3.90e-01
|
Negative-regulation-of-FGFR2-signaling
|
28
|
5.31e-01
|
6.84e-01
|
0.15900
|
1.14e-01
|
-0.111000
|
2.94e-01
|
3.10e-01
|
Mitotic-G2-G2/M-phases
|
178
|
1.38e-02
|
6.27e-02
|
0.15900
|
9.65e-02
|
-0.126000
|
2.61e-02
|
3.64e-03
|
Signaling-by-VEGF
|
100
|
1.03e-01
|
2.44e-01
|
0.15900
|
-1.19e-01
|
0.105000
|
3.98e-02
|
6.86e-02
|
RHOQ-GTPase-cycle
|
59
|
1.99e-01
|
3.74e-01
|
0.15900
|
-8.37e-02
|
0.135000
|
2.66e-01
|
7.32e-02
|
Toll-Like-Receptor-4-(TLR4)-Cascade
|
124
|
3.81e-02
|
1.30e-01
|
0.15800
|
8.63e-02
|
-0.133000
|
9.67e-02
|
1.07e-02
|
Regulation-of-TP53-Activity-through-Methylation
|
17
|
4.42e-01
|
6.12e-01
|
0.15800
|
1.54e-01
|
-0.037900
|
2.73e-01
|
7.87e-01
|
Platelet-homeostasis
|
83
|
4.66e-03
|
2.65e-02
|
0.15800
|
1.58e-01
|
-0.009010
|
1.30e-02
|
8.87e-01
|
Macroautophagy
|
111
|
7.82e-02
|
2.01e-01
|
0.15800
|
1.22e-01
|
-0.100000
|
2.67e-02
|
6.73e-02
|
FGFR3-ligand-binding-and-activation
|
11
|
7.12e-01
|
8.19e-01
|
0.15800
|
-1.40e-01
|
0.072600
|
4.21e-01
|
6.76e-01
|
FGFR3c-ligand-binding-and-activation
|
11
|
7.12e-01
|
8.19e-01
|
0.15800
|
-1.40e-01
|
0.072600
|
4.21e-01
|
6.76e-01
|
Sema4D-in-semaphorin-signaling
|
23
|
1.70e-01
|
3.38e-01
|
0.15800
|
1.57e-01
|
0.011400
|
1.92e-01
|
9.25e-01
|
Signaling-by-BMP
|
26
|
5.55e-02
|
1.64e-01
|
0.15700
|
-7.93e-02
|
-0.136000
|
4.84e-01
|
2.31e-01
|
Recycling-pathway-of-L1
|
27
|
7.08e-02
|
1.91e-01
|
0.15700
|
1.49e-01
|
0.049600
|
1.80e-01
|
6.56e-01
|
InlB-mediated-entry-of-Listeria-monocytogenes-into-host-cell
|
14
|
4.48e-01
|
6.18e-01
|
0.15700
|
-1.56e-01
|
0.020200
|
3.13e-01
|
8.96e-01
|
Clathrin-mediated-endocytosis
|
134
|
4.68e-02
|
1.47e-01
|
0.15700
|
9.88e-02
|
-0.122000
|
4.82e-02
|
1.47e-02
|
NOTCH3-Activation-and-Transmission-of-Signal-to-the-Nucleus
|
24
|
4.78e-01
|
6.45e-01
|
0.15700
|
-1.39e-01
|
0.071300
|
2.37e-01
|
5.46e-01
|
Signaling-by-RAF1-mutants
|
39
|
4.00e-01
|
5.70e-01
|
0.15600
|
9.36e-02
|
-0.125000
|
3.12e-01
|
1.77e-01
|
Glycosphingolipid-metabolism
|
39
|
2.97e-01
|
4.74e-01
|
0.15600
|
-6.91e-02
|
0.140000
|
4.55e-01
|
1.31e-01
|
Reproduction
|
75
|
1.78e-01
|
3.49e-01
|
0.15600
|
1.23e-01
|
-0.095100
|
6.50e-02
|
1.54e-01
|
G2/M-Checkpoints
|
130
|
3.36e-02
|
1.22e-01
|
0.15600
|
8.27e-02
|
-0.132000
|
1.03e-01
|
9.40e-03
|
TICAM1-dependent-activation-of-IRF3/IRF7
|
11
|
3.12e-01
|
4.91e-01
|
0.15600
|
-1.39e-01
|
-0.070500
|
4.26e-01
|
6.86e-01
|
MECP2-regulates-neuronal-receptors-and-channels
|
17
|
2.51e-01
|
4.27e-01
|
0.15600
|
-1.54e-01
|
-0.021900
|
2.72e-01
|
8.76e-01
|
G-beta:gamma-signalling-through-CDC42
|
19
|
3.27e-01
|
5.04e-01
|
0.15500
|
1.55e-01
|
-0.015600
|
2.43e-01
|
9.06e-01
|
SUMOylation-of-transcription-factors
|
18
|
4.40e-01
|
6.10e-01
|
0.15500
|
-3.83e-02
|
0.150000
|
7.79e-01
|
2.70e-01
|
Activation-of-PPARGC1A-(PGC-1alpha)-by-phosphorylation
|
10
|
6.69e-01
|
7.94e-01
|
0.15400
|
-4.77e-02
|
0.147000
|
7.94e-01
|
4.21e-01
|
RAF-independent-MAPK1/3-activation
|
23
|
1.85e-01
|
3.59e-01
|
0.15400
|
-1.54e-01
|
-0.010500
|
2.01e-01
|
9.30e-01
|
Resolution-of-D-loop-Structures-through-Synthesis-Dependent-Strand-Annealing-(SDSA)
|
26
|
7.63e-02
|
1.98e-01
|
0.15400
|
1.43e-01
|
0.058300
|
2.08e-01
|
6.07e-01
|
Interleukin-20-family-signaling
|
19
|
5.23e-01
|
6.78e-01
|
0.15400
|
-1.42e-01
|
0.059300
|
2.85e-01
|
6.54e-01
|
Glutamate-binding,-activation-of-AMPA-receptors-and-synaptic-plasticity
|
30
|
4.22e-02
|
1.38e-01
|
0.15300
|
1.33e-01
|
0.076900
|
2.09e-01
|
4.66e-01
|
Trafficking-of-AMPA-receptors
|
30
|
4.22e-02
|
1.38e-01
|
0.15300
|
1.33e-01
|
0.076900
|
2.09e-01
|
4.66e-01
|
G2/M-Transition
|
176
|
1.67e-02
|
7.19e-02
|
0.15300
|
8.87e-02
|
-0.125000
|
4.22e-02
|
4.26e-03
|
BMAL1:CLOCK,NPAS2-activates-circadian-gene-expression
|
25
|
1.64e-01
|
3.32e-01
|
0.15300
|
-1.10e-02
|
-0.152000
|
9.24e-01
|
1.87e-01
|
mRNA-decay-by-5’-to-3’-exoribonuclease
|
15
|
4.17e-01
|
5.87e-01
|
0.15300
|
1.29e-02
|
-0.152000
|
9.31e-01
|
3.07e-01
|
Toll-like-Receptor-Cascades
|
143
|
2.66e-02
|
1.01e-01
|
0.15200
|
7.89e-02
|
-0.130000
|
1.03e-01
|
7.37e-03
|
Formation-of-Senescence-Associated-Heterochromatin-Foci-(SAHF)
|
11
|
7.47e-01
|
8.45e-01
|
0.15200
|
-7.56e-02
|
0.132000
|
6.64e-01
|
4.50e-01
|
Semaphorin-interactions
|
63
|
4.24e-03
|
2.42e-02
|
0.15200
|
3.87e-02
|
0.147000
|
5.95e-01
|
4.39e-02
|
Regulation-of-cholesterol-biosynthesis-by-SREBP-(SREBF)
|
53
|
4.81e-02
|
1.49e-01
|
0.15200
|
1.29e-02
|
-0.151000
|
8.71e-01
|
5.69e-02
|
RHOB-GTPase-cycle
|
69
|
5.54e-04
|
4.66e-03
|
0.15200
|
1.01e-01
|
0.113000
|
1.46e-01
|
1.05e-01
|
Synthesis-of-Leukotrienes-(LT)-and-Eoxins-(EX)
|
15
|
2.04e-01
|
3.77e-01
|
0.15200
|
8.50e-02
|
0.125000
|
5.68e-01
|
4.00e-01
|
RHO-GTPases-activate-CIT
|
18
|
1.79e-01
|
3.50e-01
|
0.15100
|
1.40e-01
|
0.057500
|
3.04e-01
|
6.73e-01
|
FOXO-mediated-transcription-of-cell-death-genes
|
15
|
7.17e-01
|
8.24e-01
|
0.15100
|
-9.07e-02
|
0.121000
|
5.43e-01
|
4.17e-01
|
Diseases-associated-with-O-glycosylation-of-proteins
|
62
|
1.19e-03
|
8.66e-03
|
0.15100
|
1.08e-01
|
0.106000
|
1.40e-01
|
1.50e-01
|
Signaling-by-Insulin-receptor
|
71
|
2.06e-01
|
3.79e-01
|
0.15100
|
1.22e-01
|
-0.089800
|
7.63e-02
|
1.91e-01
|
HDMs-demethylate-histones
|
23
|
9.89e-02
|
2.37e-01
|
0.15100
|
-1.34e-01
|
-0.070000
|
2.66e-01
|
5.61e-01
|
Synthesis-of-PIPs-at-the-plasma-membrane
|
52
|
1.69e-02
|
7.25e-02
|
0.15100
|
2.46e-02
|
0.149000
|
7.59e-01
|
6.29e-02
|
Synthesis-of-Prostaglandins-(PG)-and-Thromboxanes-(TX)
|
14
|
6.78e-01
|
8.00e-01
|
0.15100
|
1.33e-01
|
-0.071000
|
3.88e-01
|
6.45e-01
|
Striated-Muscle-Contraction
|
32
|
3.98e-01
|
5.70e-01
|
0.15100
|
1.35e-01
|
-0.068200
|
1.87e-01
|
5.04e-01
|
Potential-therapeutics-for-SARS
|
81
|
1.93e-01
|
3.67e-01
|
0.15100
|
-1.10e-01
|
0.103000
|
8.57e-02
|
1.10e-01
|
Activation-of-IRF3/IRF7-mediated-by-TBK1/IKK-epsilon
|
16
|
1.95e-01
|
3.69e-01
|
0.15000
|
-1.29e-01
|
-0.077200
|
3.72e-01
|
5.93e-01
|
Apoptotic-execution-phase
|
44
|
3.90e-02
|
1.32e-01
|
0.15000
|
1.49e-01
|
0.017700
|
8.69e-02
|
8.39e-01
|
trans-Golgi-Network-Vesicle-Budding
|
71
|
1.21e-01
|
2.71e-01
|
0.15000
|
6.45e-02
|
-0.136000
|
3.47e-01
|
4.82e-02
|
Sensory-processing-of-sound-by-inner-hair-cells-of-the-cochlea
|
63
|
5.94e-02
|
1.74e-01
|
0.15000
|
1.46e-01
|
-0.033000
|
4.44e-02
|
6.51e-01
|
Toll-Like-Receptor-9-(TLR9)-Cascade
|
89
|
1.57e-01
|
3.21e-01
|
0.15000
|
9.54e-02
|
-0.116000
|
1.19e-01
|
5.90e-02
|
Cell-extracellular-matrix-interactions
|
16
|
2.04e-01
|
3.77e-01
|
0.15000
|
-1.32e-01
|
-0.070300
|
3.59e-01
|
6.27e-01
|
mRNA-decay-by-3’-to-5’-exoribonuclease
|
15
|
6.79e-01
|
8.01e-01
|
0.15000
|
-7.50e-02
|
0.130000
|
6.15e-01
|
3.84e-01
|
Presynaptic-function-of-Kainate-receptors
|
20
|
4.39e-01
|
6.09e-01
|
0.14900
|
-3.90e-02
|
0.144000
|
7.63e-01
|
2.65e-01
|
Gap-junction-assembly
|
16
|
7.01e-01
|
8.13e-01
|
0.14900
|
-1.22e-01
|
0.085800
|
3.99e-01
|
5.52e-01
|
Signaling-by-BRAF-and-RAF1-fusions
|
62
|
2.94e-01
|
4.71e-01
|
0.14900
|
1.08e-01
|
-0.102000
|
1.40e-01
|
1.64e-01
|
G-protein-beta:gamma-signalling
|
30
|
4.00e-01
|
5.70e-01
|
0.14900
|
-6.07e-02
|
0.136000
|
5.65e-01
|
1.98e-01
|
SHC1-events-in-ERBB2-signaling
|
22
|
2.97e-01
|
4.74e-01
|
0.14800
|
1.22e-02
|
-0.148000
|
9.21e-01
|
2.30e-01
|
Signaling-by-FGFR1-in-disease
|
34
|
1.49e-01
|
3.10e-01
|
0.14800
|
1.02e-02
|
-0.148000
|
9.18e-01
|
1.36e-01
|
WNT5A-dependent-internalization-of-FZD4
|
15
|
3.77e-01
|
5.53e-01
|
0.14800
|
-1.48e-01
|
-0.005560
|
3.21e-01
|
9.70e-01
|
RAB-geranylgeranylation
|
63
|
2.93e-01
|
4.71e-01
|
0.14800
|
1.07e-01
|
-0.102000
|
1.42e-01
|
1.61e-01
|
Metabolism-of-porphyrins
|
26
|
5.42e-01
|
6.91e-01
|
0.14700
|
-7.79e-02
|
0.125000
|
4.91e-01
|
2.70e-01
|
Dectin-2-family
|
20
|
3.90e-01
|
5.65e-01
|
0.14700
|
1.45e-01
|
-0.025100
|
2.61e-01
|
8.46e-01
|
Apoptotic-cleavage-of-cellular-proteins
|
37
|
7.47e-02
|
1.98e-01
|
0.14700
|
1.46e-01
|
0.016500
|
1.24e-01
|
8.62e-01
|
RNA-Polymerase-III-Abortive-And-Retractive-Initiation
|
41
|
1.89e-01
|
3.60e-01
|
0.14700
|
3.67e-02
|
-0.142000
|
6.84e-01
|
1.15e-01
|
RNA-Polymerase-III-Transcription
|
41
|
1.89e-01
|
3.60e-01
|
0.14700
|
3.67e-02
|
-0.142000
|
6.84e-01
|
1.15e-01
|
G-alpha-(z)-signalling-events
|
46
|
3.59e-01
|
5.34e-01
|
0.14700
|
-8.14e-02
|
0.122000
|
3.39e-01
|
1.52e-01
|
FLT3-signaling-in-disease
|
27
|
1.11e-01
|
2.55e-01
|
0.14700
|
-3.82e-02
|
-0.142000
|
7.31e-01
|
2.03e-01
|
AURKA-Activation-by-TPX2
|
70
|
1.64e-01
|
3.32e-01
|
0.14600
|
1.29e-01
|
-0.069000
|
6.26e-02
|
3.18e-01
|
CDC42-GTPase-cycle
|
156
|
1.53e-03
|
1.05e-02
|
0.14600
|
-3.35e-02
|
0.142000
|
4.70e-01
|
2.17e-03
|
Interconversion-of-nucleotide-di–and-triphosphates
|
27
|
3.12e-01
|
4.91e-01
|
0.14600
|
3.06e-02
|
-0.143000
|
7.83e-01
|
2.00e-01
|
RHOBTB3-ATPase-cycle
|
10
|
7.53e-01
|
8.48e-01
|
0.14600
|
1.32e-01
|
-0.062100
|
4.70e-01
|
7.34e-01
|
B-WICH-complex-positively-regulates-rRNA-expression
|
29
|
5.33e-01
|
6.85e-01
|
0.14600
|
-1.20e-01
|
0.082200
|
2.62e-01
|
4.43e-01
|
Negative-regulators-of-DDX58/IFIH1-signaling
|
32
|
9.44e-02
|
2.29e-01
|
0.14500
|
-2.57e-02
|
-0.143000
|
8.02e-01
|
1.61e-01
|
Caspase-mediated-cleavage-of-cytoskeletal-proteins
|
12
|
3.54e-01
|
5.30e-01
|
0.14500
|
5.13e-02
|
0.136000
|
7.58e-01
|
4.15e-01
|
Tryptophan-catabolism
|
12
|
6.96e-01
|
8.10e-01
|
0.14500
|
-1.34e-01
|
0.056800
|
4.22e-01
|
7.33e-01
|
Transport-of-small-molecules
|
677
|
1.16e-06
|
3.51e-05
|
0.14500
|
1.17e-01
|
-0.085700
|
1.82e-07
|
1.35e-04
|
Presynaptic-phase-of-homologous-DNA-pairing-and-strand-exchange
|
39
|
7.23e-02
|
1.94e-01
|
0.14500
|
1.44e-01
|
0.015000
|
1.20e-01
|
8.71e-01
|
Downregulation-of-TGF-beta-receptor-signaling
|
25
|
6.09e-01
|
7.45e-01
|
0.14500
|
8.89e-02
|
-0.114000
|
4.41e-01
|
3.23e-01
|
Regulation-of-RUNX2-expression-and-activity
|
68
|
8.07e-03
|
3.97e-02
|
0.14500
|
-2.17e-02
|
-0.143000
|
7.57e-01
|
4.14e-02
|
Anti-inflammatory-response-favouring-Leishmania-parasite-infection
|
152
|
1.54e-02
|
6.81e-02
|
0.14500
|
-6.24e-02
|
0.130000
|
1.84e-01
|
5.46e-03
|
Leishmania-parasite-growth-and-survival
|
152
|
1.54e-02
|
6.81e-02
|
0.14500
|
-6.24e-02
|
0.130000
|
1.84e-01
|
5.46e-03
|
Transcriptional-regulation-by-RUNX2
|
114
|
5.09e-02
|
1.55e-01
|
0.14400
|
6.58e-02
|
-0.129000
|
2.25e-01
|
1.76e-02
|
Transcriptional-regulation-of-granulopoiesis
|
31
|
5.22e-01
|
6.78e-01
|
0.14400
|
-8.26e-02
|
0.118000
|
4.26e-01
|
2.54e-01
|
SMAD2/SMAD3:SMAD4-heterotrimer-regulates-transcription
|
31
|
7.05e-02
|
1.91e-01
|
0.14400
|
-1.35e-01
|
-0.051600
|
1.94e-01
|
6.19e-01
|
Formation-of-the-Early-Elongation-Complex
|
33
|
5.02e-02
|
1.54e-01
|
0.14400
|
6.41e-02
|
0.129000
|
5.24e-01
|
1.99e-01
|
Formation-of-the-HIV-1-Early-Elongation-Complex
|
33
|
5.02e-02
|
1.54e-01
|
0.14400
|
6.41e-02
|
0.129000
|
5.24e-01
|
1.99e-01
|
Caspase-activation-via-extrinsic-apoptotic-signalling-pathway
|
24
|
6.41e-01
|
7.74e-01
|
0.14400
|
-1.04e-01
|
0.100000
|
3.79e-01
|
3.95e-01
|
Signaling-by-CSF3-(G-CSF)
|
27
|
7.91e-02
|
2.02e-01
|
0.14400
|
-1.23e-01
|
-0.074500
|
2.67e-01
|
5.03e-01
|
Uptake-and-function-of-anthrax-toxins
|
11
|
8.03e-01
|
8.87e-01
|
0.14400
|
8.72e-02
|
-0.115000
|
6.16e-01
|
5.11e-01
|
Signaling-by-WNT-in-cancer
|
33
|
2.31e-01
|
4.08e-01
|
0.14400
|
1.41e-01
|
-0.025200
|
1.60e-01
|
8.02e-01
|
Signal-attenuation
|
10
|
7.19e-01
|
8.25e-01
|
0.14300
|
1.35e-01
|
-0.047900
|
4.59e-01
|
7.93e-01
|
Neurexins-and-neuroligins
|
52
|
6.53e-03
|
3.38e-02
|
0.14300
|
9.16e-02
|
0.110000
|
2.53e-01
|
1.69e-01
|
Assembly-and-cell-surface-presentation-of-NMDA-receptors
|
25
|
9.83e-02
|
2.36e-01
|
0.14300
|
1.22e-01
|
0.074600
|
2.91e-01
|
5.18e-01
|
Phenylalanine-and-tyrosine-metabolism
|
10
|
4.72e-01
|
6.40e-01
|
0.14300
|
-3.27e-02
|
-0.139000
|
8.58e-01
|
4.46e-01
|
Downstream-signaling-of-activated-FGFR1
|
26
|
3.00e-01
|
4.76e-01
|
0.14300
|
-1.41e-01
|
0.020400
|
2.12e-01
|
8.57e-01
|
Homologous-DNA-Pairing-and-Strand-Exchange
|
42
|
3.43e-02
|
1.23e-01
|
0.14300
|
1.36e-01
|
0.043800
|
1.28e-01
|
6.23e-01
|
Plasma-lipoprotein-clearance
|
33
|
3.97e-01
|
5.70e-01
|
0.14300
|
5.85e-02
|
-0.130000
|
5.61e-01
|
1.96e-01
|
RND3-GTPase-cycle
|
41
|
1.09e-01
|
2.52e-01
|
0.14200
|
1.42e-01
|
-0.005690
|
1.15e-01
|
9.50e-01
|
G1/S-Transition
|
127
|
5.15e-02
|
1.56e-01
|
0.14200
|
7.06e-02
|
-0.124000
|
1.69e-01
|
1.61e-02
|
Cell-Cycle,-Mitotic
|
479
|
9.44e-05
|
1.08e-03
|
0.14200
|
1.14e-01
|
-0.084900
|
1.78e-05
|
1.41e-03
|
Post-translational-modification:-synthesis-of-GPI-anchored-proteins
|
76
|
1.14e-01
|
2.59e-01
|
0.14200
|
1.31e-01
|
-0.056300
|
4.90e-02
|
3.96e-01
|
Initial-triggering-of-complement
|
28
|
5.24e-01
|
6.78e-01
|
0.14200
|
-1.23e-01
|
0.071300
|
2.60e-01
|
5.14e-01
|
GABA-synthesis,-release,-reuptake-and-degradation
|
17
|
7.06e-01
|
8.16e-01
|
0.14200
|
8.09e-02
|
-0.117000
|
5.63e-01
|
4.04e-01
|
DAG-and-IP3-signaling
|
39
|
4.24e-02
|
1.39e-01
|
0.14200
|
4.66e-02
|
0.134000
|
6.14e-01
|
1.47e-01
|
Xenobiotics
|
15
|
6.53e-01
|
7.82e-01
|
0.14100
|
-5.57e-02
|
0.130000
|
7.09e-01
|
3.83e-01
|
Attenuation-phase
|
22
|
3.75e-01
|
5.51e-01
|
0.14100
|
-1.40e-01
|
0.021800
|
2.57e-01
|
8.59e-01
|
Cell-junction-organization
|
78
|
2.17e-01
|
3.89e-01
|
0.14100
|
1.14e-01
|
-0.083000
|
8.08e-02
|
2.05e-01
|
Activation-of-the-AP-1-family-of-transcription-factors
|
10
|
7.68e-01
|
8.60e-01
|
0.14100
|
6.07e-02
|
-0.128000
|
7.40e-01
|
4.85e-01
|
Ca-dependent-events
|
35
|
1.46e-01
|
3.06e-01
|
0.14100
|
-2.04e-03
|
0.141000
|
9.83e-01
|
1.48e-01
|
RHOA-GTPase-cycle
|
144
|
7.26e-04
|
5.81e-03
|
0.14100
|
-9.92e-03
|
0.140000
|
8.37e-01
|
3.63e-03
|
Endogenous-sterols
|
25
|
5.87e-01
|
7.27e-01
|
0.14000
|
1.19e-01
|
-0.074800
|
3.04e-01
|
5.18e-01
|
Mitotic-G1-phase-and-G1/S-transition
|
144
|
5.38e-02
|
1.61e-01
|
0.14000
|
7.75e-02
|
-0.117000
|
1.08e-01
|
1.57e-02
|
Retrograde-transport-at-the-Trans-Golgi-Network
|
46
|
3.75e-01
|
5.51e-01
|
0.14000
|
1.19e-01
|
-0.073800
|
1.63e-01
|
3.86e-01
|
Olfactory-Signaling-Pathway
|
37
|
4.00e-01
|
5.71e-01
|
0.14000
|
1.25e-01
|
-0.063000
|
1.89e-01
|
5.07e-01
|
HDR-through-Homologous-Recombination-(HRR)
|
65
|
6.23e-02
|
1.77e-01
|
0.14000
|
1.38e-01
|
-0.023000
|
5.47e-02
|
7.49e-01
|
Base-Excision-Repair
|
45
|
4.34e-02
|
1.41e-01
|
0.14000
|
1.37e-01
|
0.028200
|
1.13e-01
|
7.44e-01
|
SLC-transporter-disorders
|
93
|
5.71e-03
|
3.08e-02
|
0.13900
|
1.39e-01
|
0.001500
|
2.00e-02
|
9.80e-01
|
Regulation-of-gene-expression-in-beta-cells
|
18
|
6.99e-01
|
8.12e-01
|
0.13900
|
-7.83e-02
|
0.115000
|
5.65e-01
|
3.98e-01
|
Spry-regulation-of-FGF-signaling
|
15
|
4.77e-01
|
6.45e-01
|
0.13900
|
1.39e-01
|
-0.009730
|
3.52e-01
|
9.48e-01
|
The-canonical-retinoid-cycle-in-rods-(twilight-vision)
|
19
|
5.05e-01
|
6.64e-01
|
0.13800
|
3.48e-02
|
-0.134000
|
7.93e-01
|
3.13e-01
|
Inositol-phosphate-metabolism
|
46
|
1.62e-02
|
7.07e-02
|
0.13800
|
8.52e-02
|
0.109000
|
3.17e-01
|
2.02e-01
|
NOD1/2-Signaling-Pathway
|
30
|
6.81e-02
|
1.88e-01
|
0.13800
|
-8.70e-02
|
-0.107000
|
4.09e-01
|
3.11e-01
|
PLC-beta-mediated-events
|
47
|
6.19e-02
|
1.76e-01
|
0.13700
|
1.12e-02
|
0.137000
|
8.94e-01
|
1.04e-01
|
Chaperone-Mediated-Autophagy
|
19
|
2.45e-01
|
4.21e-01
|
0.13700
|
-4.10e-02
|
-0.131000
|
7.57e-01
|
3.22e-01
|
Signaling-by-FGFR2-IIIa-TM
|
19
|
6.03e-01
|
7.40e-01
|
0.13700
|
1.26e-01
|
-0.054700
|
3.41e-01
|
6.80e-01
|
Phospholipid-metabolism
|
195
|
9.06e-03
|
4.39e-02
|
0.13700
|
1.23e-01
|
-0.060900
|
3.00e-03
|
1.42e-01
|
Diseases-of-glycosylation
|
130
|
2.88e-04
|
2.79e-03
|
0.13700
|
1.86e-02
|
0.136000
|
7.15e-01
|
7.33e-03
|
Cargo-concentration-in-the-ER
|
33
|
6.07e-02
|
1.74e-01
|
0.13700
|
-1.18e-01
|
-0.070300
|
2.42e-01
|
4.85e-01
|
Fatty-acid-metabolism
|
155
|
4.94e-04
|
4.26e-03
|
0.13700
|
6.68e-03
|
-0.137000
|
8.86e-01
|
3.27e-03
|
CaMK-IV-mediated-phosphorylation-of-CREB
|
10
|
7.71e-01
|
8.61e-01
|
0.13700
|
-5.57e-02
|
0.125000
|
7.61e-01
|
4.93e-01
|
TRAF6-mediated-IRF7-activation
|
15
|
3.98e-01
|
5.70e-01
|
0.13700
|
-1.67e-02
|
-0.136000
|
9.11e-01
|
3.63e-01
|
Synthesis-of-IP3-and-IP4-in-the-cytosol
|
25
|
2.99e-01
|
4.76e-01
|
0.13700
|
-8.51e-03
|
0.136000
|
9.41e-01
|
2.37e-01
|
RUNX2-regulates-bone-development
|
31
|
5.91e-01
|
7.31e-01
|
0.13700
|
1.03e-01
|
-0.089500
|
3.20e-01
|
3.88e-01
|
O-linked-glycosylation
|
98
|
5.58e-03
|
3.03e-02
|
0.13600
|
1.04e-03
|
0.136000
|
9.86e-01
|
1.95e-02
|
FGFR4-ligand-binding-and-activation
|
11
|
3.80e-01
|
5.56e-01
|
0.13600
|
-1.02e-01
|
-0.090500
|
5.59e-01
|
6.03e-01
|
YAP1–and-WWTR1-(TAZ)-stimulated-gene-expression
|
12
|
5.06e-01
|
6.64e-01
|
0.13600
|
-1.36e-01
|
-0.008520
|
4.15e-01
|
9.59e-01
|
G-beta:gamma-signalling-through-PLC-beta
|
19
|
4.68e-01
|
6.38e-01
|
0.13600
|
-2.39e-02
|
0.134000
|
8.57e-01
|
3.11e-01
|
PI-3K-cascade:FGFR1
|
16
|
5.32e-01
|
6.84e-01
|
0.13600
|
-1.34e-01
|
0.024600
|
3.54e-01
|
8.64e-01
|
PECAM1-interactions
|
12
|
6.44e-01
|
7.76e-01
|
0.13500
|
-2.95e-02
|
0.132000
|
8.60e-01
|
4.28e-01
|
FGFR2c-ligand-binding-and-activation
|
10
|
8.37e-01
|
9.06e-01
|
0.13500
|
8.07e-02
|
-0.108000
|
6.59e-01
|
5.52e-01
|
Sensory-processing-of-sound-by-outer-hair-cells-of-the-cochlea
|
48
|
2.09e-01
|
3.82e-01
|
0.13500
|
1.30e-01
|
-0.037600
|
1.20e-01
|
6.52e-01
|
Glycogen-metabolism
|
25
|
5.64e-01
|
7.07e-01
|
0.13500
|
1.20e-01
|
-0.061100
|
2.98e-01
|
5.97e-01
|
AKT-phosphorylates-targets-in-the-cytosol
|
14
|
5.44e-01
|
6.91e-01
|
0.13500
|
-1.50e-02
|
0.134000
|
9.23e-01
|
3.85e-01
|
Cardiac-conduction
|
112
|
1.17e-03
|
8.55e-03
|
0.13500
|
1.34e-01
|
0.018000
|
1.46e-02
|
7.42e-01
|
Glycogen-breakdown-(glycogenolysis)
|
14
|
5.42e-01
|
6.91e-01
|
0.13400
|
1.34e-01
|
-0.014000
|
3.86e-01
|
9.28e-01
|
Transcription-Coupled-Nucleotide-Excision-Repair-(TC-NER)
|
77
|
3.37e-02
|
1.22e-01
|
0.13400
|
1.33e-01
|
-0.012000
|
4.36e-02
|
8.56e-01
|
TP53-Regulates-Transcription-of-Genes-Involved-in-Cytochrome-C-Release
|
18
|
5.22e-01
|
6.78e-01
|
0.13300
|
1.31e-01
|
-0.028000
|
3.38e-01
|
8.37e-01
|
Toll-Like-Receptor-3-(TLR3)-Cascade
|
88
|
1.50e-01
|
3.12e-01
|
0.13300
|
6.28e-02
|
-0.118000
|
3.08e-01
|
5.65e-02
|
TGF-beta-receptor-signaling-activates-SMADs
|
31
|
5.65e-01
|
7.07e-01
|
0.13300
|
7.38e-02
|
-0.111000
|
4.77e-01
|
2.85e-01
|
Post-translational-protein-phosphorylation
|
99
|
2.04e-01
|
3.77e-01
|
0.13300
|
1.00e-01
|
-0.087800
|
8.48e-02
|
1.31e-01
|
Removal-of-the-Flap-Intermediate
|
14
|
5.80e-01
|
7.23e-01
|
0.13300
|
-2.21e-02
|
0.131000
|
8.86e-01
|
3.95e-01
|
TNF-signaling
|
42
|
3.97e-01
|
5.70e-01
|
0.13300
|
6.13e-02
|
-0.118000
|
4.91e-01
|
1.85e-01
|
PI-3K-cascade:FGFR4
|
17
|
2.42e-01
|
4.19e-01
|
0.13300
|
-8.49e-02
|
-0.102000
|
5.44e-01
|
4.65e-01
|
PI3K/AKT-Signaling-in-Cancer
|
98
|
1.87e-01
|
3.60e-01
|
0.13300
|
-1.07e-01
|
0.079100
|
6.81e-02
|
1.76e-01
|
Metabolism-of-nitric-oxide:-NOS3-activation-and-regulation
|
15
|
4.07e-01
|
5.78e-01
|
0.13300
|
-1.31e-01
|
-0.020400
|
3.80e-01
|
8.91e-01
|
Regulation-of-PLK1-Activity-at-G2/M-Transition
|
84
|
2.71e-01
|
4.51e-01
|
0.13200
|
9.22e-02
|
-0.094700
|
1.44e-01
|
1.33e-01
|
Golgi-to-ER-retrograde-transport
|
109
|
4.02e-02
|
1.34e-01
|
0.13200
|
1.25e-01
|
-0.039800
|
2.35e-02
|
4.72e-01
|
Inactivation,-recovery-and-regulation-of-the-phototransduction-cascade
|
30
|
4.62e-01
|
6.31e-01
|
0.13200
|
4.89e-02
|
-0.122000
|
6.43e-01
|
2.47e-01
|
The-phototransduction-cascade
|
30
|
4.62e-01
|
6.31e-01
|
0.13200
|
4.89e-02
|
-0.122000
|
6.43e-01
|
2.47e-01
|
Hyaluronan-metabolism
|
16
|
2.76e-01
|
4.55e-01
|
0.13100
|
7.68e-02
|
0.107000
|
5.95e-01
|
4.60e-01
|
Glucagon-type-ligand-receptors
|
28
|
1.01e-01
|
2.41e-01
|
0.13100
|
9.21e-02
|
0.093600
|
3.99e-01
|
3.91e-01
|
Metabolism
|
1892
|
1.65e-12
|
6.98e-11
|
0.13100
|
9.09e-02
|
-0.094600
|
3.66e-11
|
5.66e-12
|
Telomere-C-strand-(Lagging-Strand)-Synthesis
|
34
|
9.70e-02
|
2.34e-01
|
0.13100
|
4.25e-02
|
0.124000
|
6.68e-01
|
2.12e-01
|
Inhibition-of-replication-initiation-of-damaged-DNA-by-RB1/E2F1
|
13
|
7.54e-01
|
8.48e-01
|
0.13100
|
1.17e-01
|
-0.058800
|
4.66e-01
|
7.14e-01
|
Other-interleukin-signaling
|
22
|
7.05e-01
|
8.15e-01
|
0.13100
|
-8.22e-02
|
0.101000
|
5.05e-01
|
4.10e-01
|
Hedgehog-‘on’-state
|
83
|
1.74e-03
|
1.16e-02
|
0.13100
|
-6.60e-02
|
-0.113000
|
2.98e-01
|
7.60e-02
|
Acetylcholine-binding-and-downstream-events
|
10
|
6.49e-01
|
7.80e-01
|
0.13000
|
-9.54e-03
|
0.130000
|
9.58e-01
|
4.76e-01
|
Postsynaptic-nicotinic-acetylcholine-receptors
|
10
|
6.49e-01
|
7.80e-01
|
0.13000
|
-9.54e-03
|
0.130000
|
9.58e-01
|
4.76e-01
|
Transcriptional-Regulation-by-E2F6
|
33
|
5.41e-01
|
6.91e-01
|
0.13000
|
6.82e-02
|
-0.111000
|
4.98e-01
|
2.70e-01
|
Pre-NOTCH-Expression-and-Processing
|
50
|
2.15e-01
|
3.88e-01
|
0.13000
|
-3.53e-02
|
0.125000
|
6.66e-01
|
1.25e-01
|
Regulation-of-Insulin-like-Growth-Factor-(IGF)-transport-and-uptake-by-Insulin-like-Growth-Factor-Binding-Proteins-(IGFBPs)
|
111
|
1.89e-01
|
3.60e-01
|
0.13000
|
9.17e-02
|
-0.092100
|
9.48e-02
|
9.34e-02
|
ATF4-activates-genes-in-response-to-endoplasmic-reticulum–stress
|
24
|
3.27e-01
|
5.04e-01
|
0.13000
|
1.67e-03
|
-0.130000
|
9.89e-01
|
2.71e-01
|
MyD88-independent-TLR4-cascade
|
92
|
1.18e-01
|
2.66e-01
|
0.13000
|
5.28e-02
|
-0.118000
|
3.81e-01
|
4.95e-02
|
TRIF(TICAM1)-mediated-TLR4-signaling
|
92
|
1.18e-01
|
2.66e-01
|
0.13000
|
5.28e-02
|
-0.118000
|
3.81e-01
|
4.95e-02
|
Acyl-chain-remodelling-of-PI
|
13
|
7.83e-01
|
8.72e-01
|
0.12900
|
6.57e-02
|
-0.111000
|
6.82e-01
|
4.87e-01
|
Tie2-Signaling
|
18
|
6.00e-01
|
7.38e-01
|
0.12900
|
-3.89e-02
|
0.123000
|
7.75e-01
|
3.67e-01
|
Interleukin-12-signaling
|
44
|
4.17e-02
|
1.38e-01
|
0.12900
|
-5.74e-02
|
-0.115000
|
5.10e-01
|
1.86e-01
|
Energy-dependent-regulation-of-mTOR-by-LKB1-AMPK
|
29
|
1.47e-01
|
3.08e-01
|
0.12900
|
1.22e-01
|
0.041200
|
2.56e-01
|
7.01e-01
|
Phase-4—resting-membrane-potential
|
15
|
8.01e-01
|
8.87e-01
|
0.12800
|
-8.61e-02
|
0.095100
|
5.63e-01
|
5.24e-01
|
Metabolism-of-RNA
|
646
|
3.60e-08
|
1.30e-06
|
0.12800
|
4.09e-02
|
-0.121000
|
7.52e-02
|
1.26e-07
|
NCAM-signaling-for-neurite-out-growth
|
57
|
1.37e-02
|
6.25e-02
|
0.12800
|
7.16e-02
|
0.106000
|
3.50e-01
|
1.66e-01
|
Association-of-TriC/CCT-with-target-proteins-during-biosynthesis
|
37
|
6.66e-02
|
1.85e-01
|
0.12800
|
-1.11e-01
|
-0.063800
|
2.44e-01
|
5.01e-01
|
Thrombin-signalling-through-proteinase-activated-receptors-(PARs)
|
31
|
3.95e-01
|
5.69e-01
|
0.12700
|
-3.29e-02
|
0.123000
|
7.51e-01
|
2.37e-01
|
Diseases-of-DNA-repair
|
33
|
1.02e-01
|
2.43e-01
|
0.12700
|
1.15e-01
|
0.053200
|
2.52e-01
|
5.97e-01
|
RHO-GTPases-activate-PAKs
|
21
|
4.72e-01
|
6.40e-01
|
0.12700
|
1.25e-01
|
-0.019400
|
3.21e-01
|
8.78e-01
|
Signaling-by-cytosolic-FGFR1-fusion-mutants
|
17
|
2.83e-01
|
4.59e-01
|
0.12600
|
-7.86e-02
|
-0.097900
|
5.75e-01
|
4.84e-01
|
Nuclear-Pore-Complex-(NPC)-Disassembly
|
34
|
2.74e-01
|
4.53e-01
|
0.12500
|
1.25e-01
|
-0.012900
|
2.08e-01
|
8.97e-01
|
Signaling-by-NOTCH4
|
79
|
2.66e-02
|
1.01e-01
|
0.12500
|
-3.56e-03
|
-0.125000
|
9.56e-01
|
5.41e-02
|
VEGFA-VEGFR2-Pathway
|
92
|
2.75e-01
|
4.53e-01
|
0.12500
|
-9.28e-02
|
0.084000
|
1.24e-01
|
1.63e-01
|
Competing-endogenous-RNAs-(ceRNAs)-regulate-PTEN-translation
|
10
|
8.70e-01
|
9.30e-01
|
0.12500
|
-8.80e-02
|
0.088800
|
6.30e-01
|
6.27e-01
|
NS1-Mediated-Effects-on-Host-Pathways
|
36
|
3.96e-01
|
5.70e-01
|
0.12500
|
1.18e-01
|
-0.040100
|
2.19e-01
|
6.77e-01
|
Fc-epsilon-receptor-(FCERI)-signaling
|
138
|
3.08e-03
|
1.88e-02
|
0.12500
|
4.13e-03
|
-0.125000
|
9.33e-01
|
1.12e-02
|
Synthesis-of-PIPs-at-the-Golgi-membrane
|
17
|
4.69e-01
|
6.38e-01
|
0.12500
|
1.23e-03
|
0.125000
|
9.93e-01
|
3.73e-01
|
Sialic-acid-metabolism
|
30
|
2.66e-01
|
4.44e-01
|
0.12400
|
1.30e-03
|
0.124000
|
9.90e-01
|
2.39e-01
|
Biosynthesis-of-DHA-derived-SPMs
|
15
|
3.37e-01
|
5.13e-01
|
0.12400
|
7.76e-02
|
0.097000
|
6.03e-01
|
5.15e-01
|
MET-activates-RAS-signaling
|
11
|
8.58e-01
|
9.24e-01
|
0.12400
|
9.28e-02
|
-0.082100
|
5.94e-01
|
6.37e-01
|
SUMOylation
|
166
|
9.21e-02
|
2.25e-01
|
0.12400
|
-9.72e-02
|
0.076400
|
3.05e-02
|
8.92e-02
|
Neuronal-System
|
352
|
6.85e-09
|
2.67e-07
|
0.12400
|
1.21e-01
|
0.023300
|
8.82e-05
|
4.52e-01
|
Voltage-gated-Potassium-channels
|
38
|
4.13e-01
|
5.82e-01
|
0.12400
|
1.15e-01
|
-0.044300
|
2.19e-01
|
6.36e-01
|
Deadenylation-dependent-mRNA-decay
|
54
|
7.82e-02
|
2.01e-01
|
0.12400
|
-1.23e-01
|
-0.008850
|
1.17e-01
|
9.10e-01
|
Cell-Cycle
|
603
|
1.23e-04
|
1.34e-03
|
0.12300
|
1.01e-01
|
-0.071000
|
2.22e-05
|
2.83e-03
|
RUNX1-regulates-genes-involved-in-megakaryocyte-differentiation-and-platelet-function
|
37
|
5.18e-01
|
6.75e-01
|
0.12300
|
-1.07e-01
|
0.060200
|
2.58e-01
|
5.26e-01
|
Carnitine-metabolism
|
12
|
4.29e-01
|
5.98e-01
|
0.12200
|
-7.63e-02
|
-0.095800
|
6.47e-01
|
5.65e-01
|
NR1H2-and-NR1H3-mediated-signaling
|
44
|
5.52e-01
|
6.96e-01
|
0.12200
|
9.11e-02
|
-0.081800
|
2.96e-01
|
3.47e-01
|
Metabolism-of-non-coding-RNA
|
50
|
5.06e-01
|
6.64e-01
|
0.12200
|
-7.81e-02
|
0.093400
|
3.39e-01
|
2.53e-01
|
snRNP-Assembly
|
50
|
5.06e-01
|
6.64e-01
|
0.12200
|
-7.81e-02
|
0.093400
|
3.39e-01
|
2.53e-01
|
Nephrin-family-interactions
|
22
|
4.60e-01
|
6.30e-01
|
0.12200
|
1.21e-01
|
-0.013700
|
3.26e-01
|
9.11e-01
|
Regulation-of-TNFR1-signaling
|
33
|
3.00e-01
|
4.76e-01
|
0.12100
|
1.06e-02
|
-0.121000
|
9.16e-01
|
2.30e-01
|
Activation-of-ATR-in-response-to-replication-stress
|
37
|
1.28e-01
|
2.80e-01
|
0.12100
|
1.17e-01
|
0.031900
|
2.19e-01
|
7.37e-01
|
Response-of-Mtb-to-phagocytosis
|
21
|
6.46e-01
|
7.77e-01
|
0.12100
|
4.76e-02
|
-0.111000
|
7.06e-01
|
3.78e-01
|
Polymerase-switching-on-the-C-strand-of-the-telomere
|
26
|
2.60e-01
|
4.38e-01
|
0.12100
|
2.34e-02
|
0.118000
|
8.37e-01
|
2.96e-01
|
Chromatin-modifying-enzymes
|
198
|
7.55e-02
|
1.98e-01
|
0.12000
|
-9.06e-02
|
0.079200
|
2.78e-02
|
5.45e-02
|
Chromatin-organization
|
198
|
7.55e-02
|
1.98e-01
|
0.12000
|
-9.06e-02
|
0.079200
|
2.78e-02
|
5.45e-02
|
Signaling-by-Receptor-Tyrosine-Kinases
|
482
|
7.02e-04
|
5.65e-03
|
0.12000
|
-6.50e-02
|
0.101000
|
1.43e-02
|
1.42e-04
|
Carboxyterminal-post-translational-modifications-of-tubulin
|
34
|
1.62e-01
|
3.29e-01
|
0.12000
|
1.16e-01
|
0.028900
|
2.40e-01
|
7.71e-01
|
Downstream-TCR-signaling
|
89
|
3.37e-03
|
2.02e-02
|
0.11900
|
-6.02e-02
|
-0.103000
|
3.26e-01
|
9.28e-02
|
Centrosome-maturation
|
77
|
2.59e-01
|
4.36e-01
|
0.11900
|
1.06e-01
|
-0.054700
|
1.09e-01
|
4.06e-01
|
Recruitment-of-mitotic-centrosome-proteins-and-complexes
|
77
|
2.59e-01
|
4.36e-01
|
0.11900
|
1.06e-01
|
-0.054700
|
1.09e-01
|
4.06e-01
|
Nucleotide-binding-domain,-leucine-rich-repeat-containing-receptor-(NLR)-signaling-pathways
|
50
|
3.31e-01
|
5.08e-01
|
0.11900
|
-1.11e-01
|
0.040800
|
1.73e-01
|
6.18e-01
|
ALK-mutants-bind-TKIs
|
11
|
5.49e-01
|
6.93e-01
|
0.11800
|
3.50e-02
|
0.113000
|
8.40e-01
|
5.17e-01
|
Nicotinate-metabolism
|
29
|
3.10e-01
|
4.89e-01
|
0.11800
|
-2.32e-03
|
-0.118000
|
9.83e-01
|
2.71e-01
|
CTLA4-inhibitory-signaling
|
21
|
2.96e-01
|
4.74e-01
|
0.11800
|
1.09e-01
|
0.044600
|
3.86e-01
|
7.24e-01
|
Transport-of-Ribonucleoproteins-into-the-Host-Nucleus
|
30
|
2.83e-01
|
4.59e-01
|
0.11800
|
1.18e-01
|
0.006300
|
2.64e-01
|
9.52e-01
|
CD209-(DC-SIGN)-signaling
|
19
|
7.90e-01
|
8.78e-01
|
0.11800
|
-8.12e-02
|
0.085400
|
5.40e-01
|
5.19e-01
|
Interferon-gamma-signaling
|
70
|
2.58e-01
|
4.36e-01
|
0.11800
|
-4.76e-02
|
0.108000
|
4.91e-01
|
1.19e-01
|
Signaling-by-ERBB2
|
47
|
9.48e-02
|
2.30e-01
|
0.11700
|
-2.54e-02
|
-0.115000
|
7.63e-01
|
1.74e-01
|
Sphingolipid-de-novo-biosynthesis
|
42
|
6.41e-02
|
1.80e-01
|
0.11700
|
-8.18e-02
|
-0.084200
|
3.59e-01
|
3.45e-01
|
Defective-HDR-through-Homologous-Recombination-(HRR)-due-to-PALB2-loss-of-function
|
24
|
3.40e-01
|
5.15e-01
|
0.11700
|
1.17e-01
|
0.013600
|
3.23e-01
|
9.08e-01
|
Defective-HDR-through-Homologous-Recombination-Repair-(HRR)-due-to-PALB2-loss-of-BRCA1-binding-function
|
24
|
3.40e-01
|
5.15e-01
|
0.11700
|
1.17e-01
|
0.013600
|
3.23e-01
|
9.08e-01
|
Defective-HDR-through-Homologous-Recombination-Repair-(HRR)-due-to-PALB2-loss-of-BRCA2/RAD51/RAD51C-binding-function
|
24
|
3.40e-01
|
5.15e-01
|
0.11700
|
1.17e-01
|
0.013600
|
3.23e-01
|
9.08e-01
|
Diseases-of-DNA-Double-Strand-Break-Repair
|
24
|
3.40e-01
|
5.15e-01
|
0.11700
|
1.17e-01
|
0.013600
|
3.23e-01
|
9.08e-01
|
Antimicrobial-peptides
|
35
|
2.58e-01
|
4.36e-01
|
0.11700
|
1.17e-01
|
0.000302
|
2.31e-01
|
9.98e-01
|
Downstream-signaling-of-activated-FGFR4
|
24
|
2.67e-01
|
4.45e-01
|
0.11700
|
-3.87e-02
|
-0.110000
|
7.43e-01
|
3.49e-01
|
TCR-signaling
|
111
|
6.40e-03
|
3.34e-02
|
0.11700
|
-1.16e-01
|
-0.016000
|
3.50e-02
|
7.71e-01
|
Interferon-alpha/beta-signaling
|
44
|
5.83e-01
|
7.25e-01
|
0.11700
|
-7.76e-02
|
0.087100
|
3.73e-01
|
3.18e-01
|
Chromosome-Maintenance
|
88
|
1.36e-01
|
2.94e-01
|
0.11600
|
1.11e-01
|
-0.036300
|
7.27e-02
|
5.56e-01
|
Signaling-by-PDGFR-in-disease
|
19
|
6.94e-01
|
8.09e-01
|
0.11600
|
-1.07e-01
|
0.045900
|
4.20e-01
|
7.29e-01
|
Signaling-by-FGFR2
|
66
|
2.93e-01
|
4.71e-01
|
0.11600
|
4.71e-02
|
-0.106000
|
5.08e-01
|
1.37e-01
|
Loss-of-Nlp-from-mitotic-centrosomes
|
67
|
3.71e-01
|
5.47e-01
|
0.11500
|
9.87e-02
|
-0.059000
|
1.62e-01
|
4.04e-01
|
Loss-of-proteins-required-for-interphase-microtubule-organization-from-the-centrosome
|
67
|
3.71e-01
|
5.47e-01
|
0.11500
|
9.87e-02
|
-0.059000
|
1.62e-01
|
4.04e-01
|
Regulation-of-TP53-Activity-through-Phosphorylation
|
88
|
1.84e-01
|
3.59e-01
|
0.11500
|
1.06e-01
|
-0.043700
|
8.51e-02
|
4.78e-01
|
Thromboxane-signalling-through-TP-receptor
|
23
|
3.48e-01
|
5.23e-01
|
0.11400
|
2.11e-02
|
0.112000
|
8.61e-01
|
3.51e-01
|
Transcriptional-regulation-by-small-RNAs
|
46
|
2.68e-01
|
4.46e-01
|
0.11400
|
1.13e-01
|
-0.018500
|
1.86e-01
|
8.28e-01
|
Synthesis-of-glycosylphosphatidylinositol-(GPI)
|
18
|
3.37e-01
|
5.13e-01
|
0.11400
|
-6.59e-02
|
-0.093200
|
6.28e-01
|
4.94e-01
|
Gastrin-CREB-signalling-pathway-via-PKC-and-MAPK
|
17
|
5.87e-01
|
7.27e-01
|
0.11400
|
1.13e-01
|
-0.012300
|
4.18e-01
|
9.30e-01
|
Signaling-by-TGFB-family-members
|
98
|
3.73e-02
|
1.28e-01
|
0.11400
|
6.26e-03
|
-0.113000
|
9.15e-01
|
5.22e-02
|
CASP8-activity-is-inhibited
|
10
|
8.22e-01
|
9.01e-01
|
0.11400
|
-1.06e-01
|
0.041200
|
5.62e-01
|
8.22e-01
|
Dimerization-of-procaspase-8
|
10
|
8.22e-01
|
9.01e-01
|
0.11400
|
-1.06e-01
|
0.041200
|
5.62e-01
|
8.22e-01
|
Regulation-by-c-FLIP
|
10
|
8.22e-01
|
9.01e-01
|
0.11400
|
-1.06e-01
|
0.041200
|
5.62e-01
|
8.22e-01
|
VLDLR-internalisation-and-degradation
|
12
|
4.86e-01
|
6.49e-01
|
0.11300
|
9.06e-02
|
0.068200
|
5.87e-01
|
6.83e-01
|
Developmental-Biology
|
833
|
2.36e-05
|
3.75e-04
|
0.11300
|
9.37e-02
|
-0.063100
|
3.91e-06
|
1.87e-03
|
Depolymerisation-of-the-Nuclear-Lamina
|
15
|
6.94e-01
|
8.09e-01
|
0.11300
|
1.10e-01
|
-0.027600
|
4.62e-01
|
8.53e-01
|
Protein-ubiquitination
|
60
|
5.28e-02
|
1.59e-01
|
0.11300
|
-1.09e-01
|
-0.031200
|
1.46e-01
|
6.75e-01
|
Cell-surface-interactions-at-the-vascular-wall
|
126
|
3.05e-02
|
1.12e-01
|
0.11200
|
-1.84e-02
|
0.111000
|
7.22e-01
|
3.14e-02
|
TP53-regulates-transcription-of-several-additional-cell-death-genes-whose-specific-roles-in-p53-dependent-apoptosis-remain-uncertain
|
13
|
8.64e-01
|
9.27e-01
|
0.11200
|
7.68e-02
|
-0.081700
|
6.32e-01
|
6.10e-01
|
Hedgehog-‘off’-state
|
96
|
9.42e-03
|
4.52e-02
|
0.11200
|
-1.07e-01
|
-0.032200
|
6.91e-02
|
5.86e-01
|
Interleukin-4-and-Interleukin-13-signaling
|
101
|
2.97e-01
|
4.74e-01
|
0.11200
|
-6.78e-02
|
0.089100
|
2.39e-01
|
1.21e-01
|
Interleukin-17-signaling
|
68
|
4.69e-01
|
6.38e-01
|
0.11200
|
8.07e-02
|
-0.077400
|
2.50e-01
|
2.69e-01
|
Transcriptional-regulation-by-RUNX3
|
93
|
1.55e-02
|
6.83e-02
|
0.11200
|
-2.28e-02
|
-0.109000
|
7.04e-01
|
6.80e-02
|
G-protein-activation
|
21
|
3.67e-01
|
5.43e-01
|
0.11200
|
3.05e-02
|
0.107000
|
8.09e-01
|
3.94e-01
|
COPI-mediated-anterograde-transport
|
80
|
4.18e-02
|
1.38e-01
|
0.11200
|
1.11e-01
|
0.010800
|
8.57e-02
|
8.67e-01
|
Beta-defensins
|
17
|
6.74e-01
|
7.98e-01
|
0.11200
|
1.08e-01
|
-0.028600
|
4.42e-01
|
8.38e-01
|
Organelle-biogenesis-and-maintenance
|
247
|
3.38e-02
|
1.22e-01
|
0.11100
|
-5.76e-02
|
0.095400
|
1.19e-01
|
9.69e-03
|
Processive-synthesis-on-the-lagging-strand
|
15
|
4.78e-01
|
6.45e-01
|
0.11100
|
3.55e-02
|
0.105000
|
8.12e-01
|
4.81e-01
|
Degradation-of-the-extracellular-matrix
|
99
|
8.49e-02
|
2.13e-01
|
0.11100
|
-2.31e-02
|
0.108000
|
6.91e-01
|
6.21e-02
|
Transcriptional-Regulation-by-TP53
|
338
|
4.79e-03
|
2.69e-02
|
0.11100
|
9.96e-02
|
-0.048400
|
1.61e-03
|
1.25e-01
|
Aggrephagy
|
21
|
4.08e-01
|
5.78e-01
|
0.11100
|
-1.95e-02
|
-0.109000
|
8.77e-01
|
3.87e-01
|
RHOJ-GTPase-cycle
|
55
|
5.08e-01
|
6.65e-01
|
0.11100
|
-6.34e-02
|
0.090700
|
4.16e-01
|
2.45e-01
|
Acyl-chain-remodelling-of-PG
|
16
|
6.56e-01
|
7.85e-01
|
0.11000
|
1.08e-01
|
-0.018600
|
4.53e-01
|
8.97e-01
|
Programmed-Cell-Death
|
185
|
1.24e-01
|
2.74e-01
|
0.11000
|
6.83e-02
|
-0.086100
|
1.09e-01
|
4.31e-02
|
Neddylation
|
224
|
1.16e-02
|
5.42e-02
|
0.11000
|
3.46e-02
|
-0.104000
|
3.71e-01
|
7.19e-03
|
RAC1-GTPase-cycle
|
180
|
6.45e-02
|
1.81e-01
|
0.11000
|
-4.92e-02
|
0.098000
|
2.55e-01
|
2.31e-02
|
CD28-co-stimulation
|
33
|
6.99e-01
|
8.12e-01
|
0.11000
|
-7.28e-02
|
0.081900
|
4.69e-01
|
4.15e-01
|
Transmission-across-Chemical-Synapses
|
227
|
3.10e-04
|
2.96e-03
|
0.11000
|
1.09e-01
|
0.004750
|
4.45e-03
|
9.02e-01
|
Post-chaperonin-tubulin-folding-pathway
|
17
|
4.84e-01
|
6.48e-01
|
0.10900
|
1.07e-01
|
0.022200
|
4.46e-01
|
8.74e-01
|
RNA-Pol-II-CTD-phosphorylation-and-interaction-with-CE
|
27
|
3.27e-01
|
5.04e-01
|
0.10900
|
1.07e-01
|
0.019200
|
3.34e-01
|
8.63e-01
|
RNA-Pol-II-CTD-phosphorylation-and-interaction-with-CE-during-HIV-infection
|
27
|
3.27e-01
|
5.04e-01
|
0.10900
|
1.07e-01
|
0.019200
|
3.34e-01
|
8.63e-01
|
SARS-CoV-Infections
|
147
|
2.14e-01
|
3.88e-01
|
0.10900
|
-7.56e-02
|
0.078200
|
1.13e-01
|
1.01e-01
|
Hyaluronan-uptake-and-degradation
|
12
|
6.15e-01
|
7.48e-01
|
0.10900
|
1.75e-02
|
0.107000
|
9.17e-01
|
5.20e-01
|
Intra-Golgi-and-retrograde-Golgi-to-ER-traffic
|
173
|
6.88e-02
|
1.88e-01
|
0.10900
|
9.80e-02
|
-0.047000
|
2.60e-02
|
2.86e-01
|
MAP-kinase-activation
|
61
|
4.85e-01
|
6.49e-01
|
0.10800
|
6.20e-02
|
-0.089000
|
4.02e-01
|
2.29e-01
|
SUMO-E3-ligases-SUMOylate-target-proteins
|
160
|
1.65e-01
|
3.33e-01
|
0.10800
|
-8.65e-02
|
0.065000
|
5.87e-02
|
1.56e-01
|
CREB1-phosphorylation-through-the-activation-of-Adenylate-Cyclase
|
11
|
8.76e-01
|
9.33e-01
|
0.10800
|
-5.96e-02
|
0.089600
|
7.32e-01
|
6.07e-01
|
G-beta:gamma-signalling-through-BTK
|
17
|
3.93e-01
|
5.67e-01
|
0.10800
|
7.87e-02
|
0.073400
|
5.74e-01
|
6.00e-01
|
Muscle-contraction
|
174
|
4.08e-04
|
3.64e-03
|
0.10700
|
1.02e-01
|
0.031900
|
1.96e-02
|
4.68e-01
|
Vpr-mediated-nuclear-import-of-PICs
|
32
|
4.21e-01
|
5.90e-01
|
0.10700
|
1.06e-01
|
-0.013000
|
2.98e-01
|
8.99e-01
|
TRAF3-dependent-IRF-activation-pathway
|
13
|
5.76e-01
|
7.19e-01
|
0.10700
|
-1.04e-01
|
-0.025100
|
5.16e-01
|
8.75e-01
|
Translesion-synthesis-by-Y-family-DNA-polymerases-bypasses-lesions-on-DNA-template
|
37
|
6.10e-01
|
7.46e-01
|
0.10600
|
9.30e-02
|
-0.051700
|
3.28e-01
|
5.86e-01
|
Common-Pathway-of-Fibrin-Clot-Formation
|
20
|
8.15e-01
|
8.96e-01
|
0.10600
|
7.93e-02
|
-0.070900
|
5.39e-01
|
5.83e-01
|
Removal-of-the-Flap-Intermediate-from-the-C-strand
|
17
|
6.91e-01
|
8.09e-01
|
0.10600
|
-2.55e-02
|
0.103000
|
8.56e-01
|
4.61e-01
|
Selective-autophagy
|
59
|
5.31e-01
|
6.84e-01
|
0.10600
|
6.48e-02
|
-0.084000
|
3.89e-01
|
2.64e-01
|
Caspase-activation-via-Death-Receptors-in-the-presence-of-ligand
|
15
|
5.07e-01
|
6.64e-01
|
0.10500
|
-9.78e-02
|
-0.037900
|
5.12e-01
|
8.00e-01
|
Resolution-of-D-Loop-Structures
|
33
|
2.06e-01
|
3.79e-01
|
0.10500
|
9.38e-02
|
0.046800
|
3.51e-01
|
6.42e-01
|
Regulation-of-IFNG-signaling
|
13
|
8.03e-01
|
8.87e-01
|
0.10500
|
3.71e-02
|
-0.097900
|
8.17e-01
|
5.41e-01
|
Methylation
|
14
|
5.37e-01
|
6.89e-01
|
0.10500
|
-9.83e-02
|
-0.035700
|
5.24e-01
|
8.17e-01
|
NOTCH2-Activation-and-Transmission-of-Signal-to-the-Nucleus
|
21
|
7.53e-01
|
8.48e-01
|
0.10400
|
-9.27e-02
|
0.048000
|
4.62e-01
|
7.03e-01
|
NGF-stimulated-transcription
|
39
|
4.10e-01
|
5.80e-01
|
0.10400
|
-1.02e-01
|
0.019500
|
2.69e-01
|
8.33e-01
|
HCMV-Early-Events
|
57
|
3.87e-01
|
5.62e-01
|
0.10400
|
-3.69e-02
|
0.097200
|
6.30e-01
|
2.04e-01
|
Metabolism-of-amine-derived-hormones
|
16
|
7.46e-01
|
8.44e-01
|
0.10400
|
3.14e-02
|
-0.098800
|
8.28e-01
|
4.94e-01
|
G-alpha-(12/13)-signalling-events
|
77
|
4.08e-02
|
1.36e-01
|
0.10400
|
2.97e-02
|
0.099200
|
6.52e-01
|
1.32e-01
|
HSF1-activation
|
25
|
3.86e-01
|
5.61e-01
|
0.10400
|
-1.02e-01
|
-0.020100
|
3.79e-01
|
8.62e-01
|
Platelet-sensitization-by-LDL
|
17
|
7.33e-01
|
8.35e-01
|
0.10400
|
9.86e-02
|
-0.031400
|
4.81e-01
|
8.22e-01
|
Membrane-Trafficking
|
578
|
2.43e-03
|
1.54e-02
|
0.10300
|
8.41e-02
|
-0.060200
|
5.27e-04
|
1.30e-02
|
Reversible-hydration-of-carbon-dioxide
|
12
|
7.88e-01
|
8.76e-01
|
0.10300
|
9.99e-02
|
-0.026700
|
5.49e-01
|
8.73e-01
|
PI-Metabolism
|
82
|
2.61e-02
|
1.01e-01
|
0.10300
|
3.88e-02
|
0.095900
|
5.43e-01
|
1.33e-01
|
AKT-phosphorylates-targets-in-the-nucleus
|
10
|
8.71e-01
|
9.30e-01
|
0.10300
|
4.55e-02
|
-0.092900
|
8.03e-01
|
6.11e-01
|
Syndecan-interactions
|
20
|
4.28e-01
|
5.98e-01
|
0.10300
|
3.38e-02
|
0.097000
|
7.94e-01
|
4.53e-01
|
rRNA-modification-in-the-nucleus-and-cytosol
|
58
|
5.98e-02
|
1.74e-01
|
0.10300
|
-8.49e-02
|
-0.057600
|
2.63e-01
|
4.47e-01
|
Signaling-by-the-B-Cell-Receptor-(BCR)
|
120
|
2.66e-03
|
1.67e-02
|
0.10200
|
-6.58e-02
|
-0.078500
|
2.13e-01
|
1.37e-01
|
Ion-homeostasis
|
49
|
1.52e-01
|
3.14e-01
|
0.10200
|
9.97e-02
|
0.023200
|
2.27e-01
|
7.79e-01
|
Cleavage-of-the-damaged-pyrimidine
|
16
|
6.93e-01
|
8.09e-01
|
0.10200
|
1.01e-01
|
-0.016700
|
4.86e-01
|
9.08e-01
|
Depyrimidination
|
16
|
6.93e-01
|
8.09e-01
|
0.10200
|
1.01e-01
|
-0.016700
|
4.86e-01
|
9.08e-01
|
Recognition-and-association-of-DNA-glycosylase-with-site-containing-an-affected-pyrimidine
|
16
|
6.93e-01
|
8.09e-01
|
0.10200
|
1.01e-01
|
-0.016700
|
4.86e-01
|
9.08e-01
|
Aquaporin-mediated-transport
|
47
|
2.97e-01
|
4.74e-01
|
0.10200
|
1.02e-01
|
-0.008850
|
2.28e-01
|
9.16e-01
|
ADP-signalling-through-P2Y-purinoceptor-12
|
20
|
6.43e-01
|
7.75e-01
|
0.10200
|
1.00e-01
|
-0.018500
|
4.38e-01
|
8.86e-01
|
Signaling-by-FGFR4
|
37
|
4.92e-01
|
6.55e-01
|
0.10200
|
2.63e-02
|
-0.098200
|
7.82e-01
|
3.01e-01
|
Interleukin-37-signaling
|
20
|
3.86e-01
|
5.62e-01
|
0.10200
|
-5.72e-02
|
-0.083800
|
6.58e-01
|
5.16e-01
|
Metabolism-of-nucleotides
|
93
|
4.22e-01
|
5.90e-01
|
0.10100
|
7.64e-02
|
-0.066200
|
2.03e-01
|
2.69e-01
|
Glutathione-conjugation
|
29
|
7.55e-01
|
8.48e-01
|
0.10100
|
6.16e-02
|
-0.079800
|
5.66e-01
|
4.57e-01
|
Interactions-of-Rev-with-host-cellular-proteins
|
34
|
2.30e-01
|
4.06e-01
|
0.10100
|
4.13e-02
|
0.091900
|
6.77e-01
|
3.54e-01
|
Dual-incision-in-TC-NER
|
64
|
1.12e-01
|
2.55e-01
|
0.10100
|
9.95e-02
|
0.014900
|
1.68e-01
|
8.37e-01
|
ZBP1(DAI)-mediated-induction-of-type-I-IFNs
|
20
|
7.01e-01
|
8.13e-01
|
0.10100
|
9.63e-02
|
-0.029000
|
4.56e-01
|
8.22e-01
|
Phospholipase-C-mediated-cascade;-FGFR3
|
11
|
8.02e-01
|
8.87e-01
|
0.10100
|
2.24e-02
|
-0.098000
|
8.98e-01
|
5.74e-01
|
Diseases-of-carbohydrate-metabolism
|
30
|
5.01e-01
|
6.62e-01
|
0.10000
|
-9.92e-02
|
0.013600
|
3.47e-01
|
8.98e-01
|
Signalling-to-ERKs
|
33
|
6.62e-01
|
7.88e-01
|
0.09970
|
-4.52e-02
|
0.088800
|
6.53e-01
|
3.77e-01
|
Interleukin-12-family-signaling
|
54
|
8.38e-02
|
2.11e-01
|
0.09950
|
-8.12e-02
|
-0.057500
|
3.02e-01
|
4.65e-01
|
Ca2+-pathway
|
60
|
3.99e-01
|
5.70e-01
|
0.09940
|
-3.48e-02
|
0.093100
|
6.41e-01
|
2.12e-01
|
Formation-of-HIV-elongation-complex-in-the-absence-of-HIV-Tat
|
41
|
2.21e-01
|
3.95e-01
|
0.09910
|
9.60e-02
|
0.024500
|
2.87e-01
|
7.86e-01
|
Metabolism-of-carbohydrates
|
266
|
4.82e-06
|
1.23e-04
|
0.09890
|
6.86e-02
|
0.071200
|
5.37e-02
|
4.54e-02
|
Formation-of-HIV-1-elongation-complex-containing-HIV-1-Tat
|
39
|
1.75e-01
|
3.45e-01
|
0.09860
|
8.24e-02
|
0.054200
|
3.73e-01
|
5.58e-01
|
HIV-Transcription-Elongation
|
39
|
1.75e-01
|
3.45e-01
|
0.09860
|
8.24e-02
|
0.054200
|
3.73e-01
|
5.58e-01
|
Tat-mediated-elongation-of-the-HIV-1-transcript
|
39
|
1.75e-01
|
3.45e-01
|
0.09860
|
8.24e-02
|
0.054200
|
3.73e-01
|
5.58e-01
|
Cyclin-D-associated-events-in-G1
|
45
|
5.67e-01
|
7.09e-01
|
0.09850
|
8.86e-02
|
-0.043100
|
3.04e-01
|
6.16e-01
|
G1-Phase
|
45
|
5.67e-01
|
7.09e-01
|
0.09850
|
8.86e-02
|
-0.043100
|
3.04e-01
|
6.16e-01
|
Class-C/3-(Metabotropic-glutamate/pheromone-receptors)
|
21
|
5.21e-01
|
6.78e-01
|
0.09850
|
9.75e-03
|
0.098000
|
9.38e-01
|
4.37e-01
|
CD28-dependent-PI3K/Akt-signaling
|
22
|
7.93e-01
|
8.80e-01
|
0.09830
|
-5.20e-02
|
0.083500
|
6.73e-01
|
4.98e-01
|
Sensory-Perception
|
189
|
1.64e-01
|
3.32e-01
|
0.09820
|
8.01e-02
|
-0.056800
|
5.74e-02
|
1.77e-01
|
TFAP2-(AP-2)-family-regulates-transcription-of-growth-factors-and-their-receptors
|
11
|
9.09e-01
|
9.50e-01
|
0.09790
|
-6.46e-02
|
0.073600
|
7.10e-01
|
6.73e-01
|
RHOH-GTPase-cycle
|
37
|
6.24e-01
|
7.57e-01
|
0.09770
|
-4.15e-02
|
0.088400
|
6.62e-01
|
3.52e-01
|
Gap-filling-DNA-repair-synthesis-and-ligation-in-TC-NER
|
63
|
7.76e-02
|
2.00e-01
|
0.09760
|
8.90e-02
|
0.040100
|
2.22e-01
|
5.82e-01
|
NOTCH1-Intracellular-Domain-Regulates-Transcription
|
46
|
6.03e-01
|
7.40e-01
|
0.09740
|
-4.82e-02
|
0.084600
|
5.72e-01
|
3.21e-01
|
Mitotic-Prophase
|
81
|
3.13e-01
|
4.91e-01
|
0.09730
|
9.07e-02
|
-0.035200
|
1.58e-01
|
5.84e-01
|
Cell-cell-junction-organization
|
53
|
2.74e-01
|
4.53e-01
|
0.09720
|
9.70e-02
|
-0.005760
|
2.22e-01
|
9.42e-01
|
PPARA-activates-gene-expression
|
114
|
6.42e-03
|
3.34e-02
|
0.09710
|
-7.48e-02
|
-0.061900
|
1.68e-01
|
2.53e-01
|
Recruitment-of-NuMA-to-mitotic-centrosomes
|
77
|
3.36e-01
|
5.13e-01
|
0.09690
|
9.03e-02
|
-0.035400
|
1.71e-01
|
5.92e-01
|
Base-Excision-Repair,-AP-Site-Formation
|
18
|
6.59e-01
|
7.87e-01
|
0.09680
|
9.64e-02
|
-0.008700
|
4.79e-01
|
9.49e-01
|
Glyoxylate-metabolism-and-glycine-degradation
|
30
|
5.39e-01
|
6.90e-01
|
0.09660
|
1.54e-02
|
-0.095300
|
8.84e-01
|
3.66e-01
|
Transport-to-the-Golgi-and-subsequent-modification
|
161
|
1.06e-01
|
2.47e-01
|
0.09650
|
8.98e-02
|
-0.035200
|
4.91e-02
|
4.40e-01
|
Disorders-of-transmembrane-transporters
|
169
|
1.88e-01
|
3.60e-01
|
0.09590
|
5.10e-02
|
-0.081200
|
2.52e-01
|
6.82e-02
|
Extra-nuclear-estrogen-signaling
|
71
|
2.32e-01
|
4.08e-01
|
0.09570
|
9.47e-02
|
-0.014300
|
1.68e-01
|
8.35e-01
|
PI3K-Cascade
|
38
|
3.55e-01
|
5.30e-01
|
0.09540
|
-9.53e-02
|
-0.004490
|
3.09e-01
|
9.62e-01
|
Regulation-of-lipid-metabolism-by-PPARalpha
|
116
|
6.94e-03
|
3.56e-02
|
0.09520
|
-7.01e-02
|
-0.064400
|
1.92e-01
|
2.30e-01
|
NOTCH4-Activation-and-Transmission-of-Signal-to-the-Nucleus
|
10
|
9.16e-01
|
9.52e-01
|
0.09510
|
-7.65e-02
|
0.056500
|
6.75e-01
|
7.57e-01
|
ADORA2B-mediated-anti-inflammatory-cytokines-production
|
107
|
1.44e-01
|
3.05e-01
|
0.09460
|
-1.98e-02
|
0.092500
|
7.23e-01
|
9.83e-02
|
Transport-of-Mature-mRNA-derived-from-an-Intron-Containing-Transcript
|
71
|
5.74e-01
|
7.17e-01
|
0.09390
|
-6.68e-02
|
0.065900
|
3.30e-01
|
3.37e-01
|
Integration-of-energy-metabolism
|
104
|
2.57e-02
|
9.95e-02
|
0.09320
|
8.76e-02
|
0.031900
|
1.22e-01
|
5.74e-01
|
Amyloid-fiber-formation
|
44
|
4.88e-01
|
6.52e-01
|
0.09320
|
-2.35e-02
|
0.090200
|
7.87e-01
|
3.00e-01
|
Biosynthesis-of-specialized-proresolving-mediators-(SPMs)
|
17
|
5.26e-01
|
6.79e-01
|
0.09320
|
8.36e-02
|
0.041100
|
5.50e-01
|
7.69e-01
|
HIV-Life-Cycle
|
137
|
1.89e-01
|
3.60e-01
|
0.09320
|
8.54e-02
|
-0.037200
|
8.40e-02
|
4.52e-01
|
MTOR-signalling
|
41
|
4.83e-01
|
6.48e-01
|
0.09280
|
9.09e-02
|
-0.018700
|
3.14e-01
|
8.36e-01
|
Regulation-of-TP53-Activity
|
153
|
7.57e-02
|
1.98e-01
|
0.09270
|
9.03e-02
|
-0.020900
|
5.37e-02
|
6.56e-01
|
Rev-mediated-nuclear-export-of-HIV-RNA
|
33
|
3.52e-01
|
5.27e-01
|
0.09240
|
2.19e-02
|
0.089800
|
8.28e-01
|
3.72e-01
|
Pyroptosis
|
21
|
7.55e-01
|
8.48e-01
|
0.09230
|
8.66e-02
|
-0.031900
|
4.92e-01
|
8.00e-01
|
SHC-mediated-cascade:FGFR4
|
17
|
6.20e-01
|
7.54e-01
|
0.09200
|
-1.20e-02
|
-0.091200
|
9.32e-01
|
5.15e-01
|
NRAGE-signals-death-through-JNK
|
58
|
2.29e-01
|
4.06e-01
|
0.09170
|
4.79e-03
|
0.091600
|
9.50e-01
|
2.27e-01
|
FCGR3A-mediated-phagocytosis
|
69
|
2.77e-01
|
4.55e-01
|
0.09160
|
-9.05e-02
|
0.014400
|
1.93e-01
|
8.36e-01
|
Leishmania-phagocytosis
|
69
|
2.77e-01
|
4.55e-01
|
0.09160
|
-9.05e-02
|
0.014400
|
1.93e-01
|
8.36e-01
|
Parasite-infection
|
69
|
2.77e-01
|
4.55e-01
|
0.09160
|
-9.05e-02
|
0.014400
|
1.93e-01
|
8.36e-01
|
SUMOylation-of-DNA-replication-proteins
|
44
|
5.10e-01
|
6.67e-01
|
0.09150
|
8.82e-02
|
-0.024400
|
3.11e-01
|
7.79e-01
|
Arachidonic-acid-metabolism
|
46
|
2.78e-01
|
4.55e-01
|
0.09130
|
9.04e-02
|
0.012600
|
2.89e-01
|
8.82e-01
|
Apoptosis
|
159
|
2.90e-01
|
4.66e-01
|
0.09120
|
5.65e-02
|
-0.071500
|
2.18e-01
|
1.19e-01
|
Resolution-of-D-loop-Structures-through-Holliday-Junction-Intermediates
|
32
|
3.66e-01
|
5.43e-01
|
0.09080
|
8.75e-02
|
0.024200
|
3.91e-01
|
8.13e-01
|
Deubiquitination
|
232
|
2.91e-02
|
1.08e-01
|
0.09080
|
2.33e-02
|
-0.087800
|
5.41e-01
|
2.11e-02
|
Maturation-of-nucleoprotein
|
11
|
9.10e-01
|
9.50e-01
|
0.09080
|
5.00e-02
|
-0.075700
|
7.74e-01
|
6.64e-01
|
Nuclear-import-of-Rev-protein
|
31
|
3.00e-01
|
4.76e-01
|
0.09050
|
6.58e-02
|
0.062200
|
5.26e-01
|
5.49e-01
|
GABA-receptor-activation
|
53
|
6.19e-01
|
7.53e-01
|
0.09030
|
-4.66e-02
|
0.077300
|
5.57e-01
|
3.30e-01
|
G-protein-mediated-events
|
51
|
1.86e-01
|
3.60e-01
|
0.09020
|
3.08e-02
|
0.084800
|
7.03e-01
|
2.95e-01
|
DNA-Double-Strand-Break-Response
|
42
|
5.48e-01
|
6.93e-01
|
0.09010
|
-2.57e-02
|
0.086400
|
7.73e-01
|
3.33e-01
|
RUNX2-regulates-osteoblast-differentiation
|
24
|
4.76e-01
|
6.44e-01
|
0.08980
|
8.63e-02
|
0.024700
|
4.64e-01
|
8.34e-01
|
Nuclear-Envelope-Breakdown
|
51
|
2.93e-01
|
4.71e-01
|
0.08970
|
8.96e-02
|
0.004190
|
2.68e-01
|
9.59e-01
|
Defensins
|
18
|
5.95e-01
|
7.34e-01
|
0.08930
|
8.73e-02
|
0.018900
|
5.21e-01
|
8.89e-01
|
RHOU-GTPase-cycle
|
40
|
5.85e-01
|
7.26e-01
|
0.08920
|
8.48e-02
|
-0.027500
|
3.53e-01
|
7.63e-01
|
Regulation-of-actin-dynamics-for-phagocytic-cup-formation
|
71
|
3.30e-01
|
5.06e-01
|
0.08910
|
-8.68e-02
|
0.020100
|
2.06e-01
|
7.69e-01
|
Signaling-by-NTRKs
|
131
|
1.35e-01
|
2.94e-01
|
0.08890
|
-2.08e-02
|
0.086400
|
6.81e-01
|
8.75e-02
|
Effects-of-PIP2-hydrolysis
|
26
|
3.87e-01
|
5.62e-01
|
0.08880
|
5.09e-02
|
0.072700
|
6.53e-01
|
5.21e-01
|
Insulin-processing
|
26
|
3.88e-01
|
5.62e-01
|
0.08880
|
7.32e-02
|
0.050200
|
5.18e-01
|
6.58e-01
|
LDL-clearance
|
19
|
8.59e-01
|
9.24e-01
|
0.08830
|
7.30e-02
|
-0.049800
|
5.82e-01
|
7.07e-01
|
G-beta:gamma-signalling-through-PI3Kgamma
|
23
|
6.03e-01
|
7.40e-01
|
0.08820
|
4.63e-06
|
0.088200
|
1.00e+00
|
4.64e-01
|
G-alpha-(s)-signalling-events
|
117
|
7.00e-02
|
1.91e-01
|
0.08820
|
2.53e-03
|
0.088200
|
9.62e-01
|
9.92e-02
|
Meiotic-recombination
|
27
|
5.17e-01
|
6.75e-01
|
0.08740
|
8.70e-02
|
0.008600
|
4.34e-01
|
9.38e-01
|
Protein-folding
|
89
|
4.95e-01
|
6.57e-01
|
0.08720
|
4.82e-02
|
-0.072600
|
4.31e-01
|
2.36e-01
|
mRNA-Capping
|
29
|
3.85e-01
|
5.61e-01
|
0.08690
|
3.87e-02
|
0.077800
|
7.19e-01
|
4.68e-01
|
Transcriptional-activation-of-mitochondrial-biogenesis
|
51
|
3.72e-01
|
5.48e-01
|
0.08690
|
-8.67e-02
|
0.005590
|
2.84e-01
|
9.45e-01
|
Transport-of-Mature-Transcript-to-Cytoplasm
|
79
|
5.83e-01
|
7.25e-01
|
0.08680
|
-6.56e-02
|
0.056900
|
3.13e-01
|
3.82e-01
|
Disassembly-of-the-destruction-complex-and-recruitment-of-AXIN-to-the-membrane
|
29
|
3.84e-01
|
5.60e-01
|
0.08680
|
7.73e-02
|
0.039400
|
4.71e-01
|
7.13e-01
|
COPI-dependent-Golgi-to-ER-retrograde-traffic
|
78
|
2.00e-01
|
3.75e-01
|
0.08670
|
8.66e-02
|
-0.001540
|
1.86e-01
|
9.81e-01
|
Nuclear-Envelope-(NE)-Reassembly
|
68
|
1.51e-01
|
3.13e-01
|
0.08660
|
8.41e-02
|
0.020700
|
2.30e-01
|
7.68e-01
|
Cell-Cell-communication
|
110
|
2.02e-01
|
3.76e-01
|
0.08630
|
8.40e-02
|
-0.019700
|
1.28e-01
|
7.21e-01
|
mRNA-Splicing—Minor-Pathway
|
53
|
4.52e-01
|
6.22e-01
|
0.08620
|
1.83e-02
|
-0.084200
|
8.17e-01
|
2.89e-01
|
Diseases-of-metabolism
|
222
|
4.60e-02
|
1.45e-01
|
0.08620
|
-2.17e-02
|
0.083400
|
5.78e-01
|
3.20e-02
|
IRE1alpha-activates-chaperones
|
49
|
6.99e-01
|
8.12e-01
|
0.08550
|
-4.94e-02
|
0.069800
|
5.49e-01
|
3.98e-01
|
Negative-regulation-of-FGFR4-signaling
|
27
|
8.32e-01
|
9.02e-01
|
0.08520
|
5.31e-02
|
-0.066700
|
6.33e-01
|
5.49e-01
|
FOXO-mediated-transcription-of-oxidative-stress,-metabolic-and-neuronal-genes
|
29
|
7.07e-01
|
8.16e-01
|
0.08470
|
2.67e-02
|
-0.080300
|
8.04e-01
|
4.54e-01
|
Export-of-Viral-Ribonucleoproteins-from-Nucleus
|
31
|
3.74e-01
|
5.50e-01
|
0.08460
|
7.44e-02
|
0.040200
|
4.73e-01
|
6.99e-01
|
PI-3K-cascade:FGFR3
|
16
|
5.84e-01
|
7.26e-01
|
0.08460
|
-6.62e-02
|
-0.052600
|
6.47e-01
|
7.16e-01
|
Pre-NOTCH-Processing-in-Golgi
|
18
|
5.96e-01
|
7.34e-01
|
0.08420
|
2.88e-02
|
0.079100
|
8.33e-01
|
5.61e-01
|
Telomere-Maintenance
|
65
|
1.49e-01
|
3.11e-01
|
0.08360
|
7.71e-02
|
0.032300
|
2.82e-01
|
6.52e-01
|
Opioid-Signalling
|
84
|
8.30e-02
|
2.10e-01
|
0.08260
|
7.41e-02
|
0.036500
|
2.40e-01
|
5.63e-01
|
Activation-of-BH3-only-proteins
|
28
|
7.80e-01
|
8.70e-01
|
0.08250
|
3.61e-02
|
-0.074200
|
7.41e-01
|
4.97e-01
|
Extension-of-Telomeres
|
50
|
2.22e-01
|
3.95e-01
|
0.08230
|
3.98e-02
|
0.072000
|
6.26e-01
|
3.78e-01
|
Signaling-by-FGFR1
|
43
|
3.05e-01
|
4.83e-01
|
0.08220
|
-7.70e-02
|
-0.028900
|
3.82e-01
|
7.43e-01
|
Infectious-disease
|
735
|
1.27e-02
|
5.86e-02
|
0.08190
|
5.38e-02
|
-0.061700
|
1.27e-02
|
4.22e-03
|
Late-Phase-of-HIV-Life-Cycle
|
125
|
3.87e-01
|
5.62e-01
|
0.08180
|
7.06e-02
|
-0.041200
|
1.72e-01
|
4.25e-01
|
Recruitment-and-ATM-mediated-phosphorylation-of-repair-and-signaling-proteins-at-DNA-double-strand-breaks
|
41
|
5.44e-01
|
6.91e-01
|
0.08180
|
-1.28e-02
|
0.080800
|
8.88e-01
|
3.71e-01
|
HIV-Infection
|
214
|
2.86e-01
|
4.62e-01
|
0.08130
|
5.58e-02
|
-0.059100
|
1.59e-01
|
1.36e-01
|
Neurotransmitter-receptors-and-postsynaptic-signal-transmission
|
167
|
5.81e-03
|
3.10e-02
|
0.08130
|
6.41e-02
|
0.050000
|
1.53e-01
|
2.65e-01
|
Factors-involved-in-megakaryocyte-development-and-platelet-production
|
112
|
6.03e-02
|
1.74e-01
|
0.08110
|
2.18e-02
|
0.078100
|
6.89e-01
|
1.53e-01
|
Signaling-by-ERBB4
|
54
|
6.71e-01
|
7.96e-01
|
0.08110
|
4.14e-02
|
-0.069700
|
5.99e-01
|
3.75e-01
|
Erythropoietin-activates-RAS
|
14
|
8.66e-01
|
9.28e-01
|
0.08090
|
2.80e-02
|
-0.075900
|
8.56e-01
|
6.23e-01
|
Regulation-of-Complement-cascade
|
49
|
3.37e-01
|
5.13e-01
|
0.08070
|
-7.98e-02
|
-0.012500
|
3.34e-01
|
8.79e-01
|
Signaling-by-NOTCH
|
172
|
3.47e-01
|
5.23e-01
|
0.08050
|
-6.38e-02
|
0.049200
|
1.49e-01
|
2.66e-01
|
Pexophagy
|
10
|
7.46e-01
|
8.44e-01
|
0.08040
|
6.87e-02
|
0.041800
|
7.07e-01
|
8.19e-01
|
Downstream-signaling-of-activated-FGFR3
|
23
|
5.64e-01
|
7.07e-01
|
0.07970
|
-2.37e-02
|
-0.076100
|
8.44e-01
|
5.27e-01
|
FGFR2-alternative-splicing
|
26
|
7.04e-01
|
8.14e-01
|
0.07970
|
1.45e-02
|
-0.078300
|
8.98e-01
|
4.89e-01
|
Transcriptional-Regulation-by-VENTX
|
37
|
6.79e-01
|
8.01e-01
|
0.07960
|
-2.54e-02
|
0.075500
|
7.89e-01
|
4.27e-01
|
FRS-mediated-FGFR4-signaling
|
19
|
6.68e-01
|
7.93e-01
|
0.07950
|
-1.13e-02
|
-0.078700
|
9.32e-01
|
5.53e-01
|
Sphingolipid-metabolism
|
81
|
4.16e-01
|
5.86e-01
|
0.07940
|
-7.58e-02
|
0.023600
|
2.38e-01
|
7.13e-01
|
Prostacyclin-signalling-through-prostacyclin-receptor
|
18
|
6.13e-01
|
7.48e-01
|
0.07870
|
3.59e-02
|
0.070000
|
7.92e-01
|
6.07e-01
|
Platelet-activation,-signaling-and-aggregation
|
244
|
2.59e-01
|
4.37e-01
|
0.07860
|
-5.25e-02
|
0.058500
|
1.57e-01
|
1.15e-01
|
Processive-synthesis-on-the-C-strand-of-the-telomere
|
19
|
5.93e-01
|
7.32e-01
|
0.07830
|
6.80e-02
|
0.039000
|
6.08e-01
|
7.69e-01
|
Host-Interactions-of-HIV-factors
|
121
|
3.10e-01
|
4.89e-01
|
0.07830
|
2.67e-02
|
-0.073600
|
6.11e-01
|
1.62e-01
|
Killing-mechanisms
|
12
|
8.04e-01
|
8.87e-01
|
0.07810
|
-3.41e-03
|
-0.078000
|
9.84e-01
|
6.40e-01
|
WNT5:FZD7-mediated-leishmania-damping
|
12
|
8.04e-01
|
8.87e-01
|
0.07810
|
-3.41e-03
|
-0.078000
|
9.84e-01
|
6.40e-01
|
Negative-regulation-of-FGFR3-signaling
|
26
|
8.16e-01
|
8.97e-01
|
0.07810
|
6.99e-02
|
-0.034700
|
5.37e-01
|
7.59e-01
|
Frs2-mediated-activation
|
12
|
8.92e-01
|
9.42e-01
|
0.07790
|
-7.32e-02
|
0.026800
|
6.61e-01
|
8.72e-01
|
Inhibition-of-DNA-recombination-at-telomere
|
21
|
8.28e-01
|
9.02e-01
|
0.07770
|
7.21e-02
|
-0.028900
|
5.67e-01
|
8.18e-01
|
ER-to-Golgi-Anterograde-Transport
|
133
|
2.35e-01
|
4.11e-01
|
0.07750
|
7.46e-02
|
-0.020800
|
1.37e-01
|
6.78e-01
|
DNA-Damage-Recognition-in-GG-NER
|
37
|
6.66e-01
|
7.92e-01
|
0.07740
|
7.46e-02
|
-0.020400
|
4.32e-01
|
8.30e-01
|
Fcgamma-receptor-(FCGR)-dependent-phagocytosis
|
95
|
5.77e-01
|
7.20e-01
|
0.07730
|
-6.20e-02
|
0.046200
|
2.96e-01
|
4.36e-01
|
Phospholipase-C-mediated-cascade:-FGFR1
|
11
|
8.70e-01
|
9.30e-01
|
0.07730
|
-7.60e-02
|
0.014300
|
6.63e-01
|
9.34e-01
|
Cargo-recognition-for-clathrin-mediated-endocytosis
|
96
|
3.27e-01
|
5.04e-01
|
0.07730
|
1.78e-02
|
-0.075200
|
7.63e-01
|
2.03e-01
|
ERK/MAPK-targets
|
22
|
6.50e-01
|
7.80e-01
|
0.07710
|
9.68e-03
|
0.076500
|
9.37e-01
|
5.35e-01
|
RHO-GTPase-cycle
|
436
|
4.47e-03
|
2.55e-02
|
0.07700
|
-1.41e-02
|
0.075700
|
6.12e-01
|
6.60e-03
|
Metabolism-of-lipids
|
674
|
2.01e-03
|
1.30e-02
|
0.07690
|
2.59e-02
|
-0.072400
|
2.50e-01
|
1.30e-03
|
Acyl-chain-remodelling-of-PC
|
23
|
7.93e-01
|
8.80e-01
|
0.07560
|
2.15e-02
|
-0.072500
|
8.58e-01
|
5.47e-01
|
Nitric-oxide-stimulates-guanylate-cyclase
|
21
|
6.61e-01
|
7.88e-01
|
0.07550
|
7.44e-02
|
0.012700
|
5.55e-01
|
9.20e-01
|
Integrin-signaling
|
27
|
8.24e-01
|
9.02e-01
|
0.07550
|
3.42e-02
|
-0.067300
|
7.59e-01
|
5.45e-01
|
G-alpha-(q)-signalling-events
|
183
|
1.20e-02
|
5.56e-02
|
0.07550
|
3.10e-02
|
0.068800
|
4.69e-01
|
1.08e-01
|
Activation-of-AMPK-downstream-of-NMDARs
|
10
|
7.83e-01
|
8.72e-01
|
0.07510
|
3.26e-02
|
0.067700
|
8.59e-01
|
7.11e-01
|
Cytosolic-sulfonation-of-small-molecules
|
17
|
6.57e-01
|
7.86e-01
|
0.07500
|
3.42e-02
|
0.066800
|
8.07e-01
|
6.33e-01
|
FCERI-mediated-MAPK-activation
|
40
|
8.10e-01
|
8.92e-01
|
0.07490
|
-5.86e-02
|
0.046600
|
5.21e-01
|
6.10e-01
|
mTORC1-mediated-signalling
|
24
|
8.32e-01
|
9.02e-01
|
0.07480
|
3.08e-02
|
-0.068100
|
7.94e-01
|
5.63e-01
|
Lysosome-Vesicle-Biogenesis
|
34
|
5.43e-01
|
6.91e-01
|
0.07470
|
-7.43e-02
|
-0.007790
|
4.53e-01
|
9.37e-01
|
DNA-Double-Strand-Break-Repair
|
129
|
3.59e-02
|
1.26e-01
|
0.07470
|
4.30e-02
|
0.061100
|
3.98e-01
|
2.31e-01
|
Formation-of-TC-NER-Pre-Incision-Complex
|
52
|
6.02e-01
|
7.39e-01
|
0.07450
|
7.14e-02
|
-0.021300
|
3.73e-01
|
7.90e-01
|
Beta-catenin-independent-WNT-signaling
|
140
|
1.09e-01
|
2.52e-01
|
0.07450
|
-9.10e-04
|
-0.074500
|
9.85e-01
|
1.28e-01
|
EGFR-downregulation
|
29
|
4.67e-01
|
6.38e-01
|
0.07440
|
-5.41e-02
|
-0.051000
|
6.14e-01
|
6.34e-01
|
FGFR3-mutant-receptor-activation
|
10
|
8.32e-01
|
9.02e-01
|
0.07430
|
-7.36e-02
|
-0.009890
|
6.87e-01
|
9.57e-01
|
Signaling-by-activated-point-mutants-of-FGFR3
|
10
|
8.32e-01
|
9.02e-01
|
0.07430
|
-7.36e-02
|
-0.009890
|
6.87e-01
|
9.57e-01
|
Signaling-by-EGFR
|
48
|
3.80e-01
|
5.56e-01
|
0.07420
|
-7.23e-02
|
-0.016700
|
3.86e-01
|
8.42e-01
|
Metabolism-of-proteins
|
1703
|
3.27e-04
|
3.05e-03
|
0.07420
|
4.85e-02
|
-0.056100
|
7.70e-04
|
1.01e-04
|
IGF1R-signaling-cascade
|
47
|
3.15e-01
|
4.93e-01
|
0.07420
|
-6.46e-02
|
-0.036500
|
4.44e-01
|
6.65e-01
|
Gene-Silencing-by-RNA
|
74
|
2.10e-01
|
3.83e-01
|
0.07420
|
7.13e-02
|
0.020500
|
2.89e-01
|
7.61e-01
|
Nucleobase-catabolism
|
33
|
8.31e-01
|
9.02e-01
|
0.07390
|
6.13e-02
|
-0.041300
|
5.42e-01
|
6.82e-01
|
IRS-mediated-signalling
|
42
|
3.46e-01
|
5.22e-01
|
0.07380
|
-6.02e-02
|
-0.042700
|
5.00e-01
|
6.32e-01
|
Chaperonin-mediated-protein-folding
|
84
|
5.65e-01
|
7.07e-01
|
0.07360
|
3.34e-02
|
-0.065600
|
5.96e-01
|
2.99e-01
|
Homology-Directed-Repair
|
100
|
1.38e-01
|
2.95e-01
|
0.07360
|
7.17e-02
|
0.016700
|
2.15e-01
|
7.73e-01
|
IRS-related-events-triggered-by-IGF1R
|
46
|
3.08e-01
|
4.86e-01
|
0.07350
|
-5.03e-02
|
-0.053600
|
5.55e-01
|
5.29e-01
|
RAF/MAP-kinase-cascade
|
263
|
2.90e-02
|
1.08e-01
|
0.07340
|
5.72e-03
|
-0.073200
|
8.73e-01
|
4.08e-02
|
Estrogen-dependent-gene-expression
|
90
|
4.71e-01
|
6.40e-01
|
0.07330
|
-6.87e-02
|
0.025600
|
2.59e-01
|
6.75e-01
|
Nucleotide-like-(purinergic)-receptors
|
15
|
6.91e-01
|
8.09e-01
|
0.07320
|
-4.05e-02
|
-0.061000
|
7.86e-01
|
6.82e-01
|
Signaling-by-Type-1-Insulin-like-Growth-Factor-1-Receptor-(IGF1R)
|
48
|
3.07e-01
|
4.86e-01
|
0.07210
|
-5.42e-02
|
-0.047600
|
5.16e-01
|
5.68e-01
|
Vesicle-mediated-transport
|
625
|
2.18e-02
|
8.75e-02
|
0.07180
|
6.33e-02
|
-0.034000
|
6.70e-03
|
1.46e-01
|
NR1H3-&-NR1H2-regulate-gene-expression-linked-to-cholesterol-transport-and-efflux
|
34
|
5.36e-01
|
6.88e-01
|
0.07180
|
1.41e-02
|
0.070400
|
8.87e-01
|
4.77e-01
|
Defective-TPR-may-confer-susceptibility-towards-thyroid-papillary-carcinoma-(TPC)
|
30
|
6.14e-01
|
7.48e-01
|
0.07180
|
7.15e-02
|
0.006210
|
4.98e-01
|
9.53e-01
|
Regulation-of-Glucokinase-by-Glucokinase-Regulatory-Protein
|
30
|
6.14e-01
|
7.48e-01
|
0.07180
|
7.15e-02
|
0.006210
|
4.98e-01
|
9.53e-01
|
Global-Genome-Nucleotide-Excision-Repair-(GG-NER)
|
82
|
1.37e-01
|
2.94e-01
|
0.07170
|
4.74e-02
|
0.053700
|
4.57e-01
|
4.00e-01
|
Vasopressin-regulates-renal-water-homeostasis-via-Aquaporins
|
40
|
6.10e-01
|
7.46e-01
|
0.07120
|
7.09e-02
|
-0.007140
|
4.38e-01
|
9.38e-01
|
Uptake-and-actions-of-bacterial-toxins
|
29
|
5.19e-01
|
6.75e-01
|
0.07110
|
-3.50e-02
|
-0.061900
|
7.44e-01
|
5.64e-01
|
Interleukin-7-signaling
|
21
|
6.43e-01
|
7.75e-01
|
0.07090
|
-6.55e-02
|
-0.027100
|
6.03e-01
|
8.30e-01
|
Degradation-of-cysteine-and-homocysteine
|
14
|
9.13e-01
|
9.51e-01
|
0.07090
|
-6.37e-02
|
0.031000
|
6.80e-01
|
8.41e-01
|
RNA-polymerase-II-transcribes-snRNA-genes
|
77
|
2.21e-01
|
3.95e-01
|
0.07030
|
-2.20e-02
|
-0.066800
|
7.39e-01
|
3.10e-01
|
NEP/NS2-Interacts-with-the-Cellular-Export-Machinery
|
30
|
4.96e-01
|
6.58e-01
|
0.07020
|
4.75e-02
|
0.051600
|
6.52e-01
|
6.24e-01
|
Signaling-by-TGF-beta-Receptor-Complex
|
71
|
2.18e-01
|
3.92e-01
|
0.06960
|
-3.30e-02
|
-0.061300
|
6.30e-01
|
3.72e-01
|
FGFR1-mutant-receptor-activation
|
27
|
5.40e-01
|
6.91e-01
|
0.06950
|
-5.20e-02
|
-0.046000
|
6.40e-01
|
6.79e-01
|
Detoxification-of-Reactive-Oxygen-Species
|
34
|
4.90e-01
|
6.54e-01
|
0.06940
|
-3.07e-02
|
-0.062300
|
7.57e-01
|
5.30e-01
|
Cell-recruitment-(pro-inflammatory-response)
|
24
|
9.00e-01
|
9.47e-01
|
0.06930
|
-4.45e-02
|
0.053000
|
7.06e-01
|
6.53e-01
|
Purinergic-signaling-in-leishmaniasis-infection
|
24
|
9.00e-01
|
9.47e-01
|
0.06930
|
-4.45e-02
|
0.053000
|
7.06e-01
|
6.53e-01
|
Signaling-by-FGFR
|
78
|
1.72e-01
|
3.41e-01
|
0.06920
|
-5.30e-02
|
-0.044400
|
4.18e-01
|
4.98e-01
|
Nuclear-Events-(kinase-and-transcription-factor-activation)
|
61
|
7.43e-01
|
8.43e-01
|
0.06900
|
-5.70e-02
|
0.038900
|
4.41e-01
|
5.99e-01
|
Tristetraprolin-(TTP,-ZFP36)-binds-and-destabilizes-mRNA
|
16
|
7.03e-01
|
8.14e-01
|
0.06820
|
-5.15e-02
|
-0.044700
|
7.21e-01
|
7.57e-01
|
Signaling-by-NTRK1-(TRKA)
|
112
|
5.45e-01
|
6.92e-01
|
0.06750
|
-3.24e-02
|
0.059200
|
5.53e-01
|
2.79e-01
|
Neutrophil-degranulation
|
420
|
1.46e-01
|
3.06e-01
|
0.06720
|
3.77e-02
|
-0.055700
|
1.85e-01
|
4.98e-02
|
Leishmania-infection
|
233
|
2.83e-01
|
4.59e-01
|
0.06710
|
-3.17e-02
|
0.059200
|
4.03e-01
|
1.19e-01
|
SHC-mediated-cascade:FGFR1
|
16
|
9.26e-01
|
9.57e-01
|
0.06710
|
-5.64e-02
|
0.036400
|
6.96e-01
|
8.01e-01
|
SUMOylation-of-SUMOylation-proteins
|
33
|
7.53e-01
|
8.48e-01
|
0.06710
|
6.51e-02
|
-0.016200
|
5.18e-01
|
8.72e-01
|
Death-Receptor-Signalling
|
132
|
4.13e-01
|
5.82e-01
|
0.06650
|
6.21e-02
|
-0.024000
|
2.18e-01
|
6.34e-01
|
SUMOylation-of-RNA-binding-proteins
|
45
|
8.13e-01
|
8.95e-01
|
0.06650
|
-5.53e-02
|
0.036800
|
5.21e-01
|
6.69e-01
|
ISG15-antiviral-mechanism
|
64
|
7.25e-01
|
8.27e-01
|
0.06640
|
3.34e-02
|
-0.057400
|
6.44e-01
|
4.27e-01
|
STAT5-activation-downstream-of-FLT3-ITD-mutants
|
10
|
9.61e-01
|
9.72e-01
|
0.06640
|
4.93e-02
|
-0.044600
|
7.87e-01
|
8.07e-01
|
Purine-catabolism
|
16
|
9.11e-01
|
9.51e-01
|
0.06630
|
-5.99e-02
|
0.028600
|
6.78e-01
|
8.43e-01
|
HDR-through-Homologous-Recombination-(HRR)-or-Single-Strand-Annealing-(SSA)
|
94
|
3.54e-01
|
5.30e-01
|
0.06560
|
6.55e-02
|
-0.004220
|
2.72e-01
|
9.44e-01
|
Regulation-of-localization-of-FOXO-transcription-factors
|
11
|
9.54e-01
|
9.68e-01
|
0.06520
|
3.75e-02
|
-0.053400
|
8.30e-01
|
7.59e-01
|
Meiotic-synapsis
|
31
|
6.74e-01
|
7.98e-01
|
0.06480
|
-3.58e-03
|
-0.064700
|
9.72e-01
|
5.33e-01
|
Signaling-by-NODAL
|
17
|
8.97e-01
|
9.47e-01
|
0.06470
|
2.32e-02
|
-0.060300
|
8.68e-01
|
6.67e-01
|
Adaptive-Immune-System
|
672
|
8.06e-02
|
2.06e-01
|
0.06460
|
-4.95e-02
|
0.041500
|
2.81e-02
|
6.55e-02
|
EPH-ephrin-mediated-repulsion-of-cells
|
44
|
4.21e-01
|
5.90e-01
|
0.06440
|
4.31e-02
|
0.047900
|
6.21e-01
|
5.83e-01
|
Termination-of-translesion-DNA-synthesis
|
30
|
5.63e-01
|
7.07e-01
|
0.06410
|
5.17e-02
|
0.037900
|
6.24e-01
|
7.19e-01
|
Intra-Golgi-traffic
|
41
|
5.36e-01
|
6.88e-01
|
0.06380
|
6.18e-02
|
0.015700
|
4.94e-01
|
8.61e-01
|
Peptide-ligand-binding-receptors
|
146
|
4.37e-01
|
6.08e-01
|
0.06360
|
-2.53e-02
|
0.058300
|
5.97e-01
|
2.24e-01
|
Activation-of-GABAB-receptors
|
41
|
8.32e-01
|
9.02e-01
|
0.06340
|
-5.43e-02
|
0.032600
|
5.47e-01
|
7.18e-01
|
GABA-B-receptor-activation
|
41
|
8.32e-01
|
9.02e-01
|
0.06340
|
-5.43e-02
|
0.032600
|
5.47e-01
|
7.18e-01
|
Synthesis-of-substrates-in-N-glycan-biosythesis
|
57
|
5.64e-01
|
7.07e-01
|
0.06320
|
-4.93e-03
|
0.063000
|
9.49e-01
|
4.11e-01
|
mRNA-Splicing
|
185
|
6.73e-02
|
1.86e-01
|
0.06310
|
-1.46e-02
|
-0.061300
|
7.32e-01
|
1.50e-01
|
Antigen-Presentation:-Folding,-assembly-and-peptide-loading-of-class-I-MHC
|
17
|
9.37e-01
|
9.59e-01
|
0.06290
|
5.05e-02
|
-0.037500
|
7.18e-01
|
7.89e-01
|
FOXO-mediated-transcription
|
61
|
6.86e-01
|
8.06e-01
|
0.06260
|
2.14e-02
|
-0.058900
|
7.72e-01
|
4.26e-01
|
TP53-regulates-transcription-of-additional-cell-cycle-genes-whose-exact-role-in-the-p53-pathway-remain-uncertain
|
19
|
9.33e-01
|
9.58e-01
|
0.06210
|
4.88e-02
|
-0.038400
|
7.13e-01
|
7.72e-01
|
MAPK1/MAPK3-signaling
|
269
|
5.46e-02
|
1.63e-01
|
0.06200
|
-2.83e-04
|
-0.062000
|
9.94e-01
|
7.97e-02
|
FRS-mediated-FGFR1-signaling
|
18
|
9.33e-01
|
9.58e-01
|
0.06180
|
-5.07e-02
|
0.035400
|
7.10e-01
|
7.95e-01
|
Biosynthesis-of-the-N-glycan-precursor-(dolichol-lipid-linked-oligosaccharide,-LLO)-and-transfer-to-a-nascent-protein
|
70
|
6.67e-01
|
7.93e-01
|
0.06170
|
-2.22e-02
|
0.057500
|
7.48e-01
|
4.05e-01
|
Amine-ligand-binding-receptors
|
30
|
5.98e-01
|
7.37e-01
|
0.06160
|
5.30e-02
|
0.031400
|
6.15e-01
|
7.66e-01
|
Intrinsic-Pathway-for-Apoptosis
|
47
|
7.56e-01
|
8.48e-01
|
0.06150
|
5.78e-02
|
-0.021000
|
4.93e-01
|
8.03e-01
|
Class-A/1-(Rhodopsin-like-receptors)
|
254
|
7.64e-02
|
1.98e-01
|
0.06140
|
-1.82e-03
|
0.061400
|
9.60e-01
|
9.16e-02
|
Formation-of-Incision-Complex-in-GG-NER
|
41
|
7.23e-01
|
8.26e-01
|
0.06110
|
-1.12e-02
|
0.060000
|
9.01e-01
|
5.06e-01
|
Ion-transport-by-P-type-ATPases
|
53
|
4.45e-01
|
6.15e-01
|
0.06090
|
5.69e-02
|
0.021900
|
4.74e-01
|
7.82e-01
|
Class-B/2-(Secretin-family-receptors)
|
79
|
2.72e-01
|
4.51e-01
|
0.06080
|
5.29e-02
|
0.030000
|
4.16e-01
|
6.45e-01
|
Transcriptional-regulation-by-RUNX1
|
171
|
1.49e-01
|
3.11e-01
|
0.06070
|
-6.06e-02
|
-0.003430
|
1.71e-01
|
9.38e-01
|
Activation-of-BAD-and-translocation-to-mitochondria
|
14
|
8.84e-01
|
9.37e-01
|
0.05980
|
5.70e-03
|
-0.059500
|
9.71e-01
|
7.00e-01
|
GPCR-downstream-signalling
|
513
|
8.58e-04
|
6.62e-03
|
0.05970
|
1.80e-02
|
0.056900
|
4.85e-01
|
2.69e-02
|
MicroRNA-(miRNA)-biogenesis
|
24
|
6.90e-01
|
8.09e-01
|
0.05930
|
2.73e-02
|
0.052700
|
8.17e-01
|
6.55e-01
|
ERKs-are-inactivated
|
13
|
8.08e-01
|
8.91e-01
|
0.05920
|
4.76e-02
|
0.035200
|
7.66e-01
|
8.26e-01
|
Estrogen-dependent-nuclear-events-downstream-of-ESR-membrane-signaling
|
23
|
6.83e-01
|
8.04e-01
|
0.05920
|
4.50e-02
|
0.038400
|
7.09e-01
|
7.50e-01
|
Insulin-receptor-signalling-cascade
|
48
|
4.54e-01
|
6.24e-01
|
0.05900
|
-4.44e-02
|
-0.038900
|
5.95e-01
|
6.41e-01
|
Complement-cascade
|
57
|
4.97e-01
|
6.58e-01
|
0.05880
|
-5.77e-02
|
-0.011400
|
4.51e-01
|
8.82e-01
|
Signaling-by-GPCR
|
575
|
1.70e-04
|
1.73e-03
|
0.05870
|
2.86e-02
|
0.051300
|
2.40e-01
|
3.49e-02
|
ADP-signalling-through-P2Y-purinoceptor-1
|
24
|
6.87e-01
|
8.08e-01
|
0.05860
|
3.08e-02
|
0.049900
|
7.94e-01
|
6.72e-01
|
Cobalamin-(Cbl,-vitamin-B12)-transport-and-metabolism
|
13
|
8.28e-01
|
9.02e-01
|
0.05850
|
-5.37e-02
|
-0.023300
|
7.38e-01
|
8.84e-01
|
HSP90-chaperone-cycle-for-steroid-hormone-receptors-(SHR)-in-the-presence-of-ligand
|
35
|
5.87e-01
|
7.27e-01
|
0.05840
|
2.84e-02
|
0.051100
|
7.71e-01
|
6.01e-01
|
Potassium-Channels
|
92
|
2.51e-01
|
4.27e-01
|
0.05830
|
5.13e-02
|
0.027600
|
3.95e-01
|
6.47e-01
|
Innate-Immune-System
|
899
|
7.08e-02
|
1.91e-01
|
0.05810
|
3.87e-02
|
-0.043300
|
4.80e-02
|
2.70e-02
|
HATs-acetylate-histones
|
80
|
7.54e-01
|
8.48e-01
|
0.05790
|
-3.16e-02
|
0.048500
|
6.25e-01
|
4.53e-01
|
HCMV-Infection
|
79
|
4.82e-01
|
6.48e-01
|
0.05760
|
5.76e-02
|
-0.000387
|
3.76e-01
|
9.95e-01
|
Antiviral-mechanism-by-IFN-stimulated-genes
|
72
|
7.38e-01
|
8.39e-01
|
0.05720
|
2.52e-02
|
-0.051300
|
7.11e-01
|
4.51e-01
|
Signaling-by-PDGFRA-extracellular-domain-mutants
|
12
|
8.31e-01
|
9.02e-01
|
0.05710
|
3.73e-02
|
0.043200
|
8.23e-01
|
7.95e-01
|
Signaling-by-PDGFRA-transmembrane,-juxtamembrane-and-kinase-domain-mutants
|
12
|
8.31e-01
|
9.02e-01
|
0.05710
|
3.73e-02
|
0.043200
|
8.23e-01
|
7.95e-01
|
Digestion
|
11
|
9.41e-01
|
9.62e-01
|
0.05690
|
5.43e-02
|
-0.016900
|
7.55e-01
|
9.23e-01
|
GPCR-ligand-binding
|
353
|
1.64e-02
|
7.11e-02
|
0.05630
|
1.35e-02
|
0.054700
|
6.64e-01
|
7.70e-02
|
Activation-of-kainate-receptors-upon-glutamate-binding
|
28
|
6.59e-01
|
7.87e-01
|
0.05600
|
3.95e-02
|
0.039700
|
7.17e-01
|
7.16e-01
|
RHO-GTPases-activate-IQGAPs
|
11
|
9.60e-01
|
9.72e-01
|
0.05560
|
2.66e-02
|
-0.048800
|
8.78e-01
|
7.79e-01
|
HSF1-dependent-transactivation
|
32
|
7.14e-01
|
8.21e-01
|
0.05520
|
-5.44e-02
|
-0.009300
|
5.94e-01
|
9.27e-01
|
COPII-mediated-vesicle-transport
|
68
|
8.32e-01
|
9.02e-01
|
0.05490
|
3.70e-02
|
-0.040600
|
5.97e-01
|
5.63e-01
|
p75-NTR-receptor-mediated-signalling
|
92
|
5.49e-01
|
6.93e-01
|
0.05470
|
5.39e-02
|
-0.009180
|
3.71e-01
|
8.79e-01
|
Nucleotide-Excision-Repair
|
108
|
2.59e-01
|
4.36e-01
|
0.05470
|
5.04e-02
|
0.021300
|
3.66e-01
|
7.03e-01
|
MAPK-family-signaling-cascades
|
306
|
6.98e-02
|
1.91e-01
|
0.05410
|
-2.56e-03
|
-0.054000
|
9.39e-01
|
1.03e-01
|
Oxidative-Stress-Induced-Senescence
|
62
|
7.86e-01
|
8.75e-01
|
0.05400
|
-4.89e-02
|
0.022900
|
5.06e-01
|
7.55e-01
|
Inwardly-rectifying-K+-channels
|
34
|
9.08e-01
|
9.50e-01
|
0.05350
|
-4.34e-02
|
0.031300
|
6.61e-01
|
7.52e-01
|
Defects-in-cobalamin-(B12)-metabolism
|
12
|
8.61e-01
|
9.24e-01
|
0.05340
|
-4.75e-02
|
-0.024400
|
7.76e-01
|
8.84e-01
|
TNFs-bind-their-physiological-receptors
|
24
|
7.30e-01
|
8.33e-01
|
0.05270
|
4.02e-02
|
0.034100
|
7.33e-01
|
7.73e-01
|
XBP1(S)-activates-chaperone-genes
|
47
|
8.38e-01
|
9.07e-01
|
0.05260
|
-2.19e-02
|
0.047800
|
7.95e-01
|
5.71e-01
|
Cytochrome-P450—arranged-by-substrate-type
|
48
|
8.90e-01
|
9.41e-01
|
0.05230
|
-3.68e-02
|
0.037200
|
6.59e-01
|
6.55e-01
|
Transport-of-vitamins,-nucleosides,-and-related-molecules
|
37
|
6.35e-01
|
7.67e-01
|
0.05210
|
-2.70e-02
|
-0.044500
|
7.76e-01
|
6.39e-01
|
Hemostasis
|
535
|
1.98e-02
|
8.16e-02
|
0.05210
|
-8.66e-04
|
0.052100
|
9.73e-01
|
3.89e-02
|
GAB1-signalosome
|
16
|
9.18e-01
|
9.53e-01
|
0.05200
|
-5.07e-02
|
0.011600
|
7.26e-01
|
9.36e-01
|
P2Y-receptors
|
11
|
8.72e-01
|
9.31e-01
|
0.05190
|
-2.89e-02
|
-0.043100
|
8.68e-01
|
8.04e-01
|
DNA-Repair
|
276
|
3.68e-02
|
1.27e-01
|
0.05190
|
4.50e-02
|
0.025800
|
1.98e-01
|
4.60e-01
|
Signaling-by-FGFR3
|
37
|
8.40e-01
|
9.08e-01
|
0.05180
|
1.49e-02
|
-0.049600
|
8.75e-01
|
6.01e-01
|
O-linked-glycosylation-of-mucins
|
52
|
6.21e-01
|
7.55e-01
|
0.05160
|
8.39e-03
|
0.050900
|
9.17e-01
|
5.25e-01
|
Purine-salvage
|
13
|
9.03e-01
|
9.48e-01
|
0.05140
|
-1.95e-03
|
-0.051400
|
9.90e-01
|
7.48e-01
|
Signaling-by-NTRK2-(TRKB)
|
25
|
7.32e-01
|
8.34e-01
|
0.05140
|
3.44e-02
|
0.038100
|
7.66e-01
|
7.42e-01
|
Retrograde-neurotrophin-signalling
|
14
|
8.92e-01
|
9.42e-01
|
0.05110
|
5.10e-02
|
0.003950
|
7.41e-01
|
9.80e-01
|
DNA-Damage/Telomere-Stress-Induced-Senescence
|
28
|
7.74e-01
|
8.64e-01
|
0.05060
|
9.99e-03
|
0.049600
|
9.27e-01
|
6.49e-01
|
Ethanol-oxidation
|
10
|
9.08e-01
|
9.50e-01
|
0.05050
|
4.86e-02
|
0.013400
|
7.90e-01
|
9.41e-01
|
Oncogene-Induced-Senescence
|
31
|
7.36e-01
|
8.37e-01
|
0.05040
|
-1.48e-02
|
-0.048100
|
8.86e-01
|
6.43e-01
|
Processing-of-SMDT1
|
15
|
9.67e-01
|
9.75e-01
|
0.05040
|
-3.69e-02
|
0.034300
|
8.05e-01
|
8.18e-01
|
Formation-of-RNA-Pol-II-elongation-complex
|
54
|
5.27e-01
|
6.79e-01
|
0.05030
|
3.13e-02
|
0.039300
|
6.90e-01
|
6.17e-01
|
RNA-Polymerase-II-Transcription-Elongation
|
54
|
5.27e-01
|
6.79e-01
|
0.05030
|
3.13e-02
|
0.039300
|
6.90e-01
|
6.17e-01
|
Platelet-degranulation
|
118
|
7.52e-01
|
8.48e-01
|
0.05020
|
4.00e-02
|
-0.030400
|
4.53e-01
|
5.68e-01
|
Negative-regulation-of-MET-activity
|
20
|
8.26e-01
|
9.02e-01
|
0.04990
|
-4.80e-02
|
-0.013600
|
7.10e-01
|
9.16e-01
|
Cell-death-signalling-via-NRAGE,-NRIF-and-NADE
|
73
|
5.41e-01
|
6.91e-01
|
0.04960
|
4.90e-02
|
0.007850
|
4.69e-01
|
9.08e-01
|
mRNA-Splicing—Major-Pathway
|
175
|
1.35e-01
|
2.94e-01
|
0.04950
|
-3.90e-02
|
-0.030400
|
3.73e-01
|
4.87e-01
|
Metabolism-of-vitamins-and-cofactors
|
168
|
4.25e-01
|
5.93e-01
|
0.04900
|
-4.82e-02
|
0.008800
|
2.81e-01
|
8.44e-01
|
Diseases-of-signal-transduction-by-growth-factor-receptors-and-second-messengers
|
412
|
1.38e-02
|
6.26e-02
|
0.04860
|
-4.24e-02
|
-0.023800
|
1.39e-01
|
4.07e-01
|
Class-I-MHC-mediated-antigen-processing-&-presentation
|
353
|
2.08e-02
|
8.48e-02
|
0.04850
|
-3.10e-02
|
-0.037300
|
3.16e-01
|
2.28e-01
|
Activation-of-the-pre-replicative-complex
|
32
|
7.37e-01
|
8.38e-01
|
0.04850
|
4.56e-02
|
0.016500
|
6.55e-01
|
8.71e-01
|
G-alpha-(i)-signalling-events
|
248
|
1.09e-01
|
2.52e-01
|
0.04810
|
1.40e-02
|
0.046100
|
7.04e-01
|
2.11e-01
|
Rab-regulation-of-trafficking
|
119
|
7.39e-01
|
8.39e-01
|
0.04790
|
4.10e-02
|
-0.024800
|
4.40e-01
|
6.40e-01
|
Glycogen-storage-diseases
|
13
|
9.73e-01
|
9.79e-01
|
0.04790
|
3.57e-02
|
-0.032000
|
8.24e-01
|
8.42e-01
|
Signaling-by-Rho-GTPases,-Miro-GTPases-and-RHOBTB3
|
622
|
2.83e-03
|
1.76e-02
|
0.04740
|
4.31e-02
|
0.019700
|
6.54e-02
|
3.99e-01
|
Antigen-processing:-Ubiquitination-&-Proteasome-degradation
|
295
|
5.24e-02
|
1.58e-01
|
0.04690
|
-2.57e-02
|
-0.039200
|
4.47e-01
|
2.46e-01
|
Processing-of-Capped-Intron-Containing-Pre-mRNA
|
235
|
9.59e-02
|
2.32e-01
|
0.04650
|
-3.78e-02
|
-0.027100
|
3.17e-01
|
4.74e-01
|
Anchoring-of-the-basal-body-to-the-plasma-membrane
|
92
|
6.44e-01
|
7.76e-01
|
0.04610
|
4.56e-02
|
-0.006770
|
4.50e-01
|
9.11e-01
|
Platelet-Aggregation-(Plug-Formation)
|
37
|
7.12e-01
|
8.20e-01
|
0.04610
|
-1.99e-02
|
-0.041500
|
8.34e-01
|
6.62e-01
|
G2/M-DNA-damage-checkpoint
|
59
|
6.56e-01
|
7.85e-01
|
0.04560
|
4.50e-02
|
0.007410
|
5.50e-01
|
9.22e-01
|
Telomere-Extension-By-Telomerase
|
22
|
9.23e-01
|
9.56e-01
|
0.04550
|
-4.37e-02
|
0.013000
|
7.23e-01
|
9.16e-01
|
Heme-degradation
|
14
|
9.71e-01
|
9.77e-01
|
0.04530
|
3.76e-02
|
-0.025200
|
8.07e-01
|
8.70e-01
|
Visual-phototransduction
|
85
|
5.47e-01
|
6.93e-01
|
0.04490
|
-8.36e-03
|
-0.044100
|
8.94e-01
|
4.81e-01
|
MAPK-targets/-Nuclear-events-mediated-by-MAP-kinases
|
31
|
8.47e-01
|
9.14e-01
|
0.04490
|
4.49e-02
|
-0.001870
|
6.65e-01
|
9.86e-01
|
Signaling-by-Retinoic-Acid
|
39
|
9.32e-01
|
9.58e-01
|
0.04470
|
-3.34e-02
|
0.029700
|
7.18e-01
|
7.48e-01
|
EGR2-and-SOX10-mediated-initiation-of-Schwann-cell-myelination
|
27
|
9.34e-01
|
9.58e-01
|
0.04460
|
-3.98e-02
|
0.020200
|
7.20e-01
|
8.56e-01
|
Negative-regulation-of-the-PI3K/AKT-network
|
106
|
7.63e-01
|
8.56e-01
|
0.04370
|
-1.85e-02
|
0.039600
|
7.42e-01
|
4.81e-01
|
Diseases-of-programmed-cell-death
|
42
|
8.00e-01
|
8.87e-01
|
0.04360
|
-4.36e-02
|
0.000200
|
6.25e-01
|
9.98e-01
|
Postmitotic-nuclear-pore-complex-(NPC)-reformation
|
27
|
9.32e-01
|
9.58e-01
|
0.04350
|
1.77e-02
|
-0.039700
|
8.73e-01
|
7.21e-01
|
Signaling-by-Rho-GTPases
|
607
|
5.17e-03
|
2.84e-02
|
0.04330
|
3.34e-02
|
0.027600
|
1.59e-01
|
2.44e-01
|
PI5P,-PP2A-and-IER3-Regulate-PI3K/AKT-Signaling
|
99
|
7.54e-01
|
8.48e-01
|
0.04320
|
-1.55e-02
|
0.040400
|
7.90e-01
|
4.87e-01
|
SHC-mediated-cascade:FGFR3
|
16
|
9.49e-01
|
9.68e-01
|
0.04240
|
1.12e-02
|
-0.040900
|
9.38e-01
|
7.77e-01
|
Signal-Transduction
|
2281
|
4.57e-05
|
6.00e-04
|
0.04160
|
-7.98e-04
|
0.041600
|
9.50e-01
|
9.60e-04
|
PTEN-Regulation
|
136
|
3.66e-01
|
5.43e-01
|
0.04140
|
-3.73e-02
|
-0.018000
|
4.52e-01
|
7.17e-01
|
Synthesis-of-bile-acids-and-bile-salts-via-27-hydroxycholesterol
|
12
|
9.16e-01
|
9.52e-01
|
0.04130
|
-1.75e-02
|
-0.037500
|
9.16e-01
|
8.22e-01
|
Signaling-by-Nuclear-Receptors
|
226
|
7.09e-01
|
8.18e-01
|
0.04130
|
3.07e-02
|
-0.027600
|
4.26e-01
|
4.75e-01
|
Formation-of-Fibrin-Clot-(Clotting-Cascade)
|
37
|
9.06e-01
|
9.49e-01
|
0.04040
|
1.30e-02
|
-0.038200
|
8.91e-01
|
6.87e-01
|
Unfolded-Protein-Response-(UPR)
|
88
|
5.86e-01
|
7.26e-01
|
0.04020
|
-3.89e-02
|
-0.010200
|
5.28e-01
|
8.68e-01
|
Translocation-of-SLC2A4-(GLUT4)-to-the-plasma-membrane
|
50
|
6.83e-01
|
8.04e-01
|
0.04020
|
3.10e-02
|
0.025600
|
7.05e-01
|
7.54e-01
|
G1/S-Specific-Transcription
|
28
|
9.04e-01
|
9.49e-01
|
0.04000
|
-3.96e-02
|
0.006080
|
7.17e-01
|
9.56e-01
|
SUMOylation-of-ubiquitinylation-proteins
|
37
|
7.57e-01
|
8.49e-01
|
0.03980
|
2.83e-02
|
0.028000
|
7.66e-01
|
7.68e-01
|
Metabolism-of-steroid-hormones
|
30
|
8.10e-01
|
8.92e-01
|
0.03890
|
-2.27e-02
|
-0.031600
|
8.30e-01
|
7.64e-01
|
PKMTs-methylate-histone-lysines
|
39
|
8.86e-01
|
9.38e-01
|
0.03870
|
7.72e-03
|
-0.038000
|
9.33e-01
|
6.82e-01
|
Signal-amplification
|
31
|
8.65e-01
|
9.27e-01
|
0.03870
|
3.19e-03
|
0.038500
|
9.75e-01
|
7.10e-01
|
Meiosis
|
56
|
9.27e-01
|
9.57e-01
|
0.03840
|
2.94e-02
|
-0.024600
|
7.03e-01
|
7.50e-01
|
Asparagine-N-linked-glycosylation
|
271
|
6.90e-01
|
8.09e-01
|
0.03830
|
-2.38e-02
|
0.030100
|
5.00e-01
|
3.94e-01
|
SARS-CoV-2-Infection
|
68
|
8.97e-01
|
9.47e-01
|
0.03790
|
-1.96e-02
|
0.032400
|
7.80e-01
|
6.44e-01
|
TP53-Regulates-Transcription-of-Cell-Death-Genes
|
37
|
8.40e-01
|
9.08e-01
|
0.03730
|
5.50e-03
|
0.036900
|
9.54e-01
|
6.98e-01
|
RAB-GEFs-exchange-GTP-for-GDP-on-RABs
|
88
|
8.54e-01
|
9.21e-01
|
0.03720
|
-3.34e-02
|
0.016400
|
5.88e-01
|
7.91e-01
|
Transport-of-the-SLBP-Dependant-Mature-mRNA
|
34
|
8.65e-01
|
9.27e-01
|
0.03700
|
2.77e-03
|
0.036900
|
9.78e-01
|
7.09e-01
|
Transcriptional-regulation-of-white-adipocyte-differentiation
|
79
|
6.61e-01
|
7.88e-01
|
0.03680
|
-3.53e-02
|
-0.010500
|
5.87e-01
|
8.72e-01
|
Metabolism-of-water-soluble-vitamins-and-cofactors
|
109
|
6.94e-01
|
8.09e-01
|
0.03680
|
-3.66e-02
|
0.003180
|
5.09e-01
|
9.54e-01
|
Eicosanoid-ligand-binding-receptors
|
14
|
9.27e-01
|
9.57e-01
|
0.03470
|
-2.97e-02
|
-0.017900
|
8.48e-01
|
9.08e-01
|
Signaling-by-Non-Receptor-Tyrosine-Kinases
|
52
|
8.61e-01
|
9.24e-01
|
0.03460
|
3.44e-02
|
-0.003650
|
6.68e-01
|
9.64e-01
|
Signaling-by-PTK6
|
52
|
8.61e-01
|
9.24e-01
|
0.03460
|
3.44e-02
|
-0.003650
|
6.68e-01
|
9.64e-01
|
FRS-mediated-FGFR3-signaling
|
18
|
9.62e-01
|
9.72e-01
|
0.03460
|
9.46e-03
|
-0.033300
|
9.45e-01
|
8.07e-01
|
Transcription-of-E2F-targets-under-negative-control-by-DREAM-complex
|
19
|
9.16e-01
|
9.52e-01
|
0.03400
|
1.10e-02
|
0.032100
|
9.34e-01
|
8.08e-01
|
activated-TAK1-mediates-p38-MAPK-activation
|
18
|
9.29e-01
|
9.58e-01
|
0.03330
|
-7.93e-03
|
-0.032300
|
9.54e-01
|
8.12e-01
|
Signaling-by-KIT-in-disease
|
20
|
9.02e-01
|
9.48e-01
|
0.03320
|
2.07e-02
|
0.025900
|
8.73e-01
|
8.41e-01
|
Signaling-by-phosphorylated-juxtamembrane,-extracellular-and-kinase-domain-KIT-mutants
|
20
|
9.02e-01
|
9.48e-01
|
0.03320
|
2.07e-02
|
0.025900
|
8.73e-01
|
8.41e-01
|
Defects-of-contact-activation-system-(CAS)-and-kallikrein/kinin-system-(KKS)
|
16
|
9.27e-01
|
9.57e-01
|
0.03320
|
1.40e-02
|
0.030100
|
9.23e-01
|
8.35e-01
|
Diseases-of-hemostasis
|
16
|
9.27e-01
|
9.57e-01
|
0.03320
|
1.40e-02
|
0.030100
|
9.23e-01
|
8.35e-01
|
Transport-of-Mature-mRNAs-Derived-from-Intronless-Transcripts
|
40
|
8.29e-01
|
9.02e-01
|
0.03300
|
1.40e-02
|
0.029900
|
8.78e-01
|
7.44e-01
|
Disease
|
1478
|
2.01e-01
|
3.76e-01
|
0.03290
|
2.76e-02
|
-0.017900
|
7.36e-02
|
2.45e-01
|
Gap-junction-trafficking
|
24
|
9.15e-01
|
9.52e-01
|
0.03290
|
-3.25e-02
|
-0.005360
|
7.83e-01
|
9.64e-01
|
Transcription-of-E2F-targets-under-negative-control-by-p107-(RBL1)-and-p130-(RBL2)-in-complex-with-HDAC1
|
16
|
9.72e-01
|
9.78e-01
|
0.03250
|
-1.02e-02
|
0.030800
|
9.43e-01
|
8.31e-01
|
RNA-Polymerase-II-Pre-transcription-Events
|
75
|
9.33e-01
|
9.58e-01
|
0.03230
|
-2.22e-02
|
0.023400
|
7.39e-01
|
7.26e-01
|
Signaling-by-Interleukins
|
409
|
2.08e-01
|
3.82e-01
|
0.03140
|
-2.99e-02
|
-0.009630
|
2.99e-01
|
7.38e-01
|
Metabolism-of-fat-soluble-vitamins
|
41
|
8.51e-01
|
9.17e-01
|
0.03110
|
-2.92e-02
|
-0.010800
|
7.46e-01
|
9.05e-01
|
Transport-of-Mature-mRNA-Derived-from-an-Intronless-Transcript
|
39
|
8.37e-01
|
9.06e-01
|
0.03110
|
2.29e-02
|
0.020900
|
8.04e-01
|
8.21e-01
|
Negative-regulation-of-FGFR1-signaling
|
26
|
8.98e-01
|
9.47e-01
|
0.03100
|
2.83e-02
|
0.012800
|
8.03e-01
|
9.10e-01
|
Activation-of-G-protein-gated-Potassium-channels
|
28
|
8.80e-01
|
9.35e-01
|
0.03100
|
-2.19e-02
|
-0.022000
|
8.41e-01
|
8.41e-01
|
G-protein-gated-Potassium-channels
|
28
|
8.80e-01
|
9.35e-01
|
0.03100
|
-2.19e-02
|
-0.022000
|
8.41e-01
|
8.41e-01
|
Inhibition–of-voltage-gated-Ca2+-channels-via-Gbeta/gamma-subunits
|
28
|
8.80e-01
|
9.35e-01
|
0.03100
|
-2.19e-02
|
-0.022000
|
8.41e-01
|
8.41e-01
|
Sulfur-amino-acid-metabolism
|
27
|
9.62e-01
|
9.72e-01
|
0.03070
|
1.10e-02
|
-0.028700
|
9.21e-01
|
7.96e-01
|
Signaling-by-ALK-fusions-and-activated-point-mutants
|
52
|
9.50e-01
|
9.68e-01
|
0.03050
|
1.66e-02
|
-0.025600
|
8.36e-01
|
7.49e-01
|
Signaling-by-ALK-in-cancer
|
52
|
9.50e-01
|
9.68e-01
|
0.03050
|
1.66e-02
|
-0.025600
|
8.36e-01
|
7.49e-01
|
Constitutive-Signaling-by-AKT1-E17K-in-Cancer
|
26
|
9.75e-01
|
9.80e-01
|
0.03010
|
1.62e-02
|
-0.025400
|
8.87e-01
|
8.23e-01
|
Ephrin-signaling
|
17
|
9.34e-01
|
9.58e-01
|
0.02960
|
2.47e-02
|
0.016400
|
8.60e-01
|
9.07e-01
|
Transport-of-the-SLBP-independent-Mature-mRNA
|
33
|
8.82e-01
|
9.36e-01
|
0.02960
|
1.30e-02
|
0.026600
|
8.97e-01
|
7.92e-01
|
Surfactant-metabolism
|
23
|
9.82e-01
|
9.86e-01
|
0.02910
|
1.81e-02
|
-0.022800
|
8.81e-01
|
8.50e-01
|
Insertion-of-tail-anchored-proteins-into-the-endoplasmic-reticulum-membrane
|
20
|
9.61e-01
|
9.72e-01
|
0.02890
|
-3.45e-03
|
0.028700
|
9.79e-01
|
8.24e-01
|
Cooperation-of-PDCL-(PhLP1)-and-TRiC/CCT-in-G-protein-beta-folding
|
36
|
8.82e-01
|
9.36e-01
|
0.02780
|
-2.39e-02
|
-0.014200
|
8.04e-01
|
8.83e-01
|
Processing-of-DNA-double-strand-break-ends
|
61
|
9.03e-01
|
9.48e-01
|
0.02760
|
2.73e-02
|
-0.004450
|
7.13e-01
|
9.52e-01
|
Gap-junction-trafficking-and-regulation
|
26
|
9.30e-01
|
9.58e-01
|
0.02660
|
8.31e-03
|
0.025300
|
9.42e-01
|
8.23e-01
|
Response-to-elevated-platelet-cytosolic-Ca2+
|
123
|
9.20e-01
|
9.54e-01
|
0.02660
|
1.60e-02
|
-0.021200
|
7.59e-01
|
6.85e-01
|
HIV-Transcription-Initiation
|
45
|
9.55e-01
|
9.68e-01
|
0.02650
|
-2.45e-02
|
0.010200
|
7.76e-01
|
9.06e-01
|
RNA-Polymerase-II-HIV-Promoter-Escape
|
45
|
9.55e-01
|
9.68e-01
|
0.02650
|
-2.45e-02
|
0.010200
|
7.76e-01
|
9.06e-01
|
RNA-Polymerase-II-Promoter-Escape
|
45
|
9.55e-01
|
9.68e-01
|
0.02650
|
-2.45e-02
|
0.010200
|
7.76e-01
|
9.06e-01
|
RNA-Polymerase-II-Transcription-Initiation
|
45
|
9.55e-01
|
9.68e-01
|
0.02650
|
-2.45e-02
|
0.010200
|
7.76e-01
|
9.06e-01
|
RNA-Polymerase-II-Transcription-Initiation-And-Promoter-Clearance
|
45
|
9.55e-01
|
9.68e-01
|
0.02650
|
-2.45e-02
|
0.010200
|
7.76e-01
|
9.06e-01
|
RNA-Polymerase-II-Transcription-Pre-Initiation-And-Promoter-Opening
|
45
|
9.55e-01
|
9.68e-01
|
0.02650
|
-2.45e-02
|
0.010200
|
7.76e-01
|
9.06e-01
|
Signaling-by-WNT
|
257
|
7.69e-01
|
8.60e-01
|
0.02620
|
2.44e-02
|
-0.009650
|
5.00e-01
|
7.90e-01
|
Intrinsic-Pathway-of-Fibrin-Clot-Formation
|
22
|
9.45e-01
|
9.66e-01
|
0.02360
|
-1.94e-02
|
-0.013400
|
8.75e-01
|
9.13e-01
|
Gene-expression-(Transcription)
|
1158
|
2.09e-01
|
3.82e-01
|
0.02330
|
-2.32e-02
|
0.001300
|
1.80e-01
|
9.40e-01
|
Cytosolic-sensors-of-pathogen-associated-DNA
|
58
|
8.76e-01
|
9.33e-01
|
0.02320
|
9.40e-03
|
0.021300
|
9.01e-01
|
7.79e-01
|
Retinoid-metabolism-and-transport
|
38
|
9.09e-01
|
9.50e-01
|
0.02300
|
-1.57e-02
|
-0.016800
|
8.67e-01
|
8.58e-01
|
Cellular-response-to-heat-stress
|
92
|
9.31e-01
|
9.58e-01
|
0.02250
|
-2.10e-02
|
0.008080
|
7.27e-01
|
8.93e-01
|
tRNA-processing-in-the-nucleus
|
55
|
9.53e-01
|
9.68e-01
|
0.02230
|
6.55e-03
|
-0.021400
|
9.33e-01
|
7.84e-01
|
RNA-Polymerase-II-Transcription
|
1027
|
1.93e-01
|
3.67e-01
|
0.02220
|
-2.20e-02
|
-0.003200
|
2.31e-01
|
8.62e-01
|
Phase-I—Functionalization-of-compounds
|
83
|
8.77e-01
|
9.33e-01
|
0.02170
|
3.11e-03
|
0.021500
|
9.61e-01
|
7.35e-01
|
Cytokine-Signaling-in-Immune-system
|
606
|
3.34e-01
|
5.12e-01
|
0.02150
|
-2.04e-02
|
-0.006810
|
3.89e-01
|
7.74e-01
|
SARS-CoV-1-Infection
|
47
|
9.18e-01
|
9.53e-01
|
0.02050
|
9.18e-03
|
0.018300
|
9.13e-01
|
8.28e-01
|
PIP3-activates-AKT-signaling
|
257
|
7.69e-01
|
8.60e-01
|
0.01980
|
-1.97e-02
|
0.000921
|
5.85e-01
|
9.80e-01
|
TCF-dependent-signaling-in-response-to-WNT
|
164
|
9.38e-01
|
9.60e-01
|
0.01880
|
1.61e-02
|
-0.009710
|
7.21e-01
|
8.30e-01
|
Intracellular-signaling-by-second-messengers
|
295
|
8.83e-01
|
9.36e-01
|
0.01820
|
-8.14e-03
|
0.016300
|
8.10e-01
|
6.29e-01
|
Signaling-by-MET
|
66
|
9.70e-01
|
9.77e-01
|
0.01760
|
1.63e-02
|
-0.006530
|
8.19e-01
|
9.27e-01
|
Biological-oxidations
|
168
|
9.12e-01
|
9.51e-01
|
0.01570
|
-2.33e-03
|
0.015500
|
9.58e-01
|
7.29e-01
|
SUMOylation-of-DNA-damage-response-and-repair-proteins
|
74
|
9.27e-01
|
9.57e-01
|
0.01530
|
1.36e-02
|
0.007090
|
8.40e-01
|
9.16e-01
|
Mitochondrial-biogenesis
|
73
|
9.67e-01
|
9.75e-01
|
0.01310
|
5.41e-04
|
-0.013100
|
9.94e-01
|
8.47e-01
|
Phase-II—Conjugation-of-compounds
|
80
|
9.89e-01
|
9.92e-01
|
0.01220
|
7.40e-03
|
-0.009660
|
9.09e-01
|
8.81e-01
|
Suppression-of-phagosomal-maturation
|
12
|
9.98e-01
|
9.98e-01
|
0.01130
|
-5.90e-03
|
0.009610
|
9.72e-01
|
9.54e-01
|
Cellular-Senescence
|
124
|
9.54e-01
|
9.68e-01
|
0.00952
|
-3.77e-03
|
-0.008740
|
9.42e-01
|
8.66e-01
|
Regulation-of-HSF1-mediated-heat-shock-response
|
74
|
9.95e-01
|
9.96e-01
|
0.00905
|
-5.97e-03
|
0.006800
|
9.29e-01
|
9.19e-01
|
Generic-Transcription-Pathway
|
905
|
7.69e-01
|
8.60e-01
|
0.00861
|
-2.89e-03
|
-0.008110
|
8.82e-01
|
6.78e-01
|
Interferon-Signaling
|
152
|
9.66e-01
|
9.75e-01
|
0.00850
|
7.68e-04
|
0.008470
|
9.87e-01
|
8.57e-01
|
ESR-mediated-signaling
|
157
|
9.90e-01
|
9.92e-01
|
0.00839
|
6.62e-03
|
-0.005150
|
8.86e-01
|
9.11e-01
|
Transcription-of-the-HIV-genome
|
64
|
9.96e-01
|
9.96e-01
|
0.00803
|
6.68e-03
|
-0.004450
|
9.26e-01
|
9.51e-01
|
Immune-System
|
1704
|
6.99e-01
|
8.12e-01
|
0.00711
|
3.34e-03
|
0.006270
|
8.17e-01
|
6.64e-01
|
Post-translational-protein-modification
|
1263
|
8.72e-01
|
9.31e-01
|
0.00670
|
6.68e-03
|
-0.000508
|
6.88e-01
|
9.76e-01
|
tRNA-processing
|
113
|
9.91e-01
|
9.93e-01
|
0.00572
|
5.68e-03
|
-0.000713
|
9.17e-01
|
9.90e-01
|